nct_id,title,status,phase,enrollment,start_date,completion_date,enrollment_rate_monthly,enrollment_rate_tier,enrollment_success_pct,success_tier,status_success_score,composite_success_score,success_percentile
NCT03447535,Better Understand Children and Adolescents' Intrafamilial Oppositional Defiant Disorder,COMPLETED,,75.0,2017-12-01,2017-12-31,75.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,64.3,76.64999999999999
NCT05836935,Role of Imaging in Complications of Sinusitis,UNKNOWN,NA,30.0,2023-05-01,2023-12-01,4.267289719626168,Adequate (1-10/month),42.67289719626169,Significantly Below (<50%),50,37.4,17.549999999999997
NCT03551535,Monitored Home Exercise in Pregnancy,WITHDRAWN,NA,0.0,2018-11-01,2019-10-08,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT02889835,Clinical Performance of Incremental and Bulk Fill Composites in Class II Restorations,COMPLETED,NA,53.0,2016-03-22,2021-07-03,0.8363504406428202,Slow (<1/month),8.363504406428202,Significantly Below (<50%),100,49.2,46.650000000000006
NCT04802135,Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy,RECRUITING,,200.0,2021-03-06,2032-09-01,1.450559923755063,Adequate (1-10/month),14.505599237550632,Significantly Below (<50%),60,47.3,40.2
NCT01081535,The Effect of Intravenous (IV) Patient Controlled Analgesic (PCA) With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy,COMPLETED,NA,50.0,2009-05-01,2010-02-01,5.5144927536231885,Adequate (1-10/month),55.14492753623188,Below (50-75%),100,54.0,59.0
NCT05775835,Effects of Whole Body Vibration and Resistance Exercise on Carotis Intima Media and Muscle Architecture in Hypertension,COMPLETED,NA,43.0,2023-02-10,2024-03-15,3.280501253132832,Adequate (1-10/month),32.80501253132832,Significantly Below (<50%),100,53.4,57.25
NCT03012035,The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants,COMPLETED,NA,70.0,2017-05-18,2018-03-12,7.150335570469799,Adequate (1-10/month),71.503355704698,Below (50-75%),100,55.6,62.74999999999999
NCT06986135,The Effect of Breathing on Cognitive Performance and Stress,COMPLETED,NA,66.0,2024-08-01,2025-05-01,7.35912087912088,Adequate (1-10/month),73.5912087912088,Below (50-75%),100,55.3,62.35000000000001
NCT02897635,Integrative Approaches For Cancer Survivorship 2: Project 1,COMPLETED,NA,20.0,2016-09-01,2018-09-21,0.8117333333333334,Slow (<1/month),8.117333333333333,Significantly Below (<50%),100,46.6,36.7
NCT02687035,PARTNER II Trial: S3iCAP,COMPLETED,NA,1822.0,2015-01-01,2018-12-01,38.78439160839161,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT00575835,Oral Vitamin D Supplementation in Elderly Women,COMPLETED,NA,40.0,2006-10-01,2007-10-01,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),100,53.2,56.10000000000001
NCT01076335,Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer,COMPLETED,PHASE2,40.0,2005-05-01,2015-06-01,0.3306000543035569,Slow (<1/month),3.306000543035569,Significantly Below (<50%),100,48.2,43.6
NCT00789035,12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients,COMPLETED,PHASE2,408.0,2008-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,72.6,83.75
NCT04790435,Acute-On-Chronic Liver Failure In Cirrhotic Patients,COMPLETED,,109.0,2021-03-01,2022-02-01,9.845578635014837,Adequate (1-10/month),98.45578635014839,Met (75-100%),100,62.1,74.2
NCT02636335,"Light, Exercise Intensity and Mood in Overweight",COMPLETED,NA,26.0,2016-01-01,2017-06-01,1.5308317214700196,Adequate (1-10/month),15.308317214700196,Significantly Below (<50%),100,47.1,39.45
NCT04990635,Evaluation of Caudal Block Success With Perfusion Index,UNKNOWN,,55.0,2021-08-17,2021-09-30,38.050000000000004,Good (10-50/month),200.0,Exceeded (≥100%),50,42.7,25.1
NCT06077435,Comparative Analysis of AI Software for Enhanced Polyp Detection and Diagnosis,RECRUITING,NA,915.0,2023-03-01,2026-06-01,23.444949494949498,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,90.64999999999999
NCT06762535,fMRI Study of the Neural Mechanism of rTMS in the Treatment of Nicotine Dependence,ACTIVE_NOT_RECRUITING,NA,50.0,2023-04-01,2025-08-01,1.784290738569754,Adequate (1-10/month),17.84290738569754,Significantly Below (<50%),85,49.5,47.15
NCT02983435,Osteopathic Treatment for Chronic Low Back Pain,COMPLETED,NA,10.0,2016-12-01,2017-04-01,2.515702479338843,Adequate (1-10/month),25.157024793388434,Significantly Below (<50%),100,50.8,49.55
NCT03629535,Accuracy of Non-invasive Non-oscillometric Blood Pressure Wristband,COMPLETED,NA,8.0,2019-04-01,2019-09-10,1.5032098765432098,Adequate (1-10/month),15.032098765432098,Significantly Below (<50%),100,45.6,31.0
NCT00532935,MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066),COMPLETED,PHASE3,517.0,2008-01-26,2009-10-23,24.74446540880503,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT06354608,The Effect of Audio Book and Local Vibration on Pain and Fear in Intramuscular Injection in Children,RECRUITING,NA,120.0,2023-10-25,2024-07-01,14.6112,Good (10-50/month),146.112,Exceeded (≥100%),60,52.6,54.6
NCT04580108,Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus,COMPLETED,,446.0,2007-07-03,2019-06-26,3.1024314442413163,Adequate (1-10/month),31.024314442413164,Significantly Below (<50%),100,84.0,91.64999999999999
NCT07252908,A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder,RECRUITING,PHASE2,195.0,2025-12-22,2026-06-01,36.86832298136646,Good (10-50/month),200.0,Exceeded (≥100%),60,58.6,69.69999999999999
NCT04711408,Virtual Reality During Ultrasound Examination of Women With Endometriosis,UNKNOWN,NA,100.0,2022-06-14,2023-12-01,5.689719626168224,Adequate (1-10/month),56.89719626168224,Below (50-75%),50,43.0,25.7
NCT00963508,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",COMPLETED,PHASE3,403.0,2009-08-01,2010-03-01,57.86471698113208,Excellent (>50/month),200.0,Exceeded (≥100%),100,92.2,94.69999999999999
NCT02380508,Heterologous Effects of BCG in Healthy UK Adults,COMPLETED,NA,36.0,2015-02-01,2016-11-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),100,52.9,55.2
NCT01304108,Improving Venous Thromboembolism Prophylaxis,COMPLETED,PHASE4,3000.0,2009-01-01,2010-05-01,188.28865979381445,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT02368808,"Adolescent Bereavement Initiative in the Free State, South Africa",COMPLETED,NA,843.0,2015-01-01,2015-11-01,84.41092105263158,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT06979908,A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer,RECRUITING,PHASE2,46.0,2025-01-22,2027-01-22,1.91813698630137,Adequate (1-10/month),19.1813698630137,Significantly Below (<50%),60,41.7,23.599999999999998
NCT06318208,Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19,COMPLETED,,110.0,2021-04-20,2022-01-03,12.97829457364341,Good (10-50/month),129.7829457364341,Exceeded (≥100%),100,62.1,74.2
NCT01495208,Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment,WITHDRAWN,PHASE4,0.0,2011-12-01,2012-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT03221608,Clinical Analysis of HIPEC for T4 Colorectal Cancer After Surgery,UNKNOWN,PHASE3,300.0,2017-08-01,2024-08-01,3.5713727023856086,Adequate (1-10/month),35.71372702385609,Significantly Below (<50%),50,59.0,70.39999999999999
NCT03352908,Yale Swallow Protocol in Extubated Patients,COMPLETED,,166.0,2017-10-25,2020-10-29,4.593672727272728,Adequate (1-10/month),45.93672727272728,Significantly Below (<50%),100,61.6,73.1
NCT06921408,Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA),NOT_YET_RECRUITING,,57.0,2025-06-01,2027-12-01,1.9004162102957285,Adequate (1-10/month),19.004162102957284,Significantly Below (<50%),30,31.9,10.8
NCT06444308,Community Health Worker-led Hypertension Management,RECRUITING,NA,460.0,2024-09-09,2026-09-01,19.393905817174517,Good (10-50/month),193.93905817174516,Exceeded (≥100%),60,79.8,88.1
NCT04645108,Coached or Non-Coached Weight Loss Intervention,COMPLETED,NA,246.0,2020-11-20,2021-06-10,37.07049504950495,Good (10-50/month),200.0,Exceeded (≥100%),100,74.7,84.8
NCT00004108,DX-8951f in Treating Patients With Liver Cancer,COMPLETED,PHASE2,,1999-09-01,2005-04-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,29.65
NCT00359008,PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV),COMPLETED,,336.0,2006-07-01,2007-09-01,23.952786885245903,Good (10-50/month),200.0,Exceeded (≥100%),100,80.2,89.3
NCT00704808,Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739),COMPLETED,,180.0,2006-05-01,2008-12-01,5.798095238095239,Adequate (1-10/month),57.98095238095239,Below (50-75%),100,62.7,74.9
NCT01590108,The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects,COMPLETED,PHASE1,12.0,2012-03-01,2014-09-01,0.39964989059080963,Slow (<1/month),3.996498905908097,Significantly Below (<50%),100,46.0,33.2
NCT03625908,Optical CoherenCe Tomography-gUided Coronary Intervention in Patients With Complex lesIons: a Randomized Controlled Trial (OCCUPI Trial),COMPLETED,NA,1604.0,2019-01-09,2023-10-12,28.10924582613702,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT00823108,Rapid Administration of Insulin in Sepsis,COMPLETED,PHASE1,20.0,2009-03-01,2010-10-01,1.05146804835924,Adequate (1-10/month),10.5146804835924,Significantly Below (<50%),100,46.6,36.7
NCT00609908,The Technique of Skin Stretching for Acute Burn Treatment and Scar Reconstruction,COMPLETED,PHASE3,30.0,2007-12-01,2011-06-01,0.7145539906103286,Slow (<1/month),7.145539906103286,Significantly Below (<50%),100,47.4,40.75
NCT00582608,Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9,TERMINATED,NA,12.0,2001-10-01,2009-05-01,0.13191765980498377,Slow (<1/month),1.3191765980498376,Significantly Below (<50%),10,19.0,4.1000000000000005
NCT03991208,Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment,WITHDRAWN,PHASE4,0.0,2019-05-24,2021-05-23,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT04673825,Monitoring Spondyloarthritis With SpA-Net,COMPLETED,NA,200.0,2020-12-02,2023-07-01,6.46971307120085,Adequate (1-10/month),64.69713071200852,Below (50-75%),100,66.0,78.45
NCT03909425,Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography,COMPLETED,,35.0,2019-09-02,2021-08-16,1.4921568627450983,Adequate (1-10/month),14.921568627450982,Significantly Below (<50%),100,46.1,33.95
NCT01117025,Combined Treatment of Resistant Hypertension and Atrial Fibrillation,COMPLETED,PHASE2,26.0,2010-04-01,2012-04-01,1.0826812585499317,Adequate (1-10/month),10.826812585499317,Significantly Below (<50%),100,47.1,39.45
NCT01566825,The Influence of Amitriptyline on Learning in a Visual Discrimination Task,COMPLETED,NA,32.0,2008-08-01,2009-05-01,3.5680586080586085,Adequate (1-10/month),35.68058608058608,Significantly Below (<50%),100,52.6,54.6
NCT04443725,Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19,UNKNOWN,PHASE2,100.0,2020-07-01,2020-12-01,19.895424836601308,Good (10-50/month),198.95424836601308,Exceeded (≥100%),50,48.0,42.75
NCT05980325,Exercise for Fighting Oncology Repercussions After Treatment,NOT_YET_RECRUITING,NA,45.0,2025-01-08,2026-07-01,2.541372912801484,Adequate (1-10/month),25.413729128014843,Significantly Below (<50%),30,32.6,11.899999999999999
NCT00433225,Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation,COMPLETED,PHASE4,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.3
NCT05501925,GlideSheath Slender® Versus Conventional 6 French Arterial Sheath: Impact on the Distal Radial Artery Occlusion (SMART),UNKNOWN,NA,600.0,2022-09-15,2024-02-28,34.3954802259887,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,88.64999999999999
NCT03574025,NEUROlogical Prognosis After Cardiac Arrest in Kids,UNKNOWN,,150.0,2018-01-01,2019-08-01,7.913344887348354,Adequate (1-10/month),79.13344887348354,Met (75-100%),50,45.3,30.45
NCT05043376,Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Hospitalised Patients (Non-ICU) With COVID-19,COMPLETED,NA,50.0,2021-09-10,2021-11-21,21.13888888888889,Good (10-50/month),200.0,Exceeded (≥100%),100,59.0,70.39999999999999
NCT00672776,Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD),COMPLETED,PHASE4,40.0,2003-05-01,2007-09-01,0.7686868686868688,Slow (<1/month),7.686868686868687,Significantly Below (<50%),100,48.2,43.6
NCT00016276,"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer",TERMINATED,PHASE3,396.0,2001-05-01,,,Slow (<1/month),,Significantly Below (<50%),10,44.7,28.9
NCT02929576,"Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer",WITHDRAWN,PHASE3,0.0,2016-09-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.15
NCT01459276,A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects,COMPLETED,NA,1206.0,2011-10-01,2012-03-01,241.51736842105262,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT06092476,Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients,RECRUITING,NA,18.0,2024-08-09,2027-07-01,0.5188636363636363,Slow (<1/month),5.188636363636364,Significantly Below (<50%),60,34.4,13.700000000000001
NCT05308576,A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years,ACTIVE_NOT_RECRUITING,PHASE3,10000.0,2022-12-26,2024-04-01,658.8744588744589,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,97.1
NCT06722976,Digital Health and Exercise for Autonomous Longevity Program,ENROLLING_BY_INVITATION,NA,120.0,2024-11-05,2025-07-01,15.347899159663866,Good (10-50/month),153.47899159663868,Exceeded (≥100%),55,51.1,50.64999999999999
NCT05645276,A Study of AK129 in Patients With Advanced Malignant Tumors,RECRUITING,PHASE1,182.0,2023-03-02,2026-06-01,4.667295703454086,Adequate (1-10/month),46.672957034540865,Significantly Below (<50%),60,52.6,54.6
NCT00588276,Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors,COMPLETED,PHASE1,15.0,2005-06-01,2012-06-01,0.17856863511928042,Slow (<1/month),1.7856863511928043,Significantly Below (<50%),100,46.2,34.4
NCT04271176,Jaundice as Initial Presentation of Liver Hydatidosis (ICTEHIDA),UNKNOWN,,35.0,2009-01-01,2021-04-30,0.23665037760995114,Slow (<1/month),2.3665037760995116,Significantly Below (<50%),50,31.1,9.4
NCT02878876,Incidence of Lactose Intolerance Among Self-reported Lactose Intolerant People,COMPLETED,PHASE4,600.0,2016-01-01,2016-03-01,304.40000000000003,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT01821976,Transtibial Amputation Outcomes Study,COMPLETED,NA,250.0,2013-03-01,2020-03-01,2.9761439186546736,Adequate (1-10/month),29.76143918654674,Significantly Below (<50%),100,70.0,81.95
NCT06981676,The Developmental Origins of Obesity,RECRUITING,NA,160.0,2023-07-25,2027-03-30,3.623809523809524,Adequate (1-10/month),36.23809523809524,Significantly Below (<50%),60,50.8,49.55
NCT02644876,Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications,COMPLETED,PHASE4,864.0,2015-09-01,2018-12-10,21.99010033444816,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT04648176,Application of MOSES Technology in BPH,UNKNOWN,NA,400.0,2020-03-06,2023-06-30,10.054500412881916,Good (10-50/month),100.54500412881917,Exceeded (≥100%),50,72.0,83.25
NCT04334876,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,COMPLETED,NA,571.0,2020-04-01,2021-01-01,63.2045090909091,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT00003617,Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach,UNKNOWN,PHASE3,200.0,1995-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,41.0,22.45
NCT01298817,Use of a Soy-based Meal Replacement Weight Loss Intervention to Impact Ectopic Fat,COMPLETED,NA,24.0,2011-03-01,2012-12-01,1.1397191887675506,Adequate (1-10/month),11.397191887675506,Significantly Below (<50%),100,46.9,38.6
NCT07146217,Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection,NOT_YET_RECRUITING,PHASE2,30.0,2025-08-01,2026-10-01,2.143661971830986,Adequate (1-10/month),21.43661971830986,Significantly Below (<50%),30,31.4,10.0
NCT06852417,Qigong and Executive Attention in Older Adults with Depressive Symptoms,NOT_YET_RECRUITING,NA,200.0,2026-01-01,2028-12-31,5.559817351598174,Adequate (1-10/month),55.59817351598174,Below (50-75%),30,45.0,29.65
NCT02272517,Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder,COMPLETED,PHASE3,101.0,2014-12-01,2016-03-01,6.742192982456141,Adequate (1-10/month),67.42192982456142,Below (50-75%),100,58.1,69.0
NCT05107817,Aquatic Exercise and Reactive Balance,NOT_YET_RECRUITING,NA,44.0,2026-01-01,2027-09-01,2.2028947368421052,Adequate (1-10/month),22.028947368421054,Significantly Below (<50%),30,32.5,11.799999999999999
NCT04821817,Peribulbar Rocuronium in Adult Strabismus Surgery,COMPLETED,NA,52.0,2021-04-03,2025-02-09,1.1242045454545455,Adequate (1-10/month),11.242045454545455,Significantly Below (<50%),100,49.2,46.650000000000006
NCT01833117,Efficacy and Safety Study of FID 119515A,COMPLETED,NA,75.0,2013-05-01,2013-06-01,73.64516129032258,Excellent (>50/month),200.0,Exceeded (≥100%),100,66.0,78.45
NCT03391817,FAECAL MICROBIOTA TRANSPLANTATION IN OBESITY,UNKNOWN,NA,40.0,2018-01-19,2021-02-28,1.0718309859154929,Adequate (1-10/month),10.718309859154928,Significantly Below (<50%),50,33.2,12.35
NCT05059717,An Investigational Scan (MR DENSE) in Detecting Early Chemotherapy-Related Liver Injury Before Surgery in Patients With Resectable Colorectal Liver Metastases,WITHDRAWN,NA,0.0,2018-07-12,2022-06-24,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT05599217,Association Between Dietary Factors and Chronic Subdural Hematoma (DISH),RECRUITING,,420.0,2023-03-13,2025-03-31,17.069158878504673,Good (10-50/month),170.69158878504675,Exceeded (≥100%),60,74.9,84.89999999999999
NCT02082717,The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis,TERMINATED,PHASE4,17.0,2014-02-25,2018-08-03,0.3194320987654321,Slow (<1/month),3.194320987654321,Significantly Below (<50%),10,19.4,4.55
NCT05999617,Effectiveness of Dual Task Exercise Training in Children With Cerebral Palsy,COMPLETED,NA,30.0,2023-05-12,2023-08-31,8.227027027027027,Adequate (1-10/month),82.27027027027027,Met (75-100%),100,52.4,54.0
NCT03190317,Health Information for Infected Veterans,ACTIVE_NOT_RECRUITING,,123.0,2019-06-24,2025-09-30,1.6349868995633188,Adequate (1-10/month),16.349868995633187,Significantly Below (<50%),85,48.7,45.550000000000004
NCT01222117,A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion,COMPLETED,PHASE2,174.0,2010-12-01,2016-01-01,2.8522132471728594,Adequate (1-10/month),28.52213247172859,Significantly Below (<50%),100,63.9,76.14999999999999
NCT05300217,Evaluation of a Website to Improve Depression Literacy in Adoldescents,COMPLETED,NA,79.0,2021-01-04,2022-05-02,4.97879917184265,Adequate (1-10/month),49.7879917184265,Significantly Below (<50%),100,56.3,64.0
NCT05275140,Adapted Taekwondo on Health Status in Older Women,COMPLETED,NA,56.0,2023-05-01,2024-01-30,6.221313868613138,Adequate (1-10/month),62.21313868613139,Below (50-75%),100,54.5,59.650000000000006
NCT00874640,Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON),COMPLETED,,3711.0,2009-03-01,2011-11-01,115.85932307692309,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT02307240,"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",COMPLETED,PHASE1,43.0,2014-11-01,2019-05-31,0.7828468899521531,Slow (<1/month),7.828468899521532,Significantly Below (<50%),100,48.4,44.2
NCT01154140,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,COMPLETED,PHASE3,343.0,2011-01-13,2016-11-30,4.8607635009311,Adequate (1-10/month),48.60763500931099,Significantly Below (<50%),100,77.4,86.15
NCT03592940,The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.,COMPLETED,,100.0,2017-11-01,2018-06-30,12.630705394190873,Good (10-50/month),126.30705394190873,Exceeded (≥100%),100,61.3,72.55
NCT05331040,Radiomics in Rectal Cancer,UNKNOWN,,350.0,2020-05-01,2025-05-01,5.83461117196057,Adequate (1-10/month),58.346111719605695,Below (50-75%),50,61.3,72.55
NCT04855240,Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy,COMPLETED,PHASE2,239.0,2021-03-29,2022-03-14,20.78617142857143,Good (10-50/month),200.0,Exceeded (≥100%),100,74.1,84.65
NCT00544440,An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma,COMPLETED,PHASE2,57.0,2007-10-01,2012-08-01,0.9824915062287657,Slow (<1/month),9.824915062287657,Significantly Below (<50%),100,49.6,47.4
NCT00430040,Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.,TERMINATED,PHASE4,14.0,2007-02-01,2013-05-01,0.1868303375712407,Slow (<1/month),1.868303375712407,Significantly Below (<50%),10,19.1,4.25
NCT04742140,Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points,COMPLETED,PHASE4,180.0,2021-02-20,2021-09-01,28.389637305699484,Good (10-50/month),200.0,Exceeded (≥100%),100,69.4,81.45
NCT02021240,Ketamine in Post-operative Dental Pain and Recovery,COMPLETED,PHASE3,150.0,2014-02-10,2016-04-18,5.7218045112781954,Adequate (1-10/month),57.21804511278196,Below (50-75%),100,62.0,73.8
NCT01126840,Survivorship in Lynch Syndrome Families,COMPLETED,,303.0,2010-06-20,2022-09-19,2.061537773804202,Adequate (1-10/month),20.615377738042024,Significantly Below (<50%),100,72.6,83.75
NCT05710289,A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.,WITHDRAWN,,0.0,2023-02-01,2024-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.5
NCT03222089,Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC,WITHDRAWN,PHASE2,0.0,2017-07-20,2020-07-20,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT06356389,"A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.",COMPLETED,PHASE1,60.0,2022-03-02,2023-01-28,5.501204819277109,Adequate (1-10/month),55.012048192771076,Below (50-75%),100,54.8,61.199999999999996
NCT00778089,Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing,TERMINATED,NA,498.0,2008-07-01,2008-12-03,97.80077419354839,Excellent (>50/month),200.0,Exceeded (≥100%),10,72.8,83.89999999999999
NCT07279389,Comparative Study Between One-Shot Dilatation Versus Serial Dilatation Techniques for Access in Percutaneous Nephrolithotomy in Adult Patients,COMPLETED,NA,60.0,2022-02-27,2023-08-05,3.4854961832061067,Adequate (1-10/month),34.85496183206107,Significantly Below (<50%),100,54.8,61.199999999999996
NCT00176189,Clinical Performance of Extended All-Ceramic Fixed Partial Dentures Based on Zircon-Oxide Ceramics.,COMPLETED,NA,30.0,2005-02-01,2006-12-01,1.367065868263473,Adequate (1-10/month),13.670658682634729,Significantly Below (<50%),100,47.4,40.75
NCT04337489,Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus),COMPLETED,,15.0,2020-07-28,2021-03-26,1.8946058091286309,Adequate (1-10/month),18.94605809128631,Significantly Below (<50%),100,49.5,47.15
NCT02904889,Stimulating Engagement in Daily and Physical Activities Among Older Adults Receiving Homecare Services (Part of Basic Care Revisited),COMPLETED,NA,40.0,2016-09-01,2017-07-01,4.018481848184819,Adequate (1-10/month),40.18481848184819,Significantly Below (<50%),100,53.2,56.10000000000001
NCT04594889,Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia,UNKNOWN,NA,170.0,2020-10-14,2022-12-31,6.404455445544555,Adequate (1-10/month),64.04455445544556,Below (50-75%),50,48.6,45.1
NCT00358189,Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease,COMPLETED,,20.0,2006-10-01,2008-05-01,1.053287197231834,Adequate (1-10/month),10.53287197231834,Significantly Below (<50%),100,44.9,29.25
NCT06011889,Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome,RECRUITING,PHASE2,60.0,2024-09-04,2028-10-18,1.2135548172757475,Adequate (1-10/month),12.135548172757476,Significantly Below (<50%),60,37.8,17.849999999999998
NCT04285489,A Study on the Safety of Hakim Programmable Shunt System,COMPLETED,,130.0,2020-05-02,2020-07-28,45.48505747126437,Good (10-50/month),200.0,Exceeded (≥100%),100,68.7,81.10000000000001
NCT00836589,Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY),COMPLETED,,1997.0,2008-12-01,2016-12-01,20.803791923340178,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,95.1
NCT01936389,A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma,COMPLETED,PHASE2,10.0,2013-09-01,2014-10-01,0.7706329113924052,Slow (<1/month),7.706329113924052,Significantly Below (<50%),100,45.8,31.900000000000002
NCT04302389,Single Arm Trial of a Multi-component Commercial Digital Weight Loss Program,COMPLETED,NA,153.0,2021-02-10,2021-11-01,17.641363636363636,Good (10-50/month),176.41363636363636,Exceeded (≥100%),100,67.2,79.95
NCT04039789,Impact of Physical Activity as a Coadjuvant Treatment in the Healing of Venous Ulcers in Primary Health Care.,COMPLETED,NA,44.0,2021-05-17,2023-12-31,1.398079331941545,Adequate (1-10/month),13.980793319415449,Significantly Below (<50%),100,48.5,44.6
NCT04908189,A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment,ACTIVE_NOT_RECRUITING,PHASE3,729.0,2021-07-15,2026-11-12,11.403268242548819,Good (10-50/month),114.03268242548819,Exceeded (≥100%),85,90.5,94.25
NCT03946189,Comparison of the PaO2/FiO2 Ratio to Other Oxygenation Indexes for the Classification of Severity of Acute Respiratory Distress Syndrome,COMPLETED,,150.0,2018-03-14,2019-05-01,11.055690072639225,Good (10-50/month),110.55690072639226,Exceeded (≥100%),100,65.3,77.60000000000001
NCT06365489,"Comparison of Brachial Wrist Index Before and After Implantation of Arteriovenous Fistulas, Based on Brachial Artery",COMPLETED,,78.0,2022-12-11,2024-09-15,3.686832298136646,Adequate (1-10/month),36.86832298136646,Significantly Below (<50%),100,54.6,60.099999999999994
NCT00281489,Study Evaluating Ways of Preventing Patients From Being Awake During High-Risk Surgery and Anesthesia,COMPLETED,PHASE2,2000.0,2005-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,88.64999999999999
NCT03077789,Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France,COMPLETED,NA,250.0,2013-04-01,2021-11-01,2.4266581632653064,Adequate (1-10/month),24.266581632653065,Significantly Below (<50%),100,70.0,81.95
NCT00094289,Interactions Between Cocaine and Ethanol and Disulfiram - 1,UNKNOWN,PHASE1,16.0,2004-08-01,2005-07-01,1.4582035928143713,Adequate (1-10/month),14.58203592814371,Significantly Below (<50%),50,31.3,9.65
NCT05814289,"The Association of Telephone Head Tilt With Cervical, Thoracic, and Lumbar Spine Mobility and Disorders in Young Adults",COMPLETED,NA,40.0,2023-04-01,2024-07-01,2.664332603938731,Adequate (1-10/month),26.64332603938731,Significantly Below (<50%),100,53.2,56.10000000000001
NCT02826889,Assessing the Diagnostic Accuracy of Corrected Flow Time (FTc) and Pleth Variability Index (PVI) as Predictors of Fluid Responsiveness in Patients in the Prone Position Using the Jackson Table,COMPLETED,NA,58.0,2016-05-24,2017-07-27,4.1154312354312355,Adequate (1-10/month),41.15431235431235,Significantly Below (<50%),100,54.6,60.099999999999994
NCT07028489,Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer,RECRUITING,,130.0,2025-06-05,2029-04-01,2.8346704871060173,Adequate (1-10/month),28.346704871060176,Significantly Below (<50%),60,46.7,37.5
NCT04282889,Rotational Thromboelastometry (ROTEM) TRUE-NATEM Reference Value Validation in Liver Transplantation,COMPLETED,,40.0,2020-10-06,2021-02-01,10.31864406779661,Good (10-50/month),103.18644067796612,Exceeded (≥100%),100,56.5,64.85
NCT04666389,The Role of Statins in the Prevention of Contrast-induced Acute Kidney Injury in Patients With Cardiovascular Diseases,COMPLETED,NA,150.0,2020-10-15,2023-01-10,5.588739290085679,Adequate (1-10/month),55.88739290085679,Below (50-75%),100,62.0,73.8
NCT07097389,In Vivo Human Study on Commercial Cellobiose as a Potential Prebiotic Candidate,COMPLETED,NA,37.0,2024-07-31,2025-06-01,3.69272131147541,Adequate (1-10/month),36.9272131147541,Significantly Below (<50%),100,53.0,55.50000000000001
NCT02312089,GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles,UNKNOWN,PHASE4,200.0,2016-08-07,2024-12-31,1.9843546284224252,Adequate (1-10/month),19.84354628422425,Significantly Below (<50%),50,51.0,50.2
NCT01615289,Neural Effects of Green Tea Extract on Dorsolateral Prefrontal Cortex,COMPLETED,NA,12.0,2010-07-01,2012-01-01,0.6653551912568307,Slow (<1/month),6.6535519125683065,Significantly Below (<50%),100,46.0,33.2
NCT01369368,Treatment of Acute Leukemia Relapse After Allotransplantation,UNKNOWN,PHASE1,20.0,2013-08-01,2020-10-01,0.23254392666157372,Slow (<1/month),2.3254392666157373,Significantly Below (<50%),50,31.6,10.45
NCT01427868,Bioequivalence of LB80380 Free Base and Maleate Salt Tablets,COMPLETED,PHASE1,32.0,2010-09-01,2010-12-01,10.704175824175824,Good (10-50/month),107.04175824175823,Exceeded (≥100%),100,57.6,67.25
NCT05421468,Timing of Thyroxine Dose In Ramadan,UNKNOWN,NA,250.0,2022-03-14,2022-10-30,33.08695652173913,Good (10-50/month),200.0,Exceeded (≥100%),50,60.0,71.65
NCT03240068,Angiotensin-(1-7) in Peripheral Arterial Disease,TERMINATED,EARLY_PHASE1,6.0,2017-09-01,2020-03-09,0.1985217391304348,Slow (<1/month),1.9852173913043478,Significantly Below (<50%),10,18.5,3.45
NCT06347068,Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells,RECRUITING,PHASE1,42.0,2024-06-27,2028-05-01,0.9105982905982907,Slow (<1/month),9.105982905982907,Significantly Below (<50%),60,36.4,15.9
NCT00607568,Atomoxetine Effects in Humans,COMPLETED,PHASE1,10.0,2006-06-01,2009-09-01,0.25622895622895625,Slow (<1/month),2.5622895622895623,Significantly Below (<50%),100,45.8,31.900000000000002
NCT01507168,A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma,COMPLETED,PHASE2,185.0,2012-02-02,2015-08-20,4.348571428571429,Adequate (1-10/month),43.48571428571429,Significantly Below (<50%),100,64.8,77.10000000000001
NCT02551068,High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib,RECRUITING,NA,88.0,2015-12-01,2026-12-01,0.6666799402687905,Slow (<1/month),6.666799402687906,Significantly Below (<50%),60,40.0,21.3
NCT00043368,PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909),COMPLETED,PHASE2,31.0,2002-09-01,2007-06-01,0.5441983852364476,Slow (<1/month),5.4419838523644755,Significantly Below (<50%),100,47.5,41.3
NCT06324968,Ro60 Expression in Macrophages in Sjogren's Disease,ACTIVE_NOT_RECRUITING,NA,20.0,2024-02-09,2025-05-09,1.338021978021978,Adequate (1-10/month),13.380219780219782,Significantly Below (<50%),85,42.1,24.45
NCT00218868,Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear,COMPLETED,,66.0,2000-01-01,2007-11-01,0.7022160083886754,Slow (<1/month),7.022160083886753,Significantly Below (<50%),100,48.6,45.1
NCT05227768,Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers,COMPLETED,PHASE1,38.0,2021-11-11,2022-01-13,18.36063492063492,Good (10-50/month),183.6063492063492,Exceeded (≥100%),100,58.0,68.30000000000001
NCT01101568,A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects,COMPLETED,PHASE1,28.0,2010-04-14,2010-06-24,12.004507042253522,Good (10-50/month),120.0450704225352,Exceeded (≥100%),100,57.2,65.9
NCT03071068,A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME),COMPLETED,PHASE2,49.0,2016-12-22,2018-04-01,3.2076559139784946,Adequate (1-10/month),32.07655913978494,Significantly Below (<50%),100,53.9,58.45
NCT03095768,Lifestyle Education and Nutrition Demonstration,COMPLETED,NA,37.0,2017-04-13,2017-06-15,17.877460317460315,Good (10-50/month),178.77460317460316,Exceeded (≥100%),100,58.0,68.30000000000001
NCT06951568,Study of the Effect of Peripheral Somatosensory Stimulation on the Functionality of Patients With Cerebral Palsy and Reduced Mobility,RECRUITING,NA,20.0,2025-05-02,2025-09-30,4.031788079470199,Adequate (1-10/month),40.317880794701985,Significantly Below (<50%),60,39.6,20.4
NCT05642468,Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis,COMPLETED,PHASE2,18.0,2023-01-09,2025-07-10,0.60013143483023,Slow (<1/month),6.001314348302301,Significantly Below (<50%),100,46.4,35.5
NCT00169468,Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma,COMPLETED,PHASE2,48.0,2005-01-01,2006-01-01,4.0030684931506855,Adequate (1-10/month),40.030684931506855,Significantly Below (<50%),100,53.8,57.9
NCT04101968,The GBA Multimodal Study in Parkinson's Disease,RECRUITING,,25.0,2019-05-01,2025-12-30,0.3125256673511294,Slow (<1/month),3.1252566735112937,Significantly Below (<50%),60,33.3,12.6
NCT02826668,Influence of Lumbar Ultrasound on Resident Learning Curve for Lateral Labor Epidural Placement,TERMINATED,NA,28.0,2014-06-01,2021-03-01,0.3457687626774848,Slow (<1/month),3.4576876267748484,Significantly Below (<50%),10,20.2,5.2
NCT06990568,Impact of Probiotics on Antibiotic-associated Diarrhea in Community-acquired Pneumonia,NOT_YET_RECRUITING,PHASE4,100.0,2025-06-01,2026-12-31,5.26643598615917,Adequate (1-10/month),52.664359861591706,Below (50-75%),30,37.0,16.8
NCT03403868,Right Ventricular Haemodynamic Evaluation and Response to Treatment,UNKNOWN,NA,100.0,2016-01-01,2021-12-01,1.4086071263304025,Adequate (1-10/month),14.086071263304026,Significantly Below (<50%),50,38.0,18.25
NCT00732368,A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459),COMPLETED,PHASE3,98.0,2005-05-01,2006-01-01,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,62.8,75.1
NCT05736068,Is Casting of Displaced Pediatric Distal Forearm Fractures Non-inferior to Reduction in General Anesthesia?,ACTIVE_NOT_RECRUITING,NA,40.0,2023-09-07,2026-01-01,1.4375442739079103,Adequate (1-10/month),14.375442739079103,Significantly Below (<50%),85,43.7,27.150000000000002
NCT03992768,Feature Detection Study for Validation of Hamamatsu NanoZoomer S360MD Digital Slide Scanner System,COMPLETED,NA,540.0,2019-06-12,2021-09-30,19.545303210463732,Good (10-50/month),195.45303210463732,Exceeded (≥100%),100,95.0,96.2
NCT02146768,Low-dose-contrast Cardiac Computed Tomography,COMPLETED,,142.0,2014-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,49.7,47.65
NCT02161068,Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping,COMPLETED,,79.0,2013-12-01,2021-11-01,0.8315214384508991,Slow (<1/month),8.315214384508991,Significantly Below (<50%),100,49.7,47.65
NCT02829268,A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome,COMPLETED,PHASE1,21.0,2017-01-01,2023-02-01,0.2876867686768677,Slow (<1/month),2.876867686768677,Significantly Below (<50%),100,46.7,37.5
NCT01115868,Prevascar in African Continental Group Scarring,UNKNOWN,PHASE1,56.0,2010-04-01,2012-08-01,1.9984056271981243,Adequate (1-10/month),19.984056271981242,Significantly Below (<50%),50,39.5,20.200000000000003
NCT00409968,BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC),COMPLETED,,341.0,2006-11-27,2019-10-31,2.1986951916966744,Adequate (1-10/month),21.986951916966742,Significantly Below (<50%),100,75.6,85.3
NCT06194968,"Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study",RECRUITING,,1800.0,2023-12-30,2026-12-01,51.3514526710403,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,92.85
NCT04272268,Feasibility and Safety of Using Nasal High Flow Oxygen Postoperatively to Reduce Respiratory Complications,WITHDRAWN,,0.0,2019-10-01,2020-03-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.5
NCT05668468,A Bifido Bacteria to Improve Lactose Digestion and Tolerance,UNKNOWN,NA,35.0,2022-05-01,2024-05-01,1.4574555403556773,Adequate (1-10/month),14.574555403556774,Significantly Below (<50%),50,32.8,12.0
NCT00153868,A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer,COMPLETED,PHASE4,43.0,2003-10-01,2007-08-17,0.9243785310734464,Slow (<1/month),9.243785310734463,Significantly Below (<50%),100,48.4,44.2
NCT03835468,The Role of the Microbiota-gut-brain Axis in Brain Development and Mental Health,UNKNOWN,NA,120.0,2019-02-01,2023-03-01,2.4531900604432506,Adequate (1-10/month),24.531900604432508,Significantly Below (<50%),50,44.6,28.549999999999997
NCT00905450,Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery,COMPLETED,PHASE2,415.0,2009-06-01,2010-05-01,37.82215568862276,Good (10-50/month),200.0,Exceeded (≥100%),100,88.2,93.89999999999999
NCT06963450,NeoSCB App for Screening Jaundice in Newborns,RECRUITING,,405.0,2025-09-23,2027-03-31,22.253068592057762,Good (10-50/month),200.0,Exceeded (≥100%),60,73.7,84.3
NCT06173050,PAP Systems Internal Clinical Studies (ICS),NOT_YET_RECRUITING,NA,30.0,2024-10-01,2029-12-01,0.4839427662957075,Slow (<1/month),4.839427662957075,Significantly Below (<50%),30,26.4,7.6
NCT00936650,A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT),COMPLETED,PHASE2,78.0,1999-11-01,2001-06-01,4.107820069204153,Adequate (1-10/month),41.07820069204153,Significantly Below (<50%),100,56.2,63.74999999999999
NCT04415450,Effect of Nutrition Education on Knowledge and Healthy Dietary Practice Among Pregnant Women,COMPLETED,NA,226.0,2018-08-31,2018-09-24,226.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,78.1,86.7
NCT01730950,Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,COMPLETED,PHASE2,182.0,2012-12-20,2022-12-22,1.5161685823754791,Adequate (1-10/month),15.161685823754793,Significantly Below (<50%),100,59.6,70.95
NCT02590250,A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India,COMPLETED,,250.0,2015-12-16,2017-08-07,12.683333333333334,Good (10-50/month),126.83333333333333,Exceeded (≥100%),100,73.3,84.05
NCT05766150,Oral Microbioma and Oral Malignant Disease,UNKNOWN,,300.0,2021-12-01,2024-12-01,8.332116788321168,Adequate (1-10/month),83.32116788321167,Met (75-100%),50,57.3,66.4
NCT01434550,Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer,WITHDRAWN,NA,0.0,2012-03-01,2015-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT07235150,A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults,RECRUITING,PHASE1,76.0,2025-12-11,2027-07-27,3.9012478920741995,Adequate (1-10/month),39.01247892074199,Significantly Below (<50%),60,44.1,27.750000000000004
NCT02261350,Post-hospitalisation Nutritional Support and Gait Speed in COPD,TERMINATED,PHASE3,22.0,2014-01-01,2015-09-01,1.1014473684210526,Adequate (1-10/month),11.014473684210527,Significantly Below (<50%),10,19.8,4.8500000000000005
NCT01533350,Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase,COMPLETED,,28.0,2010-09-01,2012-01-01,1.7501437371663244,Adequate (1-10/month),17.501437371663243,Significantly Below (<50%),100,50.6,48.9
NCT00661050,"Treatment of Interstitial Cystitis/Painful Bladder Syndrome Using Alternative Techniques: Exercise, Meditation, Tai Chi",WITHDRAWN,,0.0,2008-04-01,2008-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.5
NCT04635150,National Evaluation of the Close Collaboration With Parents Training,COMPLETED,NA,768.0,2012-05-30,2018-09-30,10.102817631806396,Good (10-50/month),101.02817631806396,Exceeded (≥100%),100,95.0,96.2
NCT02380950,Effect of Moderate Alcohol Consumption to Cognitive Functioning After Roux-en Y Gastric Bypass,COMPLETED,NA,28.0,2013-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.2,24.7
NCT00778050,Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions,COMPLETED,NA,26.0,2002-10-01,2002-12-01,12.974426229508197,Good (10-50/month),129.74426229508197,Exceeded (≥100%),100,57.1,65.60000000000001
NCT05172050,"Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.",COMPLETED,PHASE2,61.0,2021-01-22,2021-06-12,13.169078014184397,Good (10-50/month),131.69078014184396,Exceeded (≥100%),100,59.9,71.45
NCT07010991,Effectiveness of Artificial Intelligence Based Educational Approach in Developing Clinical Reasoning Skills,RECRUITING,NA,40.0,2025-05-14,2025-09-10,10.231932773109245,Good (10-50/month),102.31932773109244,Exceeded (≥100%),60,46.2,34.4
NCT01069991,Asthma Self-Management For Adolescents,COMPLETED,PHASE2,345.0,2002-01-01,2007-02-01,5.655250403877221,Adequate (1-10/month),56.55250403877221,Below (50-75%),100,77.6,86.45
NCT05231291,"Association Between Handgrip Strength, Skinfold Thickness and Trunk Strength",COMPLETED,,40.0,2021-11-12,2022-01-05,22.54814814814815,Good (10-50/month),200.0,Exceeded (≥100%),100,56.5,64.85
NCT02949791,HIPEC Using High Intra-abdominal Pressure,COMPLETED,PHASE2,38.0,2014-12-01,2017-11-01,1.0851031894934335,Adequate (1-10/month),10.851031894934335,Significantly Below (<50%),100,48.0,42.75
NCT06301191,The Effect of Semaglutide on Cardiovascular Markers and Liver Function,RECRUITING,,50.0,2022-03-01,2024-05-01,1.9217171717171717,Adequate (1-10/month),19.21717171717172,Significantly Below (<50%),60,40.3,21.9
NCT01961791,Lymph Node Staging System With a Novel Concept for Gastric Cancer: a Hybrid Type of Topographic and Numeric Ones,COMPLETED,,6025.0,2000-01-01,2013-09-01,36.73898237179487,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,95.1
NCT06347991,Alberta Chiropractic SelfBack Study,RECRUITING,NA,100.0,2024-05-24,2026-03-15,4.612121212121212,Adequate (1-10/month),46.121212121212125,Significantly Below (<50%),60,46.0,33.2
NCT01071291,Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069),COMPLETED,PHASE1,37.0,2010-02-01,2010-09-01,5.312641509433963,Adequate (1-10/month),53.12641509433963,Below (50-75%),100,53.0,55.50000000000001
NCT06831591,Dubousset Functional Test: An Investigation of Its Validity and Reliability in Children With GMFCS I-II Spastic Cerebral Palsy,COMPLETED,,33.0,2025-01-24,2025-03-01,27.903333333333332,Good (10-50/month),200.0,Exceeded (≥100%),100,56.0,63.3
NCT04930991,High Dose Omeprazole in Patients With Pancreatic Cancer,RECRUITING,EARLY_PHASE1,60.0,2021-09-07,2027-09-01,0.8358810068649887,Slow (<1/month),8.358810068649886,Significantly Below (<50%),60,37.8,17.849999999999998
NCT07029191,Screening for Alterations in the Autonomic Nervous System,COMPLETED,NA,12.0,2025-11-21,2025-12-12,12.0,Good (10-50/month),120.0,Exceeded (≥100%),100,56.0,63.3
NCT02921191,"Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated",COMPLETED,,57725.0,2008-01-01,2019-02-01,433.9711039762904,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT03458091,Evaluation of Lung Atelectasis During Apneic Oxygenation Using THRIVE in Adults During Laryngeal Surgery.,COMPLETED,NA,30.0,2018-01-22,2020-10-10,0.9205645161290322,Slow (<1/month),9.205645161290322,Significantly Below (<50%),100,47.4,40.75
NCT00536991,Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer,TERMINATED,PHASE1,51.0,2006-10-01,2016-10-01,0.4249767314535998,Slow (<1/month),4.249767314535998,Significantly Below (<50%),10,22.1,5.6000000000000005
NCT01088191,Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction,COMPLETED,PHASE1,17.0,2009-03-01,2014-10-01,0.2536666666666667,Slow (<1/month),2.5366666666666666,Significantly Below (<50%),100,46.4,35.5
NCT04585191,Reducing Treatment Risk in Older Adults With Diabetes,COMPLETED,NA,450.0,2020-11-02,2024-09-01,9.791279485346676,Adequate (1-10/month),97.91279485346675,Met (75-100%),100,91.0,94.5
NCT03815591,Implementation and Dissemination of an Evidence-Based Tobacco Product Use Prevention Videogame Intervention With Adolescents,COMPLETED,NA,560.0,2019-02-01,2021-12-31,16.021052631578947,Good (10-50/month),160.21052631578948,Exceeded (≥100%),100,95.0,96.2
NCT00952991,The Effects of LAF237 on Gastric Function in Type 2 Diabetes,COMPLETED,PHASE3,18.0,2005-05-01,2006-02-01,1.9852173913043478,Adequate (1-10/month),19.852173913043476,Significantly Below (<50%),100,51.4,51.2
NCT05622591,ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML,WITHDRAWN,PHASE1,0.0,2024-06-07,2024-06-07,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.15
NCT03729791,The Effect of tDCS on Schizophrenia With Negative Symptoms,UNKNOWN,NA,44.0,2019-12-01,2020-12-01,3.6594535519125686,Adequate (1-10/month),36.594535519125685,Significantly Below (<50%),50,38.5,19.1
NCT06431191,Does Medial Raw Anchor Necessary During Tendon Repair Combined With Microfracture,ENROLLING_BY_INVITATION,NA,50.0,2023-01-01,2026-12-31,1.0424657534246577,Adequate (1-10/month),10.424657534246576,Significantly Below (<50%),55,35.5,15.0
NCT04914091,Quality Of Life and Drug Use in Patients With CAR-T Cells,RECRUITING,,70.0,2021-03-31,2033-01-31,0.49278445883441263,Slow (<1/month),4.927844588344126,Significantly Below (<50%),60,36.9,16.6
NCT04201574,Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease,COMPLETED,PHASE1,138.0,2019-12-16,2020-09-15,15.331094890510949,Good (10-50/month),153.31094890510948,Exceeded (≥100%),100,66.0,78.45
NCT02290574,Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial,TERMINATED,NA,14.0,2014-11-01,2016-03-01,0.8768724279835391,Slow (<1/month),8.768724279835393,Significantly Below (<50%),10,19.1,4.25
NCT07012174,Impact of Body Mass Index and Lipid Metabolism on Anti-PD-1 Immunotherapy Outcomes in Colorectal Cancer,COMPLETED,,142.0,2019-01-01,2025-04-30,1.8703937689311987,Adequate (1-10/month),18.70393768931199,Significantly Below (<50%),100,59.7,71.2
NCT04794374,Effects of Telerehabilitation After Discharge in COVID-19 Survivors,COMPLETED,NA,20.0,2020-11-16,2022-03-31,1.2176,Adequate (1-10/month),12.176,Significantly Below (<50%),100,46.6,36.7
NCT06546774,The Effect of Melatonin Supplementation on Cumulus Cells and IVF Outcomes,RECRUITING,NA,200.0,2021-05-01,2025-12-31,3.5706744868035196,Adequate (1-10/month),35.706744868035194,Significantly Below (<50%),60,54.0,59.0
NCT03840174,Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003),COMPLETED,PHASE1,18.0,2019-03-08,2019-11-07,2.245573770491803,Adequate (1-10/month),22.45573770491803,Significantly Below (<50%),100,51.4,51.2
NCT04728074,Effects of Vocational Rehabilitation Group Intervention on Motivation and Occupational Self-Awareness in Individuals With Intellectual Disabilities,COMPLETED,NA,49.0,2020-02-06,2020-05-12,15.537083333333333,Good (10-50/month),155.37083333333334,Exceeded (≥100%),100,58.9,70.15
NCT00152074,Salt Reduction on Blood Pressure and Cardiovascular Organ Damage,COMPLETED,PHASE3,210.0,2004-04-01,2007-12-01,4.774010455563854,Adequate (1-10/month),47.74010455563854,Significantly Below (<50%),100,66.8,79.25
NCT04106674,Two- Part Proximal Humerus - Conservative vs Operative,RECRUITING,NA,50.0,2020-10-01,2034-10-31,0.295936223993778,Slow (<1/month),2.9593622399377804,Significantly Below (<50%),60,37.0,16.8
NCT02475174,Manual Lymphatic Drainage in the Superior Member in Women in Post-surgery for Breast Cancer,UNKNOWN,NA,30.0,2015-06-01,2016-03-01,3.332846715328467,Adequate (1-10/month),33.32846715328467,Significantly Below (<50%),50,37.4,17.549999999999997
NCT00001574,A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors,COMPLETED,,40.0,1997-03-14,2019-05-06,0.15054401582591492,Slow (<1/month),1.5054401582591495,Significantly Below (<50%),100,46.5,36.05
NCT00665574,ActaVisc and ActaVisc Mx Intra-articular Injection for Pain Associated With Osteoarthritis in the Knee,TERMINATED,NA,23.0,2008-03-01,2009-06-01,1.5319912472647703,Adequate (1-10/month),15.319912472647705,Significantly Below (<50%),10,19.8,4.8500000000000005
NCT00685074,Computer-based Brief Intervention for Perinatal Substance Abuse,COMPLETED,PHASE1,143.0,2007-09-01,2011-03-01,3.4087079091620986,Adequate (1-10/month),34.087079091620986,Significantly Below (<50%),100,61.4,72.75
NCT00392574,Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea,COMPLETED,PHASE3,282.0,2006-08-01,2008-03-01,14.85134948096886,Good (10-50/month),148.5134948096886,Exceeded (≥100%),100,77.6,86.45
NCT05781074,Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）,UNKNOWN,PHASE2,25.0,2023-03-23,2025-12-30,0.751233958538993,Slow (<1/month),7.512339585389931,Significantly Below (<50%),50,32.0,11.0
NCT06427174,Analgesic Efficacy of Us Guided Fascia Iliaca Block Versus Caudal Block in Pediatric Graft Surgeries,NOT_YET_RECRUITING,NA,60.0,2025-03-01,2026-05-01,4.287323943661972,Adequate (1-10/month),42.87323943661972,Significantly Below (<50%),30,33.8,13.100000000000001
NCT06272318,Vital Signs Blood Pressure Trial,NOT_YET_RECRUITING,,50.0,2025-09-01,2026-09-30,3.8629441624365484,Adequate (1-10/month),38.629441624365484,Significantly Below (<50%),30,31.3,9.65
NCT05212818,Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults,TERMINATED,PHASE2,19.0,2022-05-10,2023-03-08,1.9150993377483443,Adequate (1-10/month),19.15099337748344,Significantly Below (<50%),10,24.5,6.6000000000000005
NCT02068118,Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology,COMPLETED,NA,990.0,2013-05-01,2018-09-28,15.250809716599191,Good (10-50/month),152.5080971659919,Exceeded (≥100%),100,95.0,96.2
NCT05855018,A Study of Atropine Sulfate in Healthy Chinese Volunteers,UNKNOWN,PHASE1,30.0,2023-05-09,2023-06-01,30.0,Good (10-50/month),200.0,Exceeded (≥100%),50,42.4,24.9
NCT00073918,"Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",COMPLETED,PHASE2,111.0,1999-02-01,2011-10-02,0.7304020752269781,Slow (<1/month),7.30402075226978,Significantly Below (<50%),100,53.9,58.45
NCT00000818,Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.,COMPLETED,PHASE1,18.0,,,,Slow (<1/month),,Significantly Below (<50%),100,41.4,23.1
NCT02655718,Short and Long Term Outcomes of Acute Coronary Syndrome in Patients With Non Obstructive Coronary Atherosclerosis,UNKNOWN,NA,200.0,2015-10-01,2018-09-01,5.711069418386492,Adequate (1-10/month),57.11069418386492,Below (50-75%),50,51.0,50.2
NCT07149818,A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia,NOT_YET_RECRUITING,,22.0,2025-09-01,2027-01-01,1.3751129363449692,Adequate (1-10/month),13.751129363449694,Significantly Below (<50%),30,24.1,6.1
NCT00001890,Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections,COMPLETED,PHASE2,80.0,1999-05-01,2001-03-01,3.6346268656716423,Adequate (1-10/month),36.34626865671642,Significantly Below (<50%),100,56.4,64.4
NCT06135090,Testing a Peer-led Trauma-focused Intervention for Significant Others of Those With BPD,UNKNOWN,PHASE1,60.0,2024-02-01,2026-01-01,2.609142857142857,Adequate (1-10/month),26.091428571428573,Significantly Below (<50%),50,39.8,20.8
NCT04478890,Hemodynamic Assessment of the Right Ventricle Using Pressure-volume Loop Catheter and Pulmonary Artery Catheter in Patients Undergoing Left Ventricular Assist Device Placement,COMPLETED,,4.0,2021-08-01,2024-12-31,0.09756410256410257,Slow (<1/month),0.9756410256410256,Significantly Below (<50%),100,43.7,27.150000000000002
NCT06413290,Doppler Evaluation of Ultrasound-guided Pectointercostal Fascial Plane Block in Cardiac Surgery,COMPLETED,,40.0,2024-05-15,2025-12-30,2.04983164983165,Adequate (1-10/month),20.4983164983165,Significantly Below (<50%),100,51.5,51.5
NCT00370890,A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy,COMPLETED,PHASE3,104.0,2006-09-04,2021-10-26,0.572366660640029,Slow (<1/month),5.72366660640029,Significantly Below (<50%),100,53.3,56.8
NCT03147690,Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Injuries in Children,TERMINATED,PHASE1,74.0,2017-11-01,2019-10-07,3.1951205673758865,Adequate (1-10/month),31.951205673758864,Significantly Below (<50%),10,28.9,8.4
NCT01808690,EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes,COMPLETED,PHASE3,52.0,2013-03-01,2016-12-02,1.1537026239067056,Adequate (1-10/month),11.537026239067057,Significantly Below (<50%),100,49.2,46.650000000000006
NCT03427190,Suicide Prevention Algorithm in the French Overseas Territories,COMPLETED,NA,259.0,2017-10-09,2020-10-16,7.1477425203989124,Adequate (1-10/month),71.47742520398913,Below (50-75%),100,70.7,82.39999999999999
NCT00626990,Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH),ACTIVE_NOT_RECRUITING,PHASE3,751.0,2007-12-01,2029-12-01,2.844753608760578,Adequate (1-10/month),28.44753608760578,Significantly Below (<50%),85,85.5,92.45
NCT03966690,Rate of Leg Curl to Leg Press During Isokinetic Testing,COMPLETED,NA,28.0,2018-08-15,2019-05-15,3.1220512820512822,Adequate (1-10/month),31.220512820512823,Significantly Below (<50%),100,52.2,53.400000000000006
NCT06038890,"The Learning Curve of Transurethral Holmium Laser Enucleation of the Prostate, Prospective Assessment",UNKNOWN,NA,200.0,2023-08-01,2025-12-01,7.137162954279016,Adequate (1-10/month),71.37162954279016,Below (50-75%),50,51.0,50.2
NCT07299890,An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer,NOT_YET_RECRUITING,PHASE2,90.0,2025-12-20,2027-11-01,4.022907488986784,Adequate (1-10/month),40.22907488986784,Significantly Below (<50%),30,36.2,15.65
NCT01963390,Metabolomics During Testosterone Therapy,COMPLETED,,60.0,2012-07-01,2017-12-01,0.9228903486609399,Slow (<1/month),9.228903486609399,Significantly Below (<50%),100,48.1,43.2
NCT01596790,COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer,COMPLETED,NA,168.0,2012-04-01,2019-09-01,1.887751937984496,Adequate (1-10/month),18.877519379844962,Significantly Below (<50%),100,63.4,75.75
NCT04350190,Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma,COMPLETED,PHASE2,25.0,2021-01-14,2022-09-15,1.2495894909688012,Adequate (1-10/month),12.495894909688012,Significantly Below (<50%),100,47.0,39.1
NCT03142490,Acupuncture as a Complementary Therapy for in Vitro Fertilization Patients: a Randomized Controlled Trial,UNKNOWN,NA,100.0,2016-12-01,2018-12-31,4.005263157894737,Adequate (1-10/month),40.05263157894737,Significantly Below (<50%),50,43.0,25.7
NCT07279090,Spatiotemporal Single-cell Atlas of Peri-implant Soft Tissue Healing,NOT_YET_RECRUITING,NA,5.0,2025-12-20,2026-12-31,0.4047872340425532,Slow (<1/month),4.047872340425532,Significantly Below (<50%),30,24.4,6.5
NCT01669590,Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle,COMPLETED,,28.0,2011-12-01,2016-09-01,0.49096774193548387,Slow (<1/month),4.909677419354838,Significantly Below (<50%),100,45.6,31.0
NCT04233190,"A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment",COMPLETED,PHASE3,472.0,2023-04-19,2024-10-30,25.65657142857143,Good (10-50/month),200.0,Exceeded (≥100%),100,92.8,94.8
NCT06322290,Epidemiological Study on Invasive Bacterial Diseases,RECRUITING,,5000.0,2021-12-09,2032-03-30,40.435706695005315,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,89.64999999999999
NCT03018990,Alcohol Challenge On Liver and Gut Measured by Liver Vein Catheterization. A Pathophysiological Intervention Trial,UNKNOWN,NA,40.0,2016-11-09,2024-12-01,0.41358695652173916,Slow (<1/month),4.135869565217392,Significantly Below (<50%),50,33.2,12.35
NCT04625790,Speech Therapy and Repetitive Transcranial Magnetic Stimulation Therapy in Post-stroke Anomic Aphasia,COMPLETED,NA,25.0,2020-11-06,2021-11-06,2.0849315068493155,Adequate (1-10/month),20.84931506849315,Significantly Below (<50%),100,52.0,53.1
NCT01815190,IgA-positive Versus IgA-negative Immune Complex Vasculitis,UNKNOWN,,300.0,2011-01-01,2016-12-01,4.225821378991208,Adequate (1-10/month),42.25821378991208,Significantly Below (<50%),50,57.3,66.4
NCT06916897,A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers,COMPLETED,PHASE1,42.0,2025-01-08,2025-02-22,28.410666666666668,Good (10-50/month),200.0,Exceeded (≥100%),100,58.4,69.39999999999999
NCT04909697,Treatment of ARDS With Sivelestat Sodium,RECRUITING,PHASE4,324.0,2022-04-18,2026-03-30,6.839500693481276,Adequate (1-10/month),68.39500693481277,Below (50-75%),60,63.9,76.14999999999999
NCT05927597,"A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants",COMPLETED,PHASE1,82.0,2019-01-09,2019-08-01,12.235686274509805,Good (10-50/month),122.35686274509806,Exceeded (≥100%),100,61.6,73.1
NCT04145297,Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas,COMPLETED,PHASE1,16.0,2020-03-17,2022-08-18,0.550950226244344,Slow (<1/month),5.50950226244344,Significantly Below (<50%),100,46.3,34.949999999999996
NCT06331897,Bronchial Asthma & Its Exacerbation,NOT_YET_RECRUITING,,50.0,2025-01-01,2026-06-01,2.949612403100775,Adequate (1-10/month),29.496124031007753,Significantly Below (<50%),30,31.3,9.65
NCT07247097,ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma,NOT_YET_RECRUITING,PHASE2,160.0,2026-04-15,2035-12-01,1.3848166050611317,Adequate (1-10/month),13.848166050611315,Significantly Below (<50%),30,36.8,16.5
NCT04719897,Life Experiences in Adolescents and the Development of Skills,COMPLETED,NA,88.0,2021-05-19,2025-10-10,1.6689844236760125,Adequate (1-10/month),16.689844236760127,Significantly Below (<50%),100,57.0,65.5
NCT07054697,Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder,COMPLETED,PHASE4,54.0,2017-01-01,2025-01-15,0.5598637602179837,Slow (<1/month),5.598637602179837,Significantly Below (<50%),100,49.3,46.9
NCT04870697,Acceptance and Commitment Therapy for Parents of Children With Cancer,UNKNOWN,NA,142.0,2021-06-28,2022-01-01,23.11486631016043,Good (10-50/month),200.0,Exceeded (≥100%),50,51.4,51.2
NCT06402097,TRIP-patch vs Duplex,COMPLETED,,20.0,2020-06-05,2020-09-25,5.435714285714286,Adequate (1-10/month),54.35714285714286,Below (50-75%),100,49.9,47.9
NCT03427697,Effect of VR and Accommdation Relax on Controlling Myopia in Children,UNKNOWN,NA,1000.0,2020-09-18,2022-12-31,36.49880095923261,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,88.64999999999999
NCT01560897,"Investigating Project of the Functional C13 Test ""Pilot Study""",UNKNOWN,PHASE1,10.0,2012-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.8,7.3999999999999995
NCT06379997,Oral Supplementation Compared With Hyaluronic Acid Infiltration in Rotator Cuff Tendinopathies,RECRUITING,NA,50.0,2024-08-10,2025-12-31,2.9960629921259843,Adequate (1-10/month),29.96062992125984,Significantly Below (<50%),60,42.0,24.05
NCT02303197,Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis,COMPLETED,PHASE3,70.0,2014-05-01,2015-12-01,3.6801381692573405,Adequate (1-10/month),36.8013816925734,Significantly Below (<50%),100,55.6,62.74999999999999
NCT06491797,"Booster of the ""More Time for Patients"" Program",NOT_YET_RECRUITING,NA,764.0,2024-08-01,2025-10-01,54.59192488262911,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,87.35000000000001
NCT03015597,Pilot Study of Contingency Management for Smoking Cessation,COMPLETED,NA,40.0,2016-10-01,2017-09-01,3.6346268656716423,Adequate (1-10/month),36.34626865671642,Significantly Below (<50%),100,53.2,56.10000000000001
NCT00566397,A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease,COMPLETED,PHASE2,402.0,2007-12-01,2010-12-01,11.165036496350364,Good (10-50/month),111.65036496350365,Exceeded (≥100%),100,87.2,93.35
NCT01365897,Effectiveness of Modafinil in Improving Cognitive Performance of University Students,COMPLETED,PHASE4,128.0,2010-09-01,2011-01-01,31.937049180327868,Good (10-50/month),200.0,Exceeded (≥100%),100,65.2,77.5
NCT03090997,Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women,UNKNOWN,NA,45.0,2018-02-15,2022-02-28,0.9293080054274084,Slow (<1/month),9.293080054274084,Significantly Below (<50%),50,33.6,12.9
NCT01234597,Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day,COMPLETED,PHASE4,219.0,2012-12-01,2015-04-01,7.833560517038778,Adequate (1-10/month),78.33560517038778,Met (75-100%),100,67.5,80.10000000000001
NCT01256697,The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa,COMPLETED,NA,34.0,2008-08-01,2011-01-01,1.1720951302378257,Adequate (1-10/month),11.720951302378255,Significantly Below (<50%),100,47.7,42.3
NCT05623397,A Deep Learning Method to Evaluate QT on Ribociclib,COMPLETED,,70.0,2023-07-28,2025-10-08,2.653549190535492,Adequate (1-10/month),26.535491905354924,Significantly Below (<50%),100,53.9,58.45
NCT02656797,Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis,COMPLETED,PHASE2,13.0,2018-01-30,2021-10-01,0.2953134328358209,Slow (<1/month),2.953134328358209,Significantly Below (<50%),100,46.0,33.2
NCT07183397,Impact of Fluid Resuscitation on Venous Congestion in Cardiac Critically-ill Patients,NOT_YET_RECRUITING,,250.0,2025-09-15,2027-12-01,9.429987608426272,Adequate (1-10/month),94.2998760842627,Met (75-100%),30,52.3,53.6
NCT05128097,Preventive Approach for the Management of the Main Geriatric Risks,UNKNOWN,,107.0,2020-06-01,2021-12-31,5.635086505190312,Adequate (1-10/month),56.35086505190312,Below (50-75%),50,41.9,23.799999999999997
NCT03666897,Markers of Recovery in StrokE Study (MORSE),COMPLETED,NA,21.0,2018-10-01,2022-04-01,0.5001877934272301,Slow (<1/month),5.001877934272301,Significantly Below (<50%),100,46.7,37.5
NCT05377697,The Effect of Lavender Scent on Sleep,COMPLETED,NA,90.0,2022-04-23,2023-09-15,5.371764705882353,Adequate (1-10/month),53.71764705882352,Below (50-75%),100,57.2,65.9
NCT00375297,Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women,COMPLETED,PHASE4,100.0,2001-01-01,2005-06-01,1.8883374689826302,Adequate (1-10/month),18.8833746898263,Significantly Below (<50%),100,58.0,68.30000000000001
NCT04249297,Predictors of Pregnancy Rate in Assisted Reproductive Technology According to Actual Guidelines,UNKNOWN,,1150.0,2020-03-03,2022-12-01,34.901296111665005,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,87.0
NCT04192097,Impact of a Curriculum About Professionalism on Stress Response During a Critical Situation,COMPLETED,NA,20.0,2019-12-15,2021-03-01,1.3773755656108597,Adequate (1-10/month),13.7737556561086,Significantly Below (<50%),100,46.6,36.7
NCT01772797,Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,COMPLETED,PHASE1,22.0,2013-06-01,2016-01-01,0.709406779661017,Slow (<1/month),7.094067796610171,Significantly Below (<50%),100,46.8,38.05
NCT06031597,Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy,UNKNOWN,PHASE3,105.0,2023-09-15,2025-12-31,3.8140811455847254,Adequate (1-10/month),38.14081145584725,Significantly Below (<50%),50,43.4,26.8
NCT00800397,Evaluation of the Noga System: Detecting of Respiratory Related Sleep Disorders in Cardiac Patients,COMPLETED,,80.0,2007-12-01,2008-12-01,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),100,54.7,60.699999999999996
NCT05681897,Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia,UNKNOWN,NA,30.0,2023-02-01,2023-02-01,30.0,Good (10-50/month),200.0,Exceeded (≥100%),50,27.4,8.05
NCT05789797,Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy,COMPLETED,,368.0,2022-05-12,2024-12-16,11.803919915700739,Good (10-50/month),118.03919915700737,Exceeded (≥100%),100,82.8,90.4
NCT02660697,3D Radiographic Evaluation of a Novel Implant Site Development Technique,COMPLETED,PHASE4,43.0,2007-12-01,2014-12-01,0.5118967540086039,Slow (<1/month),5.1189675400860395,Significantly Below (<50%),100,48.4,44.2
NCT01373697,Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel,UNKNOWN,PHASE3,144.0,2011-06-01,2011-08-01,71.8583606557377,Excellent (>50/month),200.0,Exceeded (≥100%),50,56.5,64.85
NCT00776997,LINX Reflux Management System Clinical Study Protocol,COMPLETED,NA,100.0,2008-11-01,2011-09-01,2.9439071566731143,Adequate (1-10/month),29.439071566731144,Significantly Below (<50%),100,58.0,68.30000000000001
NCT04890197,Tahini and Dermatitis in Breast Cancer,UNKNOWN,NA,50.0,2021-05-08,2021-07-15,22.38235294117647,Good (10-50/month),200.0,Exceeded (≥100%),50,44.0,27.450000000000003
NCT00679497,A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection,COMPLETED,PHASE1,30.0,2008-06-01,2010-12-01,1.0002190580503834,Adequate (1-10/month),10.002190580503836,Significantly Below (<50%),100,47.4,40.75
NCT00006110,"Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer",COMPLETED,PHASE2,82.0,1998-12-01,2013-04-01,0.47680611270296086,Slow (<1/month),4.7680611270296085,Significantly Below (<50%),100,51.6,51.949999999999996
NCT00539110,Differential Effects of Zolpidem Versus Ramelteon in Burned Children,COMPLETED,PHASE2,10.0,2009-12-01,2013-11-01,0.2127183787561146,Slow (<1/month),2.127183787561146,Significantly Below (<50%),100,45.8,31.900000000000002
NCT01291810,Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients,COMPLETED,PHASE2,66.0,2011-02-01,2014-05-01,1.6953924050632911,Adequate (1-10/month),16.953924050632914,Significantly Below (<50%),100,55.3,62.35000000000001
NCT07206810,"A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients",COMPLETED,,419.0,2018-08-01,2025-02-01,5.3679966329966335,Adequate (1-10/month),53.679966329966334,Below (50-75%),100,81.9,89.9
NCT06793410,Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation,RECRUITING,PHASE2,100.0,2025-05-12,2029-10-31,1.8640538885486835,Adequate (1-10/month),18.640538885486837,Significantly Below (<50%),60,46.0,33.2
NCT03700710,Remote Dietary Counseling to Promote Healthy Diet and Blood Pressure,COMPLETED,NA,187.0,2019-01-16,2021-06-30,6.352991071428572,Adequate (1-10/month),63.529910714285705,Below (50-75%),100,65.0,77.35
NCT00601510,"Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer",COMPLETED,PHASE1,38.0,2007-11-01,2012-01-01,0.76,Slow (<1/month),7.6,Significantly Below (<50%),100,48.0,42.75
NCT06718010,The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer,RECRUITING,,120.0,2024-12-05,2026-03-31,7.594178794178794,Adequate (1-10/month),75.94178794178794,Met (75-100%),60,45.9,32.4
NCT05670210,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.1
NCT00372710,Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions,TERMINATED,PHASE3,30.0,2002-08-01,,,Slow (<1/month),,Significantly Below (<50%),10,15.4,2.5
NCT01542710,Bimatoprost/Timolol Versus Travoprost/Timolol,COMPLETED,NA,80.0,2011-01-01,2011-12-01,7.291017964071856,Adequate (1-10/month),72.91017964071857,Below (50-75%),100,56.4,64.4
NCT00002810,High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis,COMPLETED,PHASE2,,1996-05-01,2006-05-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,29.65
NCT00752310,TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet,COMPLETED,PHASE1,23.0,2008-04-01,2008-08-01,5.738688524590164,Adequate (1-10/month),57.38688524590163,Below (50-75%),100,51.8,52.449999999999996
NCT00994110,"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",COMPLETED,PHASE3,439.0,2009-10-01,2014-09-01,7.440512249443207,Adequate (1-10/month),74.40512249443208,Below (50-75%),100,85.1,92.2
NCT07169110,Study of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants,NOT_YET_RECRUITING,,35.0,2025-12-22,2026-12-30,2.856300268096515,Adequate (1-10/month),28.56300268096515,Significantly Below (<50%),30,30.1,8.9
NCT03964610,Multimodal Retinal Imaging of Cerebrovascular Stroke,COMPLETED,,62.0,2019-11-15,2022-02-15,2.2931713244228433,Adequate (1-10/month),22.931713244228433,Significantly Below (<50%),100,53.3,56.8
NCT00584610,The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots,UNKNOWN,NA,50.0,2007-12-01,2012-07-01,0.9091995221027479,Slow (<1/month),9.091995221027478,Significantly Below (<50%),50,34.0,13.3
NCT01778010,Modafinil for Smoked Cocaine Self-Administration,COMPLETED,PHASE2,8.0,2009-03-01,2013-06-01,0.15680618158403092,Slow (<1/month),1.5680618158403092,Significantly Below (<50%),100,45.6,31.0
NCT03348410,Joint Coordination to Facilitate the Transition From Sick Leave to Employment,COMPLETED,NA,193.0,2017-11-14,2019-12-14,7.730157894736842,Adequate (1-10/month),77.30157894736843,Met (75-100%),100,65.4,77.75
NCT07083310,"The Effect of Health Education Conducted Using Two Different Methods on Women's Knowledge of Breast Cancer, Health Beliefs, Mammography Self-Efficacy, and Participation in Screening Programs",NOT_YET_RECRUITING,NA,78.0,2025-07-01,2025-10-01,25.807826086956524,Good (10-50/month),200.0,Exceeded (≥100%),30,40.2,21.65
NCT02200510,Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease,COMPLETED,NA,78.0,2011-06-01,2015-08-01,1.56,Adequate (1-10/month),15.6,Significantly Below (<50%),100,51.2,50.849999999999994
NCT00992810,Medial Versus Lateral Approach in Ultrasound (US)-Guided Supraclavicular Block,COMPLETED,NA,78.0,2009-08-01,2010-09-01,5.995757575757576,Adequate (1-10/month),59.95757575757575,Below (50-75%),100,56.2,63.74999999999999
NCT02251210,Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis,COMPLETED,PHASE2,404.0,2001-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,72.3,83.5
NCT04920513,Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.,COMPLETED,,3000.0,2021-05-01,2025-02-01,66.5597667638484,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT03773913,Integrated Community Based Health Systems Strengthening Preliminary Study in Kozah Togo,UNKNOWN,,1500.0,2015-01-01,2021-08-31,18.75924404272802,Good (10-50/month),187.5924404272802,Exceeded (≥100%),50,78.3,87.0
NCT05298813,Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness,COMPLETED,PHASE1,162.0,2021-09-29,2023-01-04,10.673766233766234,Good (10-50/month),106.73766233766233,Exceeded (≥100%),100,68.0,80.5
NCT03838913,Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB),UNKNOWN,,60.0,2019-02-15,2019-12-31,5.725391849529781,Adequate (1-10/month),57.2539184952978,Below (50-75%),50,38.1,18.6
NCT01064713,Phase II Study of Tesetaxel in Metastatic Melanoma,COMPLETED,PHASE2,17.0,2010-02-01,2014-10-01,0.3038637698179683,Slow (<1/month),3.0386376981796825,Significantly Below (<50%),100,46.4,35.5
NCT05157113,"Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population",RECRUITING,PHASE4,70.0,2022-05-31,2026-06-01,1.4574555403556773,Adequate (1-10/month),14.574555403556774,Significantly Below (<50%),60,38.6,19.400000000000002
NCT03874013,Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency,COMPLETED,PHASE3,44.0,2017-12-07,2020-03-06,1.6333658536585367,Adequate (1-10/month),16.333658536585364,Significantly Below (<50%),100,48.5,44.6
NCT03309813,Feasibility Study of ExAblate Thalamotomy for Treatment of Chronic Trigeminal Neuropathic Pain,UNKNOWN,NA,10.0,2017-12-01,2023-10-01,0.14291079812206572,Slow (<1/month),1.4291079812206575,Significantly Below (<50%),50,30.8,9.25
NCT04295213,The Inside Study II: Oligosaccharides Versus Placebo and Hard Stools,UNKNOWN,NA,196.0,2021-04-28,2023-09-01,6.9699065420560755,Adequate (1-10/month),69.69906542056074,Below (50-75%),50,50.7,49.15
NCT01333813,Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children,COMPLETED,PHASE4,300.0,2011-04-26,2011-09-28,58.91612903225806,Excellent (>50/month),200.0,Exceeded (≥100%),100,84.0,91.64999999999999
NCT02809313,Clinical and Microbiological Effects of Lactobacillus Rhamnosus in Treatment of Gingivitis,UNKNOWN,PHASE2,36.0,2016-03-01,2016-11-01,4.472816326530612,Adequate (1-10/month),44.72816326530612,Significantly Below (<50%),50,37.9,18.05
NCT03354013,Genetic Screening and Assisted Oocyte Activation in Couples with Diminished/aberrant Embryonic Development.,COMPLETED,NA,42.0,2018-01-15,2022-09-09,0.7529328621908127,Slow (<1/month),7.529328621908128,Significantly Below (<50%),100,48.4,44.2
NCT01609413,The COMparison of CALcium Bioavailability Between AlgaeCal® and a Proprietary Supplement,COMPLETED,PHASE1,20.0,2009-10-01,2010-04-01,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),100,51.6,51.949999999999996
NCT02570113,The Peregrine Post-Market Study for the Treatment of Hypertension,COMPLETED,NA,45.0,2015-11-01,2019-07-01,1.0237668161434976,Adequate (1-10/month),10.237668161434978,Significantly Below (<50%),100,48.6,45.1
NCT03204513,Impact of Powered Knee-Ankle Prosthesis Leg on Everyday Community Mobility and Social Interaction,ACTIVE_NOT_RECRUITING,NA,15.0,2016-12-01,2025-12-01,0.13891086096744754,Slow (<1/month),1.3891086096744754,Significantly Below (<50%),85,41.7,23.599999999999998
NCT03335813,Endoesophageal Brachytherapy for Patients With Esophageal Cancer,COMPLETED,NA,7.0,2018-03-06,2020-12-08,0.21138888888888888,Slow (<1/month),2.113888888888889,Significantly Below (<50%),100,45.6,31.0
NCT00397813,Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders,COMPLETED,PHASE2,77.0,2006-01-01,2018-03-01,0.5276632147681225,Slow (<1/month),5.276632147681225,Significantly Below (<50%),100,51.2,50.849999999999994
NCT05939960,Application of a New Type of Whole Blood Coagulation Time Measurement in Evaluating the Hypercoagulable State of Malignant Tumors,UNKNOWN,,354.0,2023-07-01,2024-09-30,23.579343544857768,Good (10-50/month),200.0,Exceeded (≥100%),50,66.7,79.10000000000001
NCT07069660,Compass 3: A Novel Transition Program to Reduce Disability After Stroke,RECRUITING,NA,520.0,2025-09-29,2030-03-01,9.807187112763321,Adequate (1-10/month),98.07187112763323,Met (75-100%),60,83.0,90.64999999999999
NCT04552860,vEAET for Older Veterans With Chronic Musculoskeletal Pain Pilot,COMPLETED,NA,16.0,2020-08-15,2021-08-16,1.3307103825136612,Adequate (1-10/month),13.307103825136613,Significantly Below (<50%),100,46.3,34.949999999999996
NCT01691560,Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity,COMPLETED,PHASE2,140.0,2012-08-01,2012-11-01,46.321739130434786,Good (10-50/month),200.0,Exceeded (≥100%),100,71.2,82.5
NCT05400460,Prognosis Study of Different Anterior Cruciate Ligament Surgery Methods,COMPLETED,NA,406.0,2016-06-01,2021-01-17,7.308480189237138,Adequate (1-10/month),73.08480189237137,Below (50-75%),100,82.5,90.3
NCT00427960,Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg,TERMINATED,PHASE4,55.0,2006-12-01,2008-02-01,3.9208430913348944,Adequate (1-10/month),39.20843091334895,Significantly Below (<50%),10,27.4,8.05
NCT04073160,TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer,WITHDRAWN,PHASE1,0.0,2020-06-01,2026-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT03272360,Endometriosis Biomarker Discovery Study,WITHDRAWN,,0.0,2016-09-01,2017-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.5
NCT04308460,Arthrocentesis Versus Operative Arthroscopy Treatment of TMJ Internal Derangement (TMJ),COMPLETED,NA,40.0,2017-01-10,2019-12-16,1.137943925233645,Adequate (1-10/month),11.379439252336448,Significantly Below (<50%),100,48.2,43.6
NCT06246760,"Differences in Ventilatory Function, Body Composition, and Cardiorrespiratory Fitness According to Training Status",RECRUITING,NA,1272.0,2000-01-01,2030-01-01,3.533462310640628,Adequate (1-10/month),35.33462310640628,Significantly Below (<50%),60,78.0,86.6
NCT00251160,Electrothermal Arthroscopic Capsulorrhaphy (ETAC) and Open Inferior Capsular Shift in Patients With Shoulder Instability,COMPLETED,NA,58.0,1999-12-01,2010-02-01,0.4752409152086137,Slow (<1/month),4.752409152086138,Significantly Below (<50%),100,49.6,47.4
NCT03833960,SLNB After Neoadjuvant Treatment in Node Positive Patients,COMPLETED,,65.0,2016-05-01,2019-06-01,1.7571936056838366,Adequate (1-10/month),17.571936056838368,Significantly Below (<50%),100,53.5,57.550000000000004
NCT02975960,ADMSCs for the Treatment of Systemic Sclerosis,COMPLETED,NA,7.0,2016-10-25,2018-01-20,0.47141592920353986,Slow (<1/month),4.714159292035399,Significantly Below (<50%),100,45.6,31.0
NCT06825260,PEG3350 vs Senna After Urogyn Surgery,RECRUITING,PHASE4,254.0,2025-04-23,2027-07-01,9.676795994993743,Adequate (1-10/month),96.76795994993745,Met (75-100%),60,63.3,75.55
NCT00548860,Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients,COMPLETED,PHASE3,2018.0,2007-10-01,2009-07-01,96.13133020344289,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT04766060,Indocyanine Green Fluorescent Imaging in Robotic Assisted Rectosigmoidal Resection; a Multicenter Assessment of Interobserver Variation and Comparison With Computer-based Pixel Analysis,COMPLETED,,55.0,2017-04-01,2018-11-30,2.7536184210526318,Adequate (1-10/month),27.536184210526315,Significantly Below (<50%),100,52.7,54.85
NCT02357160,The Value of Integrating Visual Arts: Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing,COMPLETED,NA,184.0,2014-11-01,2016-08-01,8.765195618153365,Adequate (1-10/month),87.65195618153365,Met (75-100%),100,69.7,81.6
NCT00213460,Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up,COMPLETED,,,2001-08-01,2003-07-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,26.450000000000003
NCT03194360,Risk Factors of Delirium in Sequential Sedation Patients in Intensive Care Unit,COMPLETED,,141.0,2015-12-01,2017-01-15,10.442919708029196,Good (10-50/month),104.42919708029197,Exceeded (≥100%),100,64.6,76.85
NCT03765060,The Efficacy and Security of the Small Stitch Technique in Emergency Surgery,UNKNOWN,NA,105.0,2018-10-01,2021-12-01,2.7624891961970612,Adequate (1-10/month),27.624891961970615,Significantly Below (<50%),50,43.4,26.8
NCT07237360,Impact of Prevention of Safe Sleeping and Unexpected Infant Death,NOT_YET_RECRUITING,,100.0,2025-11-30,2026-06-30,14.358490566037737,Good (10-50/month),143.58490566037736,Exceeded (≥100%),30,40.3,21.9
NCT03325660,Whole Body Vibration and Pelvic Floor Exercises on Urinary Incontinence,COMPLETED,NA,61.0,2016-07-03,2017-10-27,3.8603742203742204,Adequate (1-10/month),38.6037422037422,Significantly Below (<50%),100,54.9,61.6
NCT01895660,Children With Hemiparesis Arm and Hand Movement Project (CHAMP Study),COMPLETED,PHASE2,124.0,2013-07-01,2019-12-01,1.610307167235495,Adequate (1-10/month),16.10307167235495,Significantly Below (<50%),100,54.9,61.6
NCT01668160,Stability of Revision Total Hip Arthroplasty Implants Using Radiostereometric Analysis,WITHDRAWN,NA,0.0,2012-02-01,2020-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT04100460,A Double Blind Study on the Gastrointestinal Effects of Arabinoxylan (Leaf Fiber Extract).,UNKNOWN,NA,45.0,2019-09-01,2020-05-01,5.637037037037038,Adequate (1-10/month),56.37037037037038,Below (50-75%),50,38.6,19.400000000000002
NCT02163460,Repair of Large Incisional Hernias - To Drain or Not to Drain Randomised Clinical Trial,COMPLETED,PHASE2,42.0,2012-05-01,2014-01-01,2.0958688524590166,Adequate (1-10/month),20.958688524590166,Significantly Below (<50%),100,53.4,57.25
NCT06517160,Comparison of MedBook Portal and Usual Care in Medication Reconciliation at Primary Healthcare Upon Hospital Discharge,COMPLETED,NA,398.0,2023-05-02,2024-07-24,26.982449888641426,Good (10-50/month),200.0,Exceeded (≥100%),100,86.8,93.10000000000001
NCT06930560,HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms,RECRUITING,NA,300.0,2025-10-15,2027-12-31,11.315985130111525,Good (10-50/month),113.15985130111525,Exceeded (≥100%),60,67.0,79.60000000000001
NCT02283060,Sleep and Cognition After Atripla to Stribild Switch,UNKNOWN,PHASE4,30.0,2014-09-01,2016-08-01,1.3045714285714285,Adequate (1-10/month),13.045714285714286,Significantly Below (<50%),50,32.4,11.65
NCT05104060,The Effects of Manual Therapy and Scapular Exercise for the Pectoralis Minor in Individuals With Shoulder Pain,COMPLETED,NA,100.0,2021-11-17,2023-03-22,6.212244897959184,Adequate (1-10/month),62.12244897959184,Below (50-75%),100,58.0,68.30000000000001
NCT03427060,Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms,COMPLETED,PHASE2,1.0,2018-05-14,2021-02-03,0.030562248995983938,Slow (<1/month),0.3056224899598393,Significantly Below (<50%),100,45.1,30.049999999999997
NCT07271160,The Effect of Aromatherapy Foot Massage on Neuropathic Pain in Patients With Type2 Diabetes,NOT_YET_RECRUITING,NA,78.0,2025-12-01,2026-05-15,14.389818181818182,Good (10-50/month),143.89818181818183,Exceeded (≥100%),30,40.2,21.65
NCT03523260,Comparison of High-Flow Hemodialysis Catheters Placed From the Left Internal Jugular Vein(R12-022),WITHDRAWN,NA,0.0,2013-08-27,2020-01-22,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT04659460,RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study,UNKNOWN,NA,30.0,2020-12-15,2021-09-01,3.5123076923076924,Adequate (1-10/month),35.123076923076916,Significantly Below (<50%),50,37.4,17.549999999999997
NCT04482660,Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population,ENROLLING_BY_INVITATION,NA,100.0,2021-03-29,2025-12-31,1.7514384349827388,Adequate (1-10/month),17.514384349827385,Significantly Below (<50%),55,44.5,28.249999999999996
NCT00003720,SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma,COMPLETED,PHASE1,,1998-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.3
NCT03533920,Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma,COMPLETED,NA,62.0,2017-10-25,2018-09-03,6.02964856230032,Adequate (1-10/month),60.29648562300319,Below (50-75%),100,55.0,61.9
NCT04698720,Contribution of Psychological Factors in the Healing of the Diabetic Foot Ulcer,COMPLETED,NA,69.0,2019-02-01,2022-07-25,1.6538267716535433,Adequate (1-10/month),16.538267716535433,Significantly Below (<50%),100,50.5,48.75
NCT04163120,Effects of a Ketogenic Diet on PCOS Outcomes,COMPLETED,NA,14.0,2017-01-01,2017-05-01,3.5513333333333335,Adequate (1-10/month),35.513333333333335,Significantly Below (<50%),100,51.1,50.64999999999999
NCT03418220,Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD),COMPLETED,NA,82.0,2017-11-22,2020-09-08,2.4447404505386876,Adequate (1-10/month),24.447404505386878,Significantly Below (<50%),100,56.6,65.14999999999999
NCT06660420,Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel),RECRUITING,PHASE1,39.0,2025-02-25,2031-12-31,0.474864,Slow (<1/month),4.74864,Significantly Below (<50%),60,36.1,15.5
NCT00961220,O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma,COMPLETED,PHASE1,17.0,2010-02-01,2014-04-08,0.3388867059593975,Slow (<1/month),3.3888670595939754,Significantly Below (<50%),100,46.4,35.5
NCT02729220,Respiratory and Cardiovascular Effects in COPD,COMPLETED,NA,52.0,2012-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,44.2,28.000000000000004
NCT00501020,Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin,COMPLETED,PHASE4,750.0,2001-06-05,2003-02-13,36.94174757281554,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT06183320,Can Flowable Bulk Fill Composites be Used in Proximal Area of Class II Restorations,ACTIVE_NOT_RECRUITING,NA,38.0,2019-08-05,2026-12-30,0.4277810650887574,Slow (<1/month),4.277810650887575,Significantly Below (<50%),85,43.5,27.0
NCT03367520,"Helping Veterans With SMI ""StayQuit"" From Smoking After Inpatient Hospitalization",COMPLETED,NA,29.0,2017-06-07,2018-12-31,1.5432867132867132,Adequate (1-10/month),15.43286713286713,Significantly Below (<50%),100,47.3,40.2
NCT02505620,Neurocognitive Function After Therapy of OSAS,COMPLETED,,80.0,2014-09-01,2016-09-01,3.331326949384405,Adequate (1-10/month),33.31326949384405,Significantly Below (<50%),100,54.7,60.699999999999996
NCT01958320,Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus,COMPLETED,PHASE2,202.0,2013-12-01,2017-06-01,4.811330203442879,Adequate (1-10/month),48.1133020344288,Significantly Below (<50%),100,66.2,78.7
NCT03806920,Isomaltulose VS Sucrose - Postprandial Effect on Incretin Profile and Second Meal Effect,COMPLETED,NA,50.0,2016-11-05,2019-07-30,1.5265797392176528,Adequate (1-10/month),15.26579739217653,Significantly Below (<50%),100,49.0,46.050000000000004
NCT03979820,A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure,TERMINATED,PHASE1,53.0,2019-07-31,2020-04-08,6.402063492063492,Adequate (1-10/month),64.0206349206349,Below (50-75%),10,27.2,7.9
NCT05056220,Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites,RECRUITING,PHASE3,240.0,2024-02-26,2026-09-01,7.958169934640523,Adequate (1-10/month),79.58169934640523,Met (75-100%),60,57.2,65.9
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",COMPLETED,PHASE2,162.0,2015-04-20,2019-11-08,2.9652916416115453,Adequate (1-10/month),29.652916416115456,Significantly Below (<50%),100,63.0,75.35
NCT00504582,Fibrin Melanoma Axillary Node Study in Patients With Melanoma,COMPLETED,NA,121.0,2002-05-15,2020-04-09,0.5632726716623336,Slow (<1/month),5.632726716623337,Significantly Below (<50%),100,54.7,60.699999999999996
NCT05963282,Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients,COMPLETED,,9870.0,2021-11-29,2022-07-19,1295.0120689655173,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT04964882,Gastric Insufflation During Positive Pressure Ventilation,UNKNOWN,NA,78.0,2021-07-20,2022-03-05,10.413684210526316,Good (10-50/month),104.13684210526317,Exceeded (≥100%),50,46.2,34.4
NCT02493582,The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR,ACTIVE_NOT_RECRUITING,PHASE2,400.0,2015-07-01,2033-07-01,1.8518631178707226,Adequate (1-10/month),18.518631178707228,Significantly Below (<50%),85,77.5,86.3
NCT03742882,"A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects",COMPLETED,PHASE1,40.0,2018-12-06,2019-06-10,6.5462365591397855,Adequate (1-10/month),65.46236559139786,Below (50-75%),100,53.2,56.10000000000001
NCT03334682,Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.,COMPLETED,PHASE3,158.0,2018-01-31,2023-07-04,2.429050505050505,Adequate (1-10/month),24.29050505050505,Significantly Below (<50%),100,62.6,74.8
NCT02436382,Hypothermia and the Effect of Ambient Temperature,COMPLETED,NA,846.0,2015-02-01,2015-09-01,121.47283018867925,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT01105182,Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors,UNKNOWN,,48.0,2009-11-01,2011-06-01,2.5322703639514734,Adequate (1-10/month),25.32270363951474,Significantly Below (<50%),50,37.2,17.05
NCT04028882,Immune Activation as a Cause of Insulin Resistance in Adults Living With HIV-1 on Effective Antiretroviral Therapy,TERMINATED,,148.0,2020-03-03,2024-02-09,3.1329068150208625,Adequate (1-10/month),31.329068150208627,Significantly Below (<50%),10,33.2,12.35
NCT01818882,Diagnostic Value of Portable Ultrasound for Dyspneic Patient Support in the Emergency Department,TERMINATED,NA,85.0,2014-04-01,2016-01-01,4.0428125,Adequate (1-10/month),40.428125,Significantly Below (<50%),10,29.8,8.799999999999999
NCT06084182,Cognitive Function in Multiple Sclerosis,COMPLETED,NA,76.0,2021-11-15,2022-11-15,6.338191780821918,Adequate (1-10/month),63.38191780821918,Below (50-75%),100,56.1,63.55
NCT05114382,An Evaluation of the Safety and Performance of the CathVision Cube® System,COMPLETED,NA,24.0,2020-10-02,2021-08-01,2.4110891089108915,Adequate (1-10/month),24.110891089108915,Significantly Below (<50%),100,51.9,52.75
NCT06905782,"Artificial Intelligence (AI) Technology May Help Patients to Understand Bowel Preparation Better Before They go for Colonoscopy.This Study Attempts to Leverage AI Chatbot in Counselling Patients to Improve Bowel Cleanliness, Reduce Anxiety as Well as Increase Procedural Satisfaction",NOT_YET_RECRUITING,NA,96.0,2025-04-01,2026-02-02,9.51869706840391,Adequate (1-10/month),95.1869706840391,Met (75-100%),30,41.7,23.599999999999998
NCT06842082,The Videolaryngoscopy Versus Direct Laringoscopy for Residents Intubation Study,RECRUITING,NA,1008.0,2025-06-16,2025-12-29,156.54857142857142,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,93.7
NCT04491682,Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia,COMPLETED,PHASE2,36.0,2020-09-01,2022-06-20,1.667945205479452,Adequate (1-10/month),16.67945205479452,Significantly Below (<50%),100,52.9,55.2
NCT00713882,Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors,COMPLETED,,130.0,2008-04-01,2008-11-01,18.49158878504673,Good (10-50/month),184.9158878504673,Exceeded (≥100%),100,63.7,76.0
NCT00531882,Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers,COMPLETED,NA,25.0,2007-09-01,2009-02-01,1.466281310211946,Adequate (1-10/month),14.662813102119463,Significantly Below (<50%),100,47.0,39.1
NCT02887482,GLS-5700 in Dengue Virus Seropositive Adults,COMPLETED,PHASE1,160.0,2016-08-01,2018-06-01,7.280119581464873,Adequate (1-10/month),72.80119581464872,Below (50-75%),100,62.8,75.1
NCT07141082,Expressive Art Therapy for Elder Adults With Chronic Low Back Pain,RECRUITING,NA,30.0,2025-08-02,2027-12-01,1.073090481786134,Adequate (1-10/month),10.73090481786134,Significantly Below (<50%),60,35.4,14.799999999999999
NCT02613182,Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis,TERMINATED,PHASE2,34.0,2016-02-01,2018-05-01,1.2621463414634146,Adequate (1-10/month),12.621463414634146,Significantly Below (<50%),10,20.7,5.5
NCT06636682,FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer,RECRUITING,PHASE2,100.0,2024-10-14,2027-05-04,3.2660944206008584,Adequate (1-10/month),32.66094420600859,Significantly Below (<50%),60,46.0,33.2
NCT04018482,Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study),COMPLETED,PHASE4,50.0,2019-07-16,2019-08-14,50.0,Good (10-50/month),200.0,Exceeded (≥100%),100,64.0,76.35
NCT03709082,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,TERMINATED,PHASE1,3.0,2018-10-15,2021-02-03,0.10845605700712589,Slow (<1/month),1.0845605700712588,Significantly Below (<50%),10,18.2,3.15
NCT05731882,First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder,UNKNOWN,NA,10.0,2022-07-17,2024-08-01,0.4080428954423593,Slow (<1/month),4.080428954423593,Significantly Below (<50%),50,30.8,9.25
NCT05417282,MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases,COMPLETED,PHASE1,27.0,2022-07-01,2025-07-31,0.729911190053286,Slow (<1/month),7.299111900532859,Significantly Below (<50%),100,47.2,39.85
NCT04403282,Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial,TERMINATED,PHASE4,9.0,2020-09-27,2023-06-22,0.27450901803607214,Slow (<1/month),2.7450901803607217,Significantly Below (<50%),10,18.7,3.85
NCT00540982,Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction,COMPLETED,PHASE1,47.0,1997-02-20,2010-05-20,0.2957783750258425,Slow (<1/month),2.9577837502584248,Significantly Below (<50%),100,48.8,45.75
NCT05915624,Tele Nursing Counseling on Anxiety and Patient Satisfaction in Same Day Surgery,COMPLETED,NA,160.0,2022-09-01,2023-05-30,17.971955719557197,Good (10-50/month),179.71955719557195,Exceeded (≥100%),100,67.8,80.30000000000001
NCT00099424,Exercise Training in Sarcoidosis (EXTRAS Study),COMPLETED,NA,30.0,2004-02-01,2005-08-01,1.6694698354661792,Adequate (1-10/month),16.694698354661792,Significantly Below (<50%),100,52.4,54.0
NCT02182024,"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment",COMPLETED,PHASE1,35.0,2005-04-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.8,25.2
NCT04306224,A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas,COMPLETED,PHASE1,12.0,2020-06-05,2022-10-07,0.427728337236534,Slow (<1/month),4.27728337236534,Significantly Below (<50%),100,46.0,33.2
NCT05776524,Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer,RECRUITING,PHASE2,46.0,2023-06-13,2029-07-01,0.6335927601809955,Slow (<1/month),6.3359276018099555,Significantly Below (<50%),60,36.7,16.3
NCT04457024,Tennis Elbow Patients Undergoing Closed Therapy Can Easily Cause Tendon Tear,COMPLETED,,108.0,2020-01-01,2020-04-01,36.12659340659341,Good (10-50/month),200.0,Exceeded (≥100%),100,62.0,73.8
NCT03385824,Self-Advocacy for Independent Life (SAIL) After TBI,COMPLETED,NA,76.0,2018-02-01,2020-03-31,2.9321166032953103,Adequate (1-10/month),29.321166032953105,Significantly Below (<50%),100,56.1,63.55
NCT06356324,The Effects of Music and Television on Intraoperative Hypertensive Events in Cataract Surgery,COMPLETED,NA,650.0,2021-10-18,2024-04-01,22.08258928571429,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT07336524,Ankle Isometric Strength and Proprioception in Young Ice Hockey Players,NOT_YET_RECRUITING,,70.0,2025-12-15,2026-03-15,23.675555555555555,Good (10-50/month),200.0,Exceeded (≥100%),30,37.9,18.05
NCT01873924,Clinical and Neuropsychological Investigations in Batten Disease,RECRUITING,,500.0,2004-08-01,2035-08-01,1.3442854619325209,Adequate (1-10/month),13.442854619325207,Significantly Below (<50%),60,71.3,82.69999999999999
NCT02252224,Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance,COMPLETED,,3123.0,2014-09-23,2016-11-30,118.97887359199,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT05831124,A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults,COMPLETED,PHASE1,90.0,2023-04-19,2024-06-26,6.312442396313364,Adequate (1-10/month),63.12442396313364,Below (50-75%),100,57.2,65.9
NCT01534624,Stem Cell Study of Genetics and Drug Addiction,COMPLETED,,49.0,2012-02-07,2014-07-30,1.6499557522123895,Adequate (1-10/month),16.499557522123894,Significantly Below (<50%),100,47.3,40.2
NCT00869024,Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement,COMPLETED,PHASE1,25.0,2011-11-10,2016-03-29,0.4753279200499688,Slow (<1/month),4.753279200499688,Significantly Below (<50%),100,47.0,39.1
NCT04778124,HAL-RAR Technique for Treating Hemorrhoids,COMPLETED,NA,105.0,2010-01-01,2019-11-01,0.8900584795321639,Slow (<1/month),8.900584795321638,Significantly Below (<50%),100,53.4,57.25
NCT06366724,LIFT: Life Improvement Trial,RECRUITING,PHASE2,160.0,2024-09-10,2026-11-01,6.2281329923273665,Adequate (1-10/month),62.28132992327367,Below (50-75%),60,50.8,49.55
NCT01420224,Study of the Effects of Commercial Air Travel on the Lungs,COMPLETED,,9.0,2011-05-01,2011-06-01,8.83741935483871,Adequate (1-10/month),88.3741935483871,Met (75-100%),100,54.1,59.35
NCT01090024,Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids,COMPLETED,PHASE2,108.0,2010-03-01,2011-02-18,9.286779661016949,Adequate (1-10/month),92.86779661016949,Met (75-100%),100,63.6,75.9
NCT03129724,Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib,UNKNOWN,,100.0,2016-09-01,2017-07-01,10.046204620462047,Good (10-50/month),100.46204620462046,Exceeded (≥100%),50,46.3,34.949999999999996
NCT06088524,The Effects of Mental Fatigue Created by Social Media on Upper Extremity Performance,COMPLETED,,29.0,2023-01-05,2023-10-01,3.2816356877323423,Adequate (1-10/month),32.81635687732342,Significantly Below (<50%),100,50.7,49.15
NCT00798824,The Impact of Nasogastric Indwelling Versus Oral Intermittent Tube Feeding Methods on Premature Infants,COMPLETED,NA,24.0,2008-08-01,2009-12-01,1.500123203285421,Adequate (1-10/month),15.001232032854212,Significantly Below (<50%),100,46.9,38.6
NCT01243723,Study Assessing the Efficacy of Eductyl® for the Treatment of Patients With Dyschesia,COMPLETED,PHASE4,306.0,2010-11-01,2012-06-01,16.11529411764706,Good (10-50/month),161.15294117647062,Exceeded (≥100%),100,79.5,87.85
NCT00088023,Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness,TERMINATED,PHASE1,40.0,2004-03-01,2005-12-01,1.9025,Adequate (1-10/month),19.025,Significantly Below (<50%),10,26.2,7.5
NCT01612923,Safety and Efficacy of Medical Abortion Provided by Midlevel Providers or Physicians,COMPLETED,PHASE3,1180.0,2011-04-01,2012-07-01,78.59781181619256,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT01511523,Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD),UNKNOWN,NA,40.0,2012-01-01,2012-10-01,4.443795620437956,Adequate (1-10/month),44.43795620437956,Significantly Below (<50%),50,38.2,18.95
NCT07030023,Diagnosis of Wire Syndrome,ENROLLING_BY_INVITATION,,40.0,2025-03-28,2025-07-31,9.7408,Adequate (1-10/month),97.408,Met (75-100%),55,43.0,25.7
NCT05332223,The Epidemiology of Sleep Disordered Breathing in Patients With Congestive Heart Failure,COMPLETED,,116.0,2022-04-15,2023-12-31,5.649664,Adequate (1-10/month),56.49664,Below (50-75%),100,57.6,67.25
NCT07243223,Urinary Incontinence in Older Hong Kong Women: A Cross-sectional Study,NOT_YET_RECRUITING,,1100.0,2025-11-30,2027-03-01,73.4298245614035,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.85000000000001
NCT04363723,The Influence of an Acute Exacerbation During Pulmonary Rehabilitation in COPD Patients Awaiting Lung Transplantation,COMPLETED,,559.0,2020-04-23,2020-05-10,559.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT05230823,Behavioural Weight Loss Treatment for Patients with Atrial Fibrillation and Obesity in Cardiac Rehabilitation,COMPLETED,NA,14.0,2022-01-24,2023-01-31,1.1455913978494625,Adequate (1-10/month),11.455913978494623,Significantly Below (<50%),100,46.1,33.95
NCT03075423,Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC,COMPLETED,PHASE2,316.0,2017-11-01,2023-11-23,4.34660641662901,Adequate (1-10/month),43.4660641662901,Significantly Below (<50%),100,75.3,85.1
NCT01737723,Electroencephalograph for Detection of Acute Ischemic Stroke,UNKNOWN,,20.0,2011-08-01,,,Slow (<1/month),,Significantly Below (<50%),50,24.9,6.8500000000000005
NCT03016923,Functional Electrical Stimulation (FES) for Upper Extremity Hemiplegia in Children With Cerebral Palsy,COMPLETED,NA,3.0,2016-03-01,2017-08-25,0.1684870848708487,Slow (<1/month),1.6848708487084874,Significantly Below (<50%),100,45.2,30.25
NCT02652923,Contrast Ultrasound Detection of Sentinel Lymph Nodes,COMPLETED,PHASE1,98.0,2016-01-01,2022-01-12,1.3541171130276894,Adequate (1-10/month),13.541171130276897,Significantly Below (<50%),100,52.8,55.00000000000001
NCT06329323,SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours,NOT_YET_RECRUITING,,24.0,2024-04-14,2028-04-01,0.5045303867403315,Slow (<1/month),5.045303867403315,Significantly Below (<50%),30,24.3,6.3
NCT02272023,Randomized Trial of Intensive Motivational Interviewing (IMI) to Improve Drinking Outcomes Among Women,COMPLETED,NA,215.0,2015-02-01,2019-03-07,4.377658862876254,Adequate (1-10/month),43.77658862876254,Significantly Below (<50%),100,67.2,79.95
NCT04916223,Study to Determine Therapeutic Massage Dosing to Improve Quality of Life in Hospitalized Patients Receiving Palliative Care,COMPLETED,NA,405.0,2017-11-01,2019-03-26,24.17294117647059,Good (10-50/month),200.0,Exceeded (≥100%),100,87.4,93.5
NCT03722823,A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects,COMPLETED,PHASE1,37.0,2018-10-10,2019-05-07,5.3888995215311,Adequate (1-10/month),53.888995215311006,Below (50-75%),100,53.0,55.50000000000001
NCT04228523,Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED),COMPLETED,NA,24.0,2020-02-24,2021-01-01,2.3415384615384616,Adequate (1-10/month),23.415384615384617,Significantly Below (<50%),100,51.9,52.75
NCT06616623,Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer,SUSPENDED,PHASE1,24.0,2024-12-31,2026-12-31,1.0007671232876714,Adequate (1-10/month),10.007671232876714,Significantly Below (<50%),20,22.9,5.7
NCT04675723,The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection,COMPLETED,,52.0,2019-09-23,2022-05-05,1.6574659685863875,Adequate (1-10/month),16.574659685863875,Significantly Below (<50%),100,47.5,41.3
NCT06208423,Physician Reasoning on Management Cases With Large Language Models,COMPLETED,NA,92.0,2023-12-28,2024-04-19,24.783008849557522,Good (10-50/month),200.0,Exceeded (≥100%),100,62.4,74.5
NCT04462523,DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery,COMPLETED,PHASE4,40.0,2020-01-03,2022-03-31,1.4885085574572128,Adequate (1-10/month),14.885085574572127,Significantly Below (<50%),100,48.2,43.6
NCT04023123,Anterior Corneal Striae in Hypotony,COMPLETED,,98.0,2019-09-17,2020-03-23,15.867659574468085,Good (10-50/month),158.67659574468087,Exceeded (≥100%),100,61.2,72.39999999999999
NCT00610623,Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia,TERMINATED,PHASE2,92.0,2003-04-01,2005-10-01,3.0639824945295406,Adequate (1-10/month),30.63982494529541,Significantly Below (<50%),10,30.4,9.1
NCT00796523,An Intervention to Decrease Infant Crying,COMPLETED,NA,51.0,2005-08-01,2006-05-01,5.686593406593407,Adequate (1-10/month),56.86593406593408,Below (50-75%),100,54.1,59.35
NCT01589523,GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis,COMPLETED,PHASE3,5.0,2006-02-01,2019-01-22,0.03212325875897003,Slow (<1/month),0.3212325875897003,Significantly Below (<50%),100,45.4,30.65
NCT03408223,Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia,UNKNOWN,NA,100.0,2014-03-01,2022-12-01,0.9521426337191118,Slow (<1/month),9.521426337191118,Significantly Below (<50%),50,38.0,18.25
NCT00225823,Study In Adults And Adolescents With Seasonal Allergic Rhinitis.,COMPLETED,PHASE3,288.0,2005-05-01,2005-08-01,95.2904347826087,Excellent (>50/month),200.0,Exceeded (≥100%),100,83.0,90.64999999999999
NCT06786923,The Effect of taVNS on the Prognosis of Patients Undergoing Pancreatoduodenectomy,COMPLETED,NA,84.0,2025-01-08,2025-10-31,8.638378378378379,Adequate (1-10/month),86.38378378378378,Met (75-100%),100,61.7,73.35000000000001
NCT01964859,Feasibility Study for Fibroblast Autologous Skin Grafts,RECRUITING,PHASE2,80.0,2015-01-07,2028-11-01,0.48250445809391723,Slow (<1/month),4.825044580939172,Significantly Below (<50%),60,39.4,20.1
NCT01290159,The Development Of A Novel Biomarker For Early Identification Of The Individual's State Of Tolerance To Heat,COMPLETED,,10.0,2011-05-01,2013-07-01,0.3843434343434344,Slow (<1/month),3.8434343434343434,Significantly Below (<50%),100,44.1,27.750000000000004
NCT06092359,The Eye in Orbit: UCF Adaption,COMPLETED,,1.0,2022-03-01,2022-07-31,0.20026315789473684,Slow (<1/month),2.0026315789473683,Significantly Below (<50%),100,43.4,26.8
NCT02262559,Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers,COMPLETED,PHASE1,30.0,2002-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.4,24.9
NCT06356259,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants",TERMINATED,PHASE1,83.0,2023-06-07,2025-01-23,4.239127516778524,Adequate (1-10/month),42.39127516778524,Significantly Below (<50%),10,29.6,8.6
NCT06916559,Comparison of Different Methods for Measuring Urinary Oxalate and Citrate: An Observational Study,COMPLETED,,122.0,2025-03-01,2025-04-01,119.79612903225807,Excellent (>50/month),200.0,Exceeded (≥100%),100,68.1,80.7
NCT05084859,"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,30.0,2021-11-03,2022-10-20,2.601709401709402,Adequate (1-10/month),26.017094017094017,Significantly Below (<50%),10,25.4,7.199999999999999
NCT03121859,Analgesic Current Therapies for Chronic Neck Pain,COMPLETED,NA,81.0,2015-10-01,2017-04-01,4.499343065693431,Adequate (1-10/month),44.99343065693431,Significantly Below (<50%),100,56.5,64.85
NCT01026259,Local Warming of Surgical Incisions,COMPLETED,PHASE3,146.0,2005-10-01,2009-11-01,2.978713136729223,Adequate (1-10/month),29.78713136729223,Significantly Below (<50%),100,61.7,73.35000000000001
NCT00273559,A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids,UNKNOWN,,60.0,2006-01-01,2008-12-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),50,38.1,18.6
NCT00497159,A Study of the Novel Drug Dimebon in Patients With Huntington's Disease,COMPLETED,PHASE2,91.0,2007-07-01,2008-06-01,8.244166666666667,Adequate (1-10/month),82.44166666666666,Met (75-100%),100,57.3,66.4
NCT01459159,Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome,TERMINATED,PHASE2,162.0,2011-10-01,2013-02-01,10.084417177914112,Good (10-50/month),100.8441717791411,Exceeded (≥100%),10,41.0,22.45
NCT06488859,Affect Treatment for Depression and Anxiety (TAD Pilot),COMPLETED,NA,10.0,2024-03-25,2025-03-25,0.8339726027397261,Slow (<1/month),8.33972602739726,Significantly Below (<50%),100,45.8,31.900000000000002
NCT02981459,Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women,WITHDRAWN,PHASE4,0.0,2017-12-08,2018-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT06934759,Impact and Lived Experience of Parents of a Child With a Large or Giant Congenital Melanocytic Nevus,ENROLLING_BY_INVITATION,,30.0,2025-12-01,2026-08-31,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),55,37.2,17.05
NCT04203459,The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation,UNKNOWN,,80.0,2019-10-20,2022-12-31,2.084931506849315,Adequate (1-10/month),20.849315068493148,Significantly Below (<50%),50,39.7,20.599999999999998
NCT01498380,The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children,COMPLETED,NA,21.0,2012-01-01,2013-09-01,1.049655172413793,Adequate (1-10/month),10.49655172413793,Significantly Below (<50%),100,46.7,37.5
NCT00558480,Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis,WITHDRAWN,NA,0.0,2009-07-01,2012-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT04110080,Enhanced Recovery After Surgery in Kidney Transplant Donors,UNKNOWN,NA,42.0,2019-09-12,2023-06-12,0.9338787436084734,Slow (<1/month),9.338787436084734,Significantly Below (<50%),50,33.4,12.7
NCT03175380,Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US,COMPLETED,EARLY_PHASE1,15.0,2017-08-08,2019-01-10,0.8780769230769231,Slow (<1/month),8.780769230769229,Significantly Below (<50%),100,46.2,34.4
NCT06794580,The DUAL-SYSTEM HYPOTHESIS of ANOSOGNOSIA: the Interplay Between Emotional Processing and Self-Monitoring in Neurodegenerative Patients,COMPLETED,,100.0,2019-01-22,2020-07-30,5.484684684684685,Adequate (1-10/month),54.84684684684685,Below (50-75%),100,56.3,64.0
NCT04825080,Carotid Asymptomatic Stenosis,UNKNOWN,,300.0,2019-01-01,2025-01-01,4.166058394160584,Adequate (1-10/month),41.660583941605836,Significantly Below (<50%),50,57.3,66.4
NCT06169280,Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma,RECRUITING,PHASE1,20.0,2025-06-27,2030-12-31,0.30243417784401394,Slow (<1/month),3.024341778440139,Significantly Below (<50%),60,34.6,13.900000000000002
NCT01177280,Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes,COMPLETED,,10000.0,2010-09-01,2011-01-01,2495.0819672131147,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT02488980,An Evaluation of Weekly Tafenoquine,COMPLETED,PHASE2,306.0,2000-05-01,2003-03-01,9.00835589941973,Adequate (1-10/month),90.0835589941973,Met (75-100%),100,79.5,87.85
NCT04169880,Effects of High Intensity Laser Therapy (HILT) in Patients With Subacromial Impingement Syndrome,COMPLETED,NA,30.0,2014-05-05,2016-05-27,1.2127490039840638,Adequate (1-10/month),12.127490039840637,Significantly Below (<50%),100,47.4,40.75
NCT00121680,"A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma",COMPLETED,PHASE1,115.0,2005-07-01,2015-05-01,0.9748259537733223,Slow (<1/month),9.748259537733222,Significantly Below (<50%),100,54.2,59.5
NCT02418780,Tai Chi for Enhancing Motor and Cognitive Function in Parkinson's Disease,COMPLETED,NA,32.0,2014-05-01,2016-04-01,1.3895577746077032,Adequate (1-10/month),13.89557774607703,Significantly Below (<50%),100,47.6,41.8
NCT04770480,Non-pharmacological Treatment for Pain After Spine Surgery,ACTIVE_NOT_RECRUITING,NA,267.0,2021-12-10,2026-03-30,5.173443666454488,Adequate (1-10/month),51.73443666454488,Below (50-75%),85,66.9,79.4
NCT00676780,Green Tea Extract and Prostate Cancer,COMPLETED,PHASE2,33.0,2004-05-01,2008-12-01,0.5997134328358209,Slow (<1/month),5.997134328358209,Significantly Below (<50%),100,47.6,41.8
NCT02219880,Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial,COMPLETED,PHASE4,178.0,2015-10-13,2018-05-31,5.638210197710718,Adequate (1-10/month),56.38210197710718,Below (50-75%),100,64.2,76.5
NCT05347680,A Comparison Between the Intubating Laryngeal Tube Suction and the Ambu AuraGain,COMPLETED,NA,80.0,2019-09-19,2021-01-18,5.00041067761807,Adequate (1-10/month),50.0041067761807,Below (50-75%),100,56.4,64.4
NCT04366180,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,UNKNOWN,NA,314.0,2020-04-24,2020-10-01,59.7385,Excellent (>50/month),200.0,Exceeded (≥100%),50,70.1,82.19999999999999
NCT05482880,"Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region",COMPLETED,,78.0,2022-02-28,2024-12-01,2.3578152929493545,Adequate (1-10/month),23.578152929493548,Significantly Below (<50%),100,54.6,60.099999999999994
NCT03075280,Pre-ERCP High Carbohydrate Drinks Improve Patients Recovery,COMPLETED,NA,1292.0,2017-04-01,2021-04-17,26.627271496276236,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT00044980,Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer,COMPLETED,NA,,2002-07-01,2006-12-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,29.65
NCT05488080,PAINED: Project Addressing INequities in the Emergency Department,RECRUITING,NA,22032.0,2023-02-27,2026-08-23,526.8295993715633,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,93.7
NCT06652880,Digital Support Intervention for Pregnant People with Opioid Use Disorders,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,32.0,2024-06-04,2025-12-31,1.6940521739130436,Adequate (1-10/month),16.940521739130435,Significantly Below (<50%),85,48.1,43.2
NCT01642680,Optimal Timing of Physical Activity in Cancer Treatment,COMPLETED,NA,266.0,2013-01-24,2020-10-22,2.8631683168316835,Adequate (1-10/month),28.631683168316833,Significantly Below (<50%),100,71.3,82.69999999999999
NCT04186780,Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study,COMPLETED,NA,68.0,2018-09-26,2019-09-20,5.765793871866296,Adequate (1-10/month),57.65793871866296,Below (50-75%),100,55.4,62.6
NCT05775380,The Role of Pioglitazone in Vascular Transcriptional Remodeling,UNKNOWN,PHASE4,20.0,2023-06-15,2024-12-22,1.0949640287769784,Adequate (1-10/month),10.949640287769785,Significantly Below (<50%),50,31.6,10.45
NCT02075580,Totally Implantable Venous Access Devices: Quality of Life and Body Image,COMPLETED,NA,128.0,2013-09-01,2018-12-01,2.032509128847157,Adequate (1-10/month),20.325091288471572,Significantly Below (<50%),100,60.2,71.8
NCT03497780,Longitudinal Assessment of Cartilage Injury and Remodeling After Anterior Cruciate Ligament Rupture and Reconstruction:,TERMINATED,,13.0,2018-11-08,2021-03-25,0.4558986175115208,Slow (<1/month),4.558986175115208,Significantly Below (<50%),10,17.4,2.7
NCT01387880,"Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,100.0,2010-01-01,2012-03-01,3.853164556962026,Adequate (1-10/month),38.53164556962025,Significantly Below (<50%),100,58.0,68.30000000000001
NCT04919980,TVMR With the INNOVALVE System Trial - Early Feasibility Study,RECRUITING,NA,65.0,2022-09-01,2031-07-01,0.6135193798449612,Slow (<1/month),6.135193798449612,Significantly Below (<50%),60,38.2,18.95
NCT04732780,Avoidance of Hyperglycaemia in People With Type 1 Diabetes,COMPLETED,,253.0,2021-03-02,2022-04-20,18.602222222222224,Good (10-50/month),186.0222222222222,Exceeded (≥100%),100,73.6,84.2
NCT05434780,Kinesiology Taping on Calf Tightness,UNKNOWN,NA,20.0,2022-08-15,2022-12-15,4.99016393442623,Adequate (1-10/month),49.901639344262286,Significantly Below (<50%),50,36.6,16.1
NCT06580379,Spine Surgery Video Observation Study. The Creation of a Benchmark Video (RGB-Depth) Dataset to Investigate the Feasibility of Developing a Markerless Tracking System for Spine Surgery.,NOT_YET_RECRUITING,,25.0,2024-10-01,2027-10-01,0.6949771689497718,Slow (<1/month),6.949771689497718,Significantly Below (<50%),30,24.3,6.3
NCT06437379,Infection Control Measures for Patients Undergoing Percutaneous Nephrolithotomy,COMPLETED,NA,30.0,2023-09-01,2025-01-01,1.871311475409836,Adequate (1-10/month),18.71311475409836,Significantly Below (<50%),100,52.4,54.0
NCT06133179,Super-Resolution Ultrasound of the Brain in 3D,RECRUITING,NA,20.0,2024-03-22,2025-02-01,1.9265822784810127,Adequate (1-10/month),19.265822784810126,Significantly Below (<50%),60,39.6,20.4
NCT02084979,A Controlled Trial of Patient Centered Telepsychiatry Interventions,COMPLETED,NA,185.0,2014-04-01,2019-04-29,3.0374325782092777,Adequate (1-10/month),30.374325782092775,Significantly Below (<50%),100,64.8,77.10000000000001
NCT03020979,A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites,UNKNOWN,PHASE2,120.0,2017-01-01,2019-12-01,3.433082706766917,Adequate (1-10/month),34.330827067669176,Significantly Below (<50%),50,44.6,28.549999999999997
NCT02532179,Subcutaneous Immunotherapy for Mouse in Adults,COMPLETED,PHASE1,12.0,2015-10-01,2016-10-01,0.9980327868852459,Slow (<1/month),9.98032786885246,Significantly Below (<50%),100,46.0,33.2
NCT02559479,A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes,UNKNOWN,NA,100.0,2015-09-01,2017-06-01,4.763693270735525,Adequate (1-10/month),47.63693270735524,Significantly Below (<50%),50,43.0,25.7
NCT02534779,"Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products",COMPLETED,NA,49.0,2015-08-01,2016-03-01,7.002629107981221,Adequate (1-10/month),70.02629107981221,Below (50-75%),100,53.9,58.45
NCT05419479,Switch Maintenance in Pancreatic,SUSPENDED,PHASE1,46.0,2022-11-30,2028-09-30,0.6570811825434069,Slow (<1/month),6.570811825434069,Significantly Below (<50%),20,24.7,6.7
NCT02906579,"A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension",COMPLETED,PHASE2,11.0,2016-09-01,2017-03-17,1.6996954314720814,Adequate (1-10/month),16.996954314720814,Significantly Below (<50%),100,50.9,49.8
NCT00894179,Safety and Accuracy Study of Regadenoson Atropine Combination for Stress Echocardiography in Identification of Coronary Artery Disease,UNKNOWN,,110.0,2009-05-01,2011-12-01,3.547033898305085,Adequate (1-10/month),35.47033898305085,Significantly Below (<50%),50,42.1,24.45
NCT02590679,Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p,UNKNOWN,PHASE2,44.0,2013-05-01,2017-02-01,0.9762099125364433,Slow (<1/month),9.762099125364433,Significantly Below (<50%),50,33.5,12.8
NCT02775279,Association Between Telomere Length and Risk of Acute Coronary Syndrome,COMPLETED,,400.0,2016-01-01,2016-05-01,100.62809917355372,Excellent (>50/month),200.0,Exceeded (≥100%),100,90.3,94.1
NCT04573179,Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of csPCa in Lesions With PI-RADS Score 3,UNKNOWN,,60.0,2020-07-01,2021-07-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),50,38.1,18.6
NCT06039579,Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults,COMPLETED,PHASE2,44.0,2023-10-25,2024-06-24,5.511769547325104,Adequate (1-10/month),55.11769547325104,Below (50-75%),100,53.5,57.550000000000004
NCT06072196,A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC),COMPLETED,,3017.0,2023-10-04,2024-12-18,208.24825396825398,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT07136896,"Nutritional Assessment in Patient of Mucopolysaccharide """,NOT_YET_RECRUITING,NA,40.0,2025-08-16,2026-08-30,3.2126649076517153,Adequate (1-10/month),32.126649076517154,Significantly Below (<50%),30,32.2,11.3
NCT02374996,Pharmacoepigenetics of Bipolar Disorder Treatment,COMPLETED,,40.0,2015-11-01,2017-09-01,1.8173134328358211,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),100,51.5,51.5
NCT04193696,RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC),UNKNOWN,PHASE2,39.0,2020-01-10,2020-07-30,5.877029702970297,Adequate (1-10/month),58.77029702970298,Below (50-75%),50,38.1,18.6
NCT02465996,Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy,UNKNOWN,NA,200.0,2014-07-01,2015-06-01,18.17313432835821,Good (10-50/month),181.73134328358208,Exceeded (≥100%),50,56.0,63.3
NCT02545296,HIV Point-of-Care Test Evaluation in Infants,COMPLETED,NA,604.0,2015-07-01,2017-08-01,24.128293963254595,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT00788996,Reduction of Environmental Tobacco Smoke (ETS) Exposure at Home: the BIBE Study,UNKNOWN,PHASE2,552.0,2009-01-01,2011-01-01,23.01764383561644,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,88.64999999999999
NCT03096496,Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy,UNKNOWN,,161.0,2017-03-27,2022-01-01,2.814956921309592,Adequate (1-10/month),28.14956921309592,Significantly Below (<50%),50,46.2,34.4
NCT06073496,The Effectiveness of Electroacupuncture and Standard Therapy Compared to Standard Therapy in Gynecological Cancer Pain,COMPLETED,NA,58.0,2023-08-30,2023-12-19,15.905585585585586,Good (10-50/month),159.05585585585587,Exceeded (≥100%),100,59.6,70.95
NCT04006496,AML Expressive Writing,TERMINATED,NA,15.0,2019-11-04,2022-01-19,0.5657992565055763,Slow (<1/month),5.657992565055762,Significantly Below (<50%),10,19.2,4.3999999999999995
NCT04488796,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,COMPLETED,NA,148.0,2020-09-07,2020-12-16,45.0512,Good (10-50/month),200.0,Exceeded (≥100%),100,71.8,83.0
NCT05472896,TACE With Dicycloplatin(TP21) in Unresectable HCC,UNKNOWN,PHASE3,332.0,2022-06-09,2024-06-30,13.438936170212767,Good (10-50/month),134.38936170212767,Exceeded (≥100%),50,66.6,79.0
NCT01788696,Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects,COMPLETED,PHASE1,20.0,2012-06-01,2015-06-01,0.5559817351598174,Slow (<1/month),5.559817351598174,Significantly Below (<50%),100,46.6,36.7
NCT06619496,Health in Motion Pragmatic Clinical Trial - WRAPAROUND,COMPLETED,NA,63.0,2022-10-24,2024-07-01,3.1131818181818183,Adequate (1-10/month),31.131818181818183,Significantly Below (<50%),100,55.0,61.9
NCT05130996,Observational Study Evaluating Safety and Performance of IDI Dental Implant Systems in Subjects Followed for 18 Months.,RECRUITING,,121.0,2022-05-09,2024-06-01,4.884933687002653,Adequate (1-10/month),48.84933687002653,Significantly Below (<50%),60,46.0,33.2
NCT01021696,Pain in Patients With Dementia and Behavioural Disturbances,COMPLETED,PHASE2,352.0,2009-11-01,2010-10-01,32.08047904191617,Good (10-50/month),200.0,Exceeded (≥100%),100,83.2,90.9
NCT05743296,Differences in Brain Activity in the Application of Upper Limb Exercise Tasks Through Virtual Reality,COMPLETED,,25.0,2022-12-27,2023-02-20,13.836363636363638,Good (10-50/month),138.36363636363637,Exceeded (≥100%),100,55.3,62.35000000000001
NCT00005596,Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia,COMPLETED,PHASE3,1076.0,2000-04-01,2007-07-01,12.373796751038913,Good (10-50/month),123.73796751038913,Exceeded (≥100%),100,95.0,96.2
NCT01050296,Molecular Analysis Of Solid Tumors,RECRUITING,,1000.0,2010-02-10,2026-09-30,5.009874917709019,Adequate (1-10/month),50.0987491770902,Below (50-75%),60,76.3,85.45
NCT03737396,Pre-Anaesthesia CompuTerized Health Assessment,COMPLETED,NA,402.0,2018-05-03,2021-01-02,12.550646153846156,Good (10-50/month),125.50646153846155,Exceeded (≥100%),100,87.2,93.35
NCT06632496,BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study,COMPLETED,,156.0,2025-03-28,2025-09-23,26.528715083798883,Good (10-50/month),200.0,Exceeded (≥100%),100,65.8,78.05
NCT01923896,D-cycloserine and Treatment of Feeding Disorders,COMPLETED,PHASE1,16.0,2013-03-01,2013-11-01,1.987918367346939,Adequate (1-10/month),19.879183673469388,Significantly Below (<50%),100,51.3,51.0
NCT02363296,Main Study: Influence on Plasticity of Brain Temperature Sub-Study: Phase Triggered Paired Associative Stimulation (PAS),COMPLETED,NA,45.0,2016-05-03,2025-08-07,0.40490688737806685,Slow (<1/month),4.049068873780668,Significantly Below (<50%),100,48.6,45.1
NCT05972096,DBT Skills Expanded With Contextual Intervention for Long Lasting Symptoms in Borderline Personality Disorder,UNKNOWN,NA,60.0,2022-03-01,2023-10-01,3.1544041450777205,Adequate (1-10/month),31.5440414507772,Significantly Below (<50%),50,39.8,20.8
NCT05366296,"Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine",WITHDRAWN,PHASE1,0.0,2022-07-01,2023-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT03502096,Portion Size and To-go Container on Dinner Intake,COMPLETED,NA,58.0,2016-10-01,2017-12-01,4.1444131455399065,Adequate (1-10/month),41.44413145539907,Significantly Below (<50%),100,54.6,60.099999999999994
NCT04941196,Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition,COMPLETED,PHASE1,30.0,2020-10-16,2020-11-25,22.830000000000002,Good (10-50/month),200.0,Exceeded (≥100%),100,57.4,66.9
NCT01133496,Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions,COMPLETED,PHASE1,80.0,2006-12-01,2007-04-01,20.125619834710744,Good (10-50/month),200.0,Exceeded (≥100%),100,61.4,72.75
NCT05675462,Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE1,25.0,2023-03-01,2025-12-30,0.7352657004830918,Slow (<1/month),7.352657004830918,Significantly Below (<50%),50,32.0,11.0
NCT03328962,Smoking Cessation in Cancer Treatment,UNKNOWN,NA,1200.0,2017-09-15,2021-06-01,26.957933579335794,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,88.64999999999999
NCT01212562,Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery,COMPLETED,,70.0,2007-04-01,2011-08-01,1.3460518003790272,Adequate (1-10/month),13.46051800379027,Significantly Below (<50%),100,48.9,45.9
NCT02201862,Non-Invasive Chromosomal Evaluation of Trisomy Study,COMPLETED,,2000.0,2014-04-01,2019-08-01,31.252566735112936,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,95.1
NCT06571162,A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients,RECRUITING,NA,400.0,2025-01-30,2028-09-01,9.294656488549618,Adequate (1-10/month),92.94656488549619,Met (75-100%),60,75.0,85.0
NCT01973062,Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma,TERMINATED,PHASE2,1.0,2014-03-01,2015-06-01,0.06660831509846828,Slow (<1/month),0.6660831509846827,Significantly Below (<50%),10,18.1,2.9000000000000004
NCT02580162,Success in Health: Impacting Families Together,COMPLETED,NA,242.0,2015-12-01,2020-12-20,3.990509209100759,Adequate (1-10/month),39.90509209100758,Significantly Below (<50%),100,69.4,81.45
NCT02901262,Continuous Quantified EEG in NeuroIntensive Care,COMPLETED,,30.0,2016-01-01,2017-01-01,2.495081967213115,Adequate (1-10/month),24.950819672131146,Significantly Below (<50%),100,50.7,49.15
NCT00748462,Fractional CO2 Treatment of Acne Scars in Asians,COMPLETED,PHASE4,12.0,2008-07-01,2008-12-01,2.387450980392157,Adequate (1-10/month),23.87450980392157,Significantly Below (<50%),100,51.0,50.2
NCT01248962,"Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",COMPLETED,PHASE2,146.0,2010-11-01,2018-08-01,1.5704028268551236,Adequate (1-10/month),15.704028268551237,Significantly Below (<50%),100,56.7,65.3
NCT06636162,Window of Opportunity Study of DSP-0390 in Gliomas,RECRUITING,EARLY_PHASE1,20.0,2025-04-03,2026-05-17,1.4885085574572128,Adequate (1-10/month),14.885085574572127,Significantly Below (<50%),60,34.6,13.900000000000002
NCT02853162,Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study),TERMINATED,PHASE2,30.0,2016-06-01,2020-04-01,0.6522857142857142,Slow (<1/month),6.522857142857143,Significantly Below (<50%),10,20.4,5.35
NCT00002062,"Open-Label ""Compassionate"" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients",COMPLETED,NA,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.3
NCT01867762,An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE2,211.0,2013-09-09,2014-09-01,17.991148459383755,Good (10-50/month),179.91148459383754,Exceeded (≥100%),100,71.9,83.1
NCT02753062,Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma,UNKNOWN,PHASE2,22.0,2015-08-01,2023-08-01,0.2291854893908282,Slow (<1/month),2.291854893908282,Significantly Below (<50%),50,31.8,10.7
NCT01641562,Diagnosis and Prediction of Taxanes Induced Cardiac Dysfunction,COMPLETED,,60.0,2012-01-01,2017-01-31,0.9835218093699515,Slow (<1/month),9.835218093699515,Significantly Below (<50%),100,48.1,43.2
NCT03941262,Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy,COMPLETED,PHASE1,27.0,2019-07-15,2023-02-17,0.625955826351866,Slow (<1/month),6.2595582635186595,Significantly Below (<50%),100,47.2,39.85
NCT03746262,Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer,COMPLETED,,40.0,2016-05-13,2018-08-10,1.4866910866910867,Adequate (1-10/month),14.866910866910867,Significantly Below (<50%),100,46.5,36.05
NCT02893462,Setting up a Warehouse of Physiological Data and Biomedical Signals in Adult Intensive Care,RECRUITING,,1500.0,2015-01-01,2027-01-01,10.417522245037645,Good (10-50/month),104.17522245037645,Exceeded (≥100%),60,81.3,89.64999999999999
NCT04040062,Spectral Correlation Coefficient-based TMS,ENROLLING_BY_INVITATION,NA,10.0,2019-06-25,2027-10-01,0.10079470198675497,Slow (<1/month),1.0079470198675495,Significantly Below (<50%),55,32.3,11.5
NCT07033962,Fractional CO₂ Laser or 40% Urea With Topical Fluconazole Microemulsion in Onychomycosis,NOT_YET_RECRUITING,NA,40.0,2025-06-01,2026-07-01,3.082531645569621,Adequate (1-10/month),30.825316455696207,Significantly Below (<50%),30,32.2,11.3
NCT04180462,Increasing Optimal Use of HPV Vaccination in Primary Care,COMPLETED,NA,20.0,2020-01-07,2024-04-29,0.3867852604828463,Slow (<1/month),3.8678526048284625,Significantly Below (<50%),100,46.6,36.7
NCT05453162,Circadian Influence on Prolonged Exposure Therapy for PTSD,ACTIVE_NOT_RECRUITING,NA,52.0,2022-07-01,2026-04-01,1.1553868613138687,Adequate (1-10/month),11.553868613138686,Significantly Below (<50%),85,44.7,28.9
NCT06224062,Virus and Bronchial Epithelium in Children and the Elderly,UNKNOWN,NA,200.0,2022-10-28,2025-04-28,6.668127053669223,Adequate (1-10/month),66.68127053669222,Below (50-75%),50,51.0,50.2
NCT01853462,Effects of Two Supervised Training Programs for the Rehabilitation of Ankle Sprains,COMPLETED,NA,22.0,2014-12-01,2016-09-01,1.046375,Adequate (1-10/month),10.463750000000001,Significantly Below (<50%),100,46.8,38.05
NCT05512962,Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema,COMPLETED,PHASE2,25.0,2022-08-31,2023-11-30,1.6688596491228072,Adequate (1-10/month),16.688596491228072,Significantly Below (<50%),100,52.0,53.1
NCT05282862,Guided Surgery for Horizontal Bone Augmentation,UNKNOWN,NA,28.0,2019-05-28,2023-03-01,0.6207720320466132,Slow (<1/month),6.207720320466132,Significantly Below (<50%),50,32.2,11.3
NCT00836862,Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens,COMPLETED,,43.0,2009-02-01,2017-09-07,0.41685350318471337,Slow (<1/month),4.168535031847134,Significantly Below (<50%),100,46.8,38.05
NCT02335762,Dietary Conjugated Linoleic Acid (CLA) Intake Among Students in Italy,COMPLETED,,40.0,2012-01-01,2012-10-01,4.443795620437956,Adequate (1-10/month),44.43795620437956,Significantly Below (<50%),100,51.5,51.5
NCT06797362,Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors,AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,5.8500000000000005
NCT00016562,Cause and Pathogenesis of Neurometabolic Disorders,COMPLETED,,20.0,2001-05-13,2008-03-03,0.24489139179404668,Slow (<1/month),2.448913917940467,Significantly Below (<50%),100,44.9,29.25
NCT01368562,Compassionate Use Study of Methylnaltrexone,COMPLETED,NA,26.0,2003-01-24,2008-06-02,0.4046216768916156,Slow (<1/month),4.046216768916155,Significantly Below (<50%),100,47.1,39.45
NCT03657446,A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function,COMPLETED,PHASE1,36.0,2018-09-18,2018-10-26,28.837894736842106,Good (10-50/month),200.0,Exceeded (≥100%),100,57.9,67.65
NCT05763446,Predictive Factors for Massive Transfusion During Liver Transplantation,RECRUITING,,400.0,2021-07-31,2026-10-31,6.348279457768509,Adequate (1-10/month),63.482794577685084,Below (50-75%),60,68.3,80.85
NCT00204646,Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS),COMPLETED,PHASE2,,1999-02-01,2006-12-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,29.65
NCT05086146,Prognostic Impact of Cardiac Imaging During Suspected Immune Checkpoint Inhibitor Myocarditis,UNKNOWN,,100.0,2021-08-10,2024-03-01,3.259100642398287,Adequate (1-10/month),32.59100642398287,Significantly Below (<50%),50,41.3,22.85
NCT04720846,Categorized PT for Non-arthritic Hip and Groin Pain,RECRUITING,NA,70.0,2020-12-02,2026-02-01,1.1291997880233176,Adequate (1-10/month),11.291997880233176,Significantly Below (<50%),60,38.6,19.400000000000002
NCT04830046,Covid-19 Vaccine Responsiveness in MM and Waldenstrom,COMPLETED,,146.0,2021-04-15,2022-09-14,8.596208897485495,Adequate (1-10/month),85.96208897485495,Met (75-100%),100,65.0,77.35
NCT00000346,Cognitive Correlates of Substance Abuse - 11,UNKNOWN,PHASE4,80.0,,,,Slow (<1/month),,Significantly Below (<50%),50,31.4,10.0
NCT05572346,Digital App for Telerehabilitation in Respiratory Diseases,UNKNOWN,,30.0,2022-10-17,2024-01-01,2.0707482993197277,Adequate (1-10/month),20.707482993197278,Significantly Below (<50%),50,35.7,15.25
NCT04468646,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,UNKNOWN,PHASE3,100.0,2020-06-15,2020-08-30,40.05263157894737,Good (10-50/month),200.0,Exceeded (≥100%),50,48.0,42.75
NCT04363346,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,COMPLETED,PHASE1,5.0,2020-05-14,2021-02-18,0.5435714285714286,Slow (<1/month),5.435714285714286,Significantly Below (<50%),100,45.4,30.65
NCT03238846,Operations Research of the 'Real World' Effectiveness of Multi-Month Dispensing of ART for Stable Patients in CARGs in Zimbabwe,UNKNOWN,NA,4676.0,2017-07-28,2019-09-30,179.26629722921916,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.95
NCT07313046,CAREGİVER TRAİNİNG AND PRESSURE ULCER PREVENTİON İN HOME CARE,COMPLETED,NA,57.0,2024-07-12,2025-06-20,5.058542274052479,Adequate (1-10/month),50.58542274052479,Below (50-75%),100,54.6,60.099999999999994
NCT01690546,Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence,COMPLETED,PHASE2,38.0,2012-09-01,2015-02-01,1.3099886749716876,Adequate (1-10/month),13.099886749716875,Significantly Below (<50%),100,48.0,42.75
NCT04406246,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,COMPLETED,PHASE4,150.0,2020-05-21,2020-12-31,20.383928571428573,Good (10-50/month),200.0,Exceeded (≥100%),100,67.0,79.60000000000001
NCT06795646,Clinical Classification of MAFLD Based Liver Biopsy,NOT_YET_RECRUITING,,2000.0,2025-02-08,2038-12-31,11.998423334647223,Good (10-50/month),119.98423334647224,Exceeded (≥100%),30,72.3,83.5
NCT05149846,Pre-conditioning by Balloon-inflation on Myocardial Injury,WITHDRAWN,NA,0.0,2023-01-01,2024-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT05772546,Avatrombopag vs. Placebo for CIT in GI Malignancies,ACTIVE_NOT_RECRUITING,PHASE2,60.0,2023-11-01,2026-07-31,1.8209371884346959,Adequate (1-10/month),18.209371884346957,Significantly Below (<50%),85,50.3,48.35
NCT05517746,"Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants",COMPLETED,PHASE1,63.0,2019-12-18,2021-03-11,4.271091314031181,Adequate (1-10/month),42.7109131403118,Significantly Below (<50%),100,55.0,61.9
NCT05318846,A Study to Evaluate the Efficacy and Safety of HRS4800 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.,COMPLETED,PHASE2,38.0,2022-01-14,2022-03-22,17.264477611940297,Good (10-50/month),172.64477611940296,Exceeded (≥100%),100,58.0,68.30000000000001
NCT03830346,Instrument-assisted Soft Tissue Mobilization in CrossFitters,UNKNOWN,NA,21.0,2019-02-01,2019-07-01,4.2616,Adequate (1-10/month),42.616,Significantly Below (<50%),50,36.7,16.3
NCT04436146,The Effect of Laryngeal Manual Therapy as a Management of Globus,UNKNOWN,NA,70.0,2022-03-01,2023-07-01,4.375359342915811,Adequate (1-10/month),43.753593429158116,Significantly Below (<50%),50,40.6,22.2
NCT06904846,To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period,ENROLLING_BY_INVITATION,NA,70.0,2025-04-23,2026-06-30,4.921016166281755,Adequate (1-10/month),49.21016166281755,Significantly Below (<50%),55,42.1,24.45
NCT07303946,Deep Brain Stimulation of the Anterior Cingulate Bundle (ACB) and the Ventral Anterior Limb of the Internal Capsule (vALIC) in Patients With Intractable Obsessive Compulsive Disorder (OCD),NOT_YET_RECRUITING,NA,4.0,2026-01-01,2031-01-01,0.06668127053669222,Slow (<1/month),0.6668127053669223,Significantly Below (<50%),30,24.3,6.3
NCT02057146,Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts,COMPLETED,NA,50.0,2013-10-01,2019-08-22,0.7075778707577871,Slow (<1/month),7.075778707577871,Significantly Below (<50%),100,49.0,46.050000000000004
NCT05281146,Production of Fortified Biscuit With Chickpea and Crushed Peanut for Improving Cognitive Performance,COMPLETED,NA,80.0,2018-11-26,2021-07-05,2.557983193277311,Adequate (1-10/month),25.57983193277311,Significantly Below (<50%),100,56.4,64.4
NCT07342946,The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome,NOT_YET_RECRUITING,NA,32.0,2025-12-20,2027-08-01,1.6537860780984721,Adequate (1-10/month),16.53786078098472,Significantly Below (<50%),30,26.6,7.75
NCT07292246,A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study),RECRUITING,NA,15.0,2025-09-09,2029-10-01,0.3078894133513149,Slow (<1/month),3.078894133513149,Significantly Below (<50%),60,34.2,13.600000000000001
NCT04042246,"Effect of Knowledge on Vaccine Take-up in Adamawa State, Northeastern Nigeria",COMPLETED,NA,400.0,2019-09-15,2020-02-09,82.82993197278911,Excellent (>50/month),200.0,Exceeded (≥100%),100,92.0,94.6
NCT03549546,Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.,COMPLETED,NA,31.0,2018-06-14,2019-02-12,3.883292181069959,Adequate (1-10/month),38.832921810699595,Significantly Below (<50%),100,52.5,54.400000000000006
NCT02249546,Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection,UNKNOWN,PHASE4,654.0,2014-09-01,2016-10-01,26.16,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,88.64999999999999
NCT03125746,A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors,UNKNOWN,PHASE1,72.0,2017-06-12,2021-10-28,1.370656660412758,Adequate (1-10/month),13.706566604127582,Significantly Below (<50%),50,35.8,15.4
NCT02805946,Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections,COMPLETED,PHASE4,21.0,2017-04-28,2019-09-07,0.7415777262180975,Slow (<1/month),7.415777262180974,Significantly Below (<50%),100,46.7,37.5
NCT06338046,SMosE Safety and Efficacy Evaluation as a Skin Adaptogen,COMPLETED,NA,40.0,2023-10-01,2023-12-22,14.848780487804879,Good (10-50/month),148.4878048780488,Exceeded (≥100%),100,58.2,69.19999999999999
NCT00594646,HIV Non Occupational Post-Exposure Prophylaxis (PEP),COMPLETED,PHASE4,100.0,2008-02-01,2010-08-01,3.3377192982456143,Adequate (1-10/month),33.377192982456144,Significantly Below (<50%),100,58.0,68.30000000000001
NCT06059846,A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP),COMPLETED,PHASE3,1690.0,2023-12-21,2025-02-06,124.56077481840194,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT04689646,Mind Body Syndrome Therapy for Chronic Pain,RECRUITING,NA,150.0,2021-05-20,2026-06-01,2.4842219804134933,Adequate (1-10/month),24.84221980413493,Significantly Below (<50%),60,50.0,48.05
NCT07288346,Effect of Predictive Model on Double-Balloon Enteroscopy,RECRUITING,NA,338.0,2026-01-12,2027-08-31,17.26295302013423,Good (10-50/month),172.62953020134228,Exceeded (≥100%),60,70.0,81.95
NCT00043888,Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR,COMPLETED,PHASE3,60.0,2002-01-01,2003-05-01,3.765773195876289,Adequate (1-10/month),37.65773195876289,Significantly Below (<50%),100,54.8,61.199999999999996
NCT03107988,NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922),COMPLETED,PHASE1,65.0,2017-09-05,2025-01-31,0.731460258780037,Slow (<1/month),7.31460258780037,Significantly Below (<50%),100,50.2,48.199999999999996
NCT06499688,A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines,COMPLETED,PHASE3,529.0,2023-12-28,2024-05-31,103.88877419354839,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT04544488,Descriptive Evaluation of Expulsive Efforts During Pregnancy in Term Nulliparous Women by Measurement of Intra Bladder Pressure: Pilot Observational Study.,UNKNOWN,NA,45.0,2021-12-28,2022-10-01,4.945126353790614,Adequate (1-10/month),49.451263537906144,Significantly Below (<50%),50,38.6,19.400000000000002
NCT00289588,An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers,COMPLETED,NA,3000.0,2005-01-01,2005-12-01,273.41317365269464,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT02546388,Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis,COMPLETED,NA,17.0,2015-10-01,2018-08-01,0.4999806763285024,Slow (<1/month),4.999806763285024,Significantly Below (<50%),100,46.4,35.5
NCT03742388,A Genomic Analysis of Evolution of Epithelia Ovarian Tumors,UNKNOWN,,40.0,2018-11-10,2020-12-23,1.5731266149870802,Adequate (1-10/month),15.731266149870804,Significantly Below (<50%),50,31.5,10.2
NCT04968288,Natural History of KSHV-Associated Multicentric Castleman s Disease,RECRUITING,,195.0,2021-11-17,2035-01-01,1.2384310452743583,Adequate (1-10/month),12.384310452743584,Significantly Below (<50%),60,46.9,38.6
NCT06941688,"Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma",TERMINATED,PHASE2,17.0,2020-11-13,2024-12-30,0.3431564986737401,Slow (<1/month),3.431564986737401,Significantly Below (<50%),10,19.4,4.55
NCT02194088,Combined Medication for Improved Analgesia in Superficial Pain,COMPLETED,PHASE3,100.0,2014-04-01,2017-06-01,2.630942091616249,Adequate (1-10/month),26.30942091616249,Significantly Below (<50%),100,58.0,68.30000000000001
NCT04484688,Prestilol(Perindopril+Bisoprolol) in Therapy of Patients With Atrial Fibrilation,UNKNOWN,,50.0,2020-08-01,2021-12-01,3.1252566735112937,Adequate (1-10/month),31.252566735112943,Significantly Below (<50%),50,37.3,17.25
NCT02656888,Efficacy and Safety of Irlanda-1-Association on the Treatment of Common Cold in Children,WITHDRAWN,PHASE3,0.0,2019-06-01,2020-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT02625688,The Risk of Hyperbilirubinemia in Term Newborns After Placental Transfusion,COMPLETED,NA,400.0,2013-08-01,2016-12-01,9.99671592775041,Adequate (1-10/month),99.9671592775041,Met (75-100%),100,87.0,93.2
NCT04712903,Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE3,101.0,2020-12-16,2023-06-21,3.352715376226827,Adequate (1-10/month),33.52715376226827,Significantly Below (<50%),100,58.1,69.0
NCT05565703,The Use of PARO to Decrease Agitation in Persons With Dementia and/or Delirium,COMPLETED,NA,104.0,2018-10-30,2023-10-30,1.733713033953998,Adequate (1-10/month),17.33713033953998,Significantly Below (<50%),100,58.3,69.3
NCT06673303,Investigating The Role of Noise Correlations in Learning,RECRUITING,NA,40.0,2024-12-14,2025-09-01,4.665134099616859,Adequate (1-10/month),46.651340996168585,Significantly Below (<50%),60,41.2,22.650000000000002
NCT00654303,OLE Study to Evaluate Safety / Efficacy of ZD4522,COMPLETED,PHASE3,3500.0,1999-08-01,2005-02-01,52.97861760318249,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT03498703,Azathioprine in Recurrent Implantation Failure,COMPLETED,PHASE2,64.0,2018-04-25,2019-07-01,4.50962962962963,Adequate (1-10/month),45.096296296296295,Significantly Below (<50%),100,55.1,62.1
NCT04822103,A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer,COMPLETED,,155.0,2021-01-01,2021-10-31,15.571617161716173,Good (10-50/month),155.7161716171617,Exceeded (≥100%),100,65.7,77.9
NCT07088003,Yoga as Mindful Movement: A Randomized Controlled Trial,COMPLETED,NA,47.0,2021-10-04,2022-03-02,9.601879194630872,Adequate (1-10/month),96.01879194630872,Met (75-100%),100,58.8,69.89999999999999
NCT06054503,Pilot Clinical Investigation to Evaluate a Prototype of Sensor Measuring Ventilator-derived Parameters,COMPLETED,NA,59.0,2023-09-26,2024-06-06,7.0707086614173225,Adequate (1-10/month),70.70708661417322,Below (50-75%),100,54.7,60.699999999999996
NCT07059403,"A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults",RECRUITING,PHASE1,36.0,2025-08-19,2027-04-01,1.85735593220339,Adequate (1-10/month),18.5735593220339,Significantly Below (<50%),60,40.9,22.3
NCT05673603,A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment,COMPLETED,PHASE1,28.0,2021-07-20,2023-02-14,1.484878048780488,Adequate (1-10/month),14.848780487804877,Significantly Below (<50%),100,47.2,39.85
NCT01050803,Effectiveness of the Farsi Diabetes Self-management Education (FDSME) Program for People With Type 2 Diabetes,COMPLETED,NA,280.0,2009-08-01,2011-04-01,14.01842105263158,Good (10-50/month),140.1842105263158,Exceeded (≥100%),100,77.4,86.15
NCT06603103,Prospective Randomized Study Comparing the SpheriKA® (MEDACTA) and Origin® (SYMBIOS) Prostheses During Total Knee Replacement Using the Kinematic Alignment Technique,RECRUITING,NA,120.0,2024-10-03,2028-04-30,2.7990804597701153,Adequate (1-10/month),27.990804597701153,Significantly Below (<50%),60,47.6,41.8
NCT03034603,The Safety and Efficacy Test of Nutri-PEITC Jelly in Head and Neck Cancer Patients,COMPLETED,NA,96.0,2014-08-01,2023-01-01,0.9503219512195121,Slow (<1/month),9.503219512195123,Significantly Below (<50%),100,52.7,54.85
NCT02482103,The Dutch National Renal Denervation Registry,UNKNOWN,,1000.0,2013-04-01,2020-04-01,11.904575674618695,Good (10-50/month),119.04575674618695,Exceeded (≥100%),50,78.3,87.0
NCT01295203,Internet-based Physical Activity Intervention,COMPLETED,PHASE3,12287.0,2008-05-01,2009-05-01,1024.7021369863014,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT03899103,Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome,COMPLETED,PHASE3,100.0,2019-05-15,2023-12-24,1.8076009501187649,Adequate (1-10/month),18.07600950118765,Significantly Below (<50%),100,58.0,68.30000000000001
NCT06141603,Comparison of Upper and Lower Limb Maximal Exercise Capacities and Muscle Oxygenation in Patients With ILD,UNKNOWN,,30.0,2023-11-25,2024-12-30,2.2773067331670824,Adequate (1-10/month),22.77306733167082,Significantly Below (<50%),50,35.7,15.25
NCT05568303,the Role of Problem Solving in Cognitive Behavioral Therapy for Mothers With Autistic Children,COMPLETED,NA,60.0,2022-06-01,2023-01-01,8.534579439252337,Adequate (1-10/month),85.34579439252337,Met (75-100%),100,59.8,71.3
NCT07158203,Optical Diagnosis of Neoplasia Using Artificial Intelligence,NOT_YET_RECRUITING,NA,70.0,2025-09-01,2025-12-01,23.415384615384617,Good (10-50/month),200.0,Exceeded (≥100%),30,39.6,20.4
NCT02786303,Interest of Whole-body MRI Correlated to Spreading Sequences for Staging Neuroendocrine Tumors,UNKNOWN,NA,100.0,2014-04-01,2017-04-01,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),50,43.0,25.7
NCT04191603,TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY,UNKNOWN,NA,100.0,2020-10-30,2021-12-30,7.145539906103287,Adequate (1-10/month),71.45539906103286,Below (50-75%),50,43.0,25.7
NCT02020603,Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps for Acute Peptic Ulcer Bleeding,COMPLETED,NA,151.0,2012-01-01,2014-06-01,5.211383219954649,Adequate (1-10/month),52.113832199546486,Below (50-75%),100,62.1,74.2
NCT03184103,Acute Post Streptococcal Glomerulonephritis,UNKNOWN,,50.0,2017-06-27,2019-12-27,1.6670317634173057,Adequate (1-10/month),16.670317634173056,Significantly Below (<50%),50,37.3,17.25
NCT01916603,"Diet, Physical Activity and Breastfeeding Intervention on Maternal Nutrition, Offspring Growth and Development",UNKNOWN,NA,2400.0,2013-09-01,2017-03-01,57.20908379013312,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.95
NCT00684203,Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016),COMPLETED,PHASE2,120.0,2006-12-01,2007-10-01,12.01578947368421,Good (10-50/month),120.15789473684211,Exceeded (≥100%),100,64.6,76.85
NCT05337527,Neuromuscular Responses to Acute Beetroot Ingestion in Women Older Adults,COMPLETED,NA,9.0,2022-03-01,2022-04-10,6.849,Adequate (1-10/month),68.49000000000001,Below (50-75%),100,50.7,49.15
NCT03248427,Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.,COMPLETED,PHASE2,106.0,2017-07-13,2019-07-20,4.3780732700135685,Adequate (1-10/month),43.78073270013568,Significantly Below (<50%),100,58.5,69.55
NCT01026727,A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy,TERMINATED,PHASE2,2.0,2009-11-01,2010-06-01,0.28716981132075475,Slow (<1/month),2.8716981132075476,Significantly Below (<50%),10,18.2,3.15
NCT05856227,Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age,COMPLETED,PHASE3,9.0,2023-08-06,2024-12-18,0.54792,Slow (<1/month),5.4792,Significantly Below (<50%),100,45.7,31.4
NCT03187327,Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology,COMPLETED,,69.0,2013-09-01,2015-01-01,4.312854209445585,Adequate (1-10/month),43.12854209445586,Significantly Below (<50%),100,53.9,58.45
NCT03975127,Cervical Cytology - Do SMS Reminders Increase Participation in the Cervical Screening Programme?,UNKNOWN,NA,50000.0,2019-12-01,2021-03-01,3337.719298245614,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.95
NCT06716827,Bleaching Procedures Performed During Treatment With Brackets and Clear Aligners,COMPLETED,NA,56.0,2022-11-09,2024-11-09,2.3319288645690834,Adequate (1-10/month),23.319288645690836,Significantly Below (<50%),100,54.5,59.650000000000006
NCT05917327,Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease,TERMINATED,NA,1.0,2024-01-24,2025-09-15,0.05073333333333333,Slow (<1/month),0.5073333333333333,Significantly Below (<50%),10,18.1,2.9000000000000004
NCT05877027,Exercise vs. Topical Diclofenac vs. PRP,COMPLETED,NA,82.0,2024-03-20,2025-05-18,5.886981132075472,Adequate (1-10/month),58.869811320754714,Below (50-75%),100,56.6,65.14999999999999
NCT01873027,OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON,COMPLETED,PHASE3,829.0,2013-06-01,2016-07-01,22.410976909413854,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT02343627,Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail,COMPLETED,PHASE2,47.0,2014-12-01,2016-01-01,3.612828282828283,Adequate (1-10/month),36.12828282828283,Significantly Below (<50%),100,53.8,57.9
NCT03137927,"A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine",COMPLETED,PHASE1,36.0,2017-06-13,2017-12-27,5.56263959390863,Adequate (1-10/month),55.626395939086294,Below (50-75%),100,52.9,55.2
NCT04703127,Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.,UNKNOWN,PHASE3,60.0,2020-03-30,2021-01-30,5.968627450980392,Adequate (1-10/month),59.68627450980393,Below (50-75%),50,39.8,20.8
NCT06764927,Fibrinogen in Liver Transplant Subjects,NOT_YET_RECRUITING,PHASE4,30.0,2025-10-31,2026-03-01,7.547107438016529,Adequate (1-10/month),75.4710743801653,Met (75-100%),30,31.4,10.0
NCT01996527,3T MRI Biomarkers of Glioma Treatment Response,TERMINATED,EARLY_PHASE1,7.0,2012-05-01,2016-01-01,0.15901492537313433,Slow (<1/month),1.5901492537313433,Significantly Below (<50%),10,18.6,3.65
NCT03937427,Unified Airway Model,UNKNOWN,,24.0,2017-01-16,2020-04-01,0.6238770281810418,Slow (<1/month),6.238770281810417,Significantly Below (<50%),50,30.3,9.0
NCT00418327,Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma,COMPLETED,PHASE1,48.0,2005-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.8,27.3
NCT00532727,Triple Negative Breast Cancer Trial,UNKNOWN,PHASE3,400.0,2008-01-01,2020-03-01,2.7404906594643257,Adequate (1-10/month),27.404906594643258,Significantly Below (<50%),50,67.0,79.60000000000001
NCT06192927,Efficacy and Safety of TenoMiR in Lateral Epicondylitis,COMPLETED,PHASE2,123.0,2024-04-10,2025-06-12,8.747943925233646,Adequate (1-10/month),87.47943925233645,Met (75-100%),100,64.8,77.10000000000001
NCT06381427,"Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure",RECRUITING,NA,1057.0,2024-09-01,2027-03-01,35.3184193194292,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,90.64999999999999
NCT02944227,Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration,COMPLETED,PHASE4,20.0,2016-03-03,2017-08-21,1.135820895522388,Adequate (1-10/month),11.35820895522388,Significantly Below (<50%),100,46.6,36.7
NCT00774527,Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT,COMPLETED,PHASE3,82.0,2003-03-01,2011-01-01,0.8718407265106531,Slow (<1/month),8.718407265106531,Significantly Below (<50%),100,51.6,51.949999999999996
NCT06629727,The Effect Of Virtual Reality Glasses On Pain And Anxiety During The Kidney Stone Lithotripsy Procedure,ACTIVE_NOT_RECRUITING,NA,60.0,2021-07-25,2024-11-10,1.5169435215946845,Adequate (1-10/month),15.169435215946844,Significantly Below (<50%),85,45.3,30.45
NCT03370627,Effect of Anti-CD303 Antibodies in Autoimmune Diseases,COMPLETED,NA,138.0,2017-12-20,2019-05-25,8.062802303262957,Adequate (1-10/month),80.62802303262957,Met (75-100%),100,61.0,72.3
NCT01854827,Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia,COMPLETED,PHASE1,30.0,2013-10-01,2016-07-01,0.9095617529880479,Slow (<1/month),9.095617529880478,Significantly Below (<50%),100,47.4,40.75
NCT06940427,Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis,RECRUITING,PHASE2,50.0,2025-11-19,2027-09-01,2.337941628264209,Adequate (1-10/month),23.37941628264209,Significantly Below (<50%),60,42.0,24.05
NCT04163627,Changing Trends in HCC Procedures,UNKNOWN,,1000.0,2019-11-30,2021-03-25,63.28482328482328,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,91.2
NCT02009527,Arginase Inhibition in Ischemia-reperfusion Injury,COMPLETED,PHASE1,24.0,2012-01-01,2013-09-01,1.1996059113300492,Adequate (1-10/month),11.996059113300491,Significantly Below (<50%),100,46.9,38.6
NCT06741761,12-hour Time Limited Feeding in Critical Care,RECRUITING,NA,20.0,2025-03-25,2026-06-01,1.4060046189376443,Adequate (1-10/month),14.060046189376443,Significantly Below (<50%),60,34.6,13.900000000000002
NCT00309361,"Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures",COMPLETED,PHASE3,240.0,2006-02-01,2006-07-01,48.704,Good (10-50/month),200.0,Exceeded (≥100%),100,79.2,87.64999999999999
NCT05904561,Effect of Low Level Laser Therapy Versus Pulsed Ultrasound,COMPLETED,NA,48.0,2023-04-01,2023-08-20,10.362553191489361,Good (10-50/month),103.62553191489361,Exceeded (≥100%),100,58.8,69.89999999999999
NCT04540861,Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease,NO_LONGER_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,5.8500000000000005
NCT03184961,Lung Recruitment Maneuver for Predicting Fluid Responsiveness in Children,COMPLETED,NA,30.0,2017-06-15,2019-05-31,1.2772027972027973,Adequate (1-10/month),12.772027972027974,Significantly Below (<50%),100,47.4,40.75
NCT06459661,The Bowel Movement Monitoring (BoMoMo) Study,RECRUITING,,24.0,2024-05-01,2024-06-30,12.176,Good (10-50/month),121.76,Exceeded (≥100%),60,43.3,26.450000000000003
NCT06371261,Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis,RECRUITING,,35.0,2024-03-12,2028-03-01,0.7347586206896551,Slow (<1/month),7.347586206896552,Significantly Below (<50%),60,34.1,13.5
NCT02406261,A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants,COMPLETED,PHASE1,82.0,2015-04-30,2015-08-31,20.293333333333333,Good (10-50/month),200.0,Exceeded (≥100%),100,61.6,73.1
NCT01947361,Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber),UNKNOWN,,1961286.0,2012-01-01,2014-12-01,56057.78952112676,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,91.2
NCT00448461,Antithrombotic Regimens and Outcome,COMPLETED,PHASE4,850.0,2007-03-01,2008-06-01,56.49344978165939,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT02276261,The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy,COMPLETED,NA,43.0,2014-11-01,2016-06-01,2.264567474048443,Adequate (1-10/month),22.645674740484434,Significantly Below (<50%),100,53.4,57.25
NCT05732961,Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms,RECRUITING,PHASE2,70.0,2023-02-21,2026-09-01,1.6543478260869566,Adequate (1-10/month),16.543478260869566,Significantly Below (<50%),60,38.6,19.400000000000002
NCT03617861,Effect of Secretin in Functional Dyspepsia and Healthy Subjects,COMPLETED,PHASE1,20.0,2018-11-07,2019-08-01,2.2801498127340825,Adequate (1-10/month),22.801498127340828,Significantly Below (<50%),100,51.6,51.949999999999996
NCT02848261,Remote Monitoring of Diabetes in Young Children With Type 1 Diabetes,COMPLETED,NA,92.0,2016-08-15,2019-04-01,2.9202085505735145,Adequate (1-10/month),29.20208550573514,Significantly Below (<50%),100,57.4,66.9
NCT06252961,A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects,RECRUITING,PHASE2,99.0,2024-06-21,2026-02-01,5.107728813559323,Adequate (1-10/month),51.07728813559322,Below (50-75%),60,45.9,32.4
NCT06167161,Clinical Investigation and Validation of a Self-fitted Air-conduction Hearing Aid,COMPLETED,NA,21.0,2023-01-30,2023-05-30,5.327,Adequate (1-10/month),53.269999999999996,Below (50-75%),100,51.7,52.300000000000004
NCT05567861,Virtual Reality for Fibromyalgia,ACTIVE_NOT_RECRUITING,,60.0,2022-10-11,2025-09-01,1.7295454545454545,Adequate (1-10/month),17.295454545454543,Significantly Below (<50%),85,48.6,45.1
NCT00673361,"Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",TERMINATED,PHASE2,9.0,2007-03-01,2009-01-01,0.40767857142857145,Slow (<1/month),4.076785714285715,Significantly Below (<50%),10,18.7,3.85
NCT01333761,Cardiox Shunt Detection Technology Study,TERMINATED,PHASE3,71.0,2011-04-01,2012-07-01,4.729190371991248,Adequate (1-10/month),47.291903719912476,Significantly Below (<50%),10,28.7,8.3
NCT03847961,Efficacy and Safety Study of CA330 Hemoadsorption Device on IL-6 Removal in Septic Patients,UNKNOWN,NA,144.0,2018-12-17,2020-10-01,6.702385321100918,Adequate (1-10/month),67.02385321100918,Below (50-75%),50,46.5,36.05
NCT07177261,Inter-Brain Synchrony in Schizophrenia,RECRUITING,NA,100.0,2025-12-01,2027-11-30,4.175582990397805,Adequate (1-10/month),41.755829903978054,Significantly Below (<50%),60,46.0,33.2
NCT03413761,"Antioxidant Supplements, Genetics and Chemotherapy Outcomes",COMPLETED,,1771.0,2004-12-18,2013-11-12,16.582356198092896,Good (10-50/month),165.82356198092893,Exceeded (≥100%),100,93.3,95.1
NCT04370561,Outcome Following Semitubular Plate vs. Polyaxial Locking Plates,COMPLETED,NA,45.0,2016-01-01,2019-01-01,1.2498175182481752,Adequate (1-10/month),12.498175182481752,Significantly Below (<50%),100,48.6,45.1
NCT03550261,"Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia",COMPLETED,,30.0,2018-05-17,2021-11-15,0.7145539906103286,Slow (<1/month),7.145539906103286,Significantly Below (<50%),100,45.7,31.4
NCT06940661,Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis,NOT_YET_RECRUITING,PHASE2,33.0,2025-06-01,2028-07-01,0.892113676731794,Slow (<1/month),8.92113676731794,Significantly Below (<50%),30,26.6,7.75
NCT00174161,The Symptom Experience of Women With Perimenstrual Syndrome;Women's Health Related Quality of Life.,UNKNOWN,,1000.0,2005-08-01,2005-12-01,249.50819672131146,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,91.2
NCT01251861,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,ACTIVE_NOT_RECRUITING,PHASE2,108.0,2010-12-23,2026-03-18,0.5908554996405464,Slow (<1/month),5.908554996405464,Significantly Below (<50%),85,49.1,46.300000000000004
NCT03967561,Progressive vs. Non-progressive Water-based Aerobic Training on Type 2 Diabetes Control: a Randomized Clinical Trial,UNKNOWN,NA,50.0,2019-06-10,2019-11-15,9.632911392405063,Adequate (1-10/month),96.32911392405063,Met (75-100%),50,44.0,27.450000000000003
NCT05008861,Gut Microbiota Reconstruction for NSCLC Immunotherapy,UNKNOWN,PHASE1,20.0,2021-09-01,2022-12-30,1.255257731958763,Adequate (1-10/month),12.552577319587629,Significantly Below (<50%),50,31.6,10.45
NCT07255742,Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.,COMPLETED,NA,50.0,2025-08-01,2025-12-04,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,59.0,70.39999999999999
NCT06578442,Effectiveness of Electromagnetic Field Therapy in Chronic Constipation,COMPLETED,NA,40.0,2019-02-01,2020-01-31,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),100,53.2,56.10000000000001
NCT02101242,Regional Cerebral Oxygen Saturation Under General Anesthesia A Pilot Study,TERMINATED,,42.0,2014-05-11,2014-09-17,9.910697674418603,Adequate (1-10/month),99.10697674418604,Met (75-100%),10,29.7,8.7
NCT00521742,Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease,COMPLETED,PHASE3,300.0,2001-03-01,2003-01-01,13.609538002980626,Good (10-50/month),136.09538002980625,Exceeded (≥100%),100,79.0,87.35000000000001
NCT00981942,Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec,COMPLETED,PHASE3,10.0,2009-09-01,2010-12-01,0.6675438596491229,Slow (<1/month),6.675438596491229,Significantly Below (<50%),100,45.8,31.900000000000002
NCT04170842,"Music During Paediatric Outpatient Wound Dressing Changes: Impact on Anxiety, Pain and Patient Satisfaction",COMPLETED,NA,48.0,2016-12-23,2019-03-28,1.7710545454545454,Adequate (1-10/month),17.710545454545453,Significantly Below (<50%),100,53.8,57.9
NCT06978842,Seizure Prediction Using Wearable EEG,RECRUITING,,150.0,2025-06-19,2026-03-01,17.905882352941177,Good (10-50/month),179.05882352941177,Exceeded (≥100%),60,53.3,56.8
NCT03866642,Two Year Follow up of Cadence Total Ankle Replacement,UNKNOWN,,40.0,2018-09-01,2019-07-01,4.018481848184819,Adequate (1-10/month),40.18481848184819,Significantly Below (<50%),50,36.5,16.0
NCT01134042,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,COMPLETED,PHASE3,587.0,2010-06-01,2011-10-01,36.69051334702259,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT04432142,Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial,ACTIVE_NOT_RECRUITING,,45.0,2021-04-01,2026-12-01,0.6617391304347826,Slow (<1/month),6.6173913043478265,Significantly Below (<50%),85,42.4,24.9
NCT02418442,Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry,RECRUITING,,20000.0,2015-07-01,2028-12-01,124.19420644634845,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,92.85
NCT01735942,Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions,WITHDRAWN,EARLY_PHASE1,0.0,2012-10-01,2016-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT03791242,Ketogenic Diet and CPAP Previous Bariatric Surgery,COMPLETED,NA,66.0,2019-03-21,2021-05-19,2.543088607594937,Adequate (1-10/month),25.430886075949367,Significantly Below (<50%),100,55.3,62.35000000000001
NCT02205242,BACE Trial Substudy 1 - PROactive Substudy,COMPLETED,PHASE3,60.0,2014-09-01,2020-04-01,0.8957332025502698,Slow (<1/month),8.957332025502698,Significantly Below (<50%),100,49.8,47.8
NCT05547542,Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing,COMPLETED,PHASE1,19.0,2023-03-02,2024-08-06,1.10585086042065,Adequate (1-10/month),11.058508604206502,Significantly Below (<50%),100,46.5,36.05
NCT05115942,Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.,COMPLETED,PHASE3,248.0,2021-12-30,2024-10-22,7.350652385589094,Adequate (1-10/month),73.50652385589095,Below (50-75%),100,69.8,81.69999999999999
NCT00079742,A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis,COMPLETED,PHASE2,68.0,2003-09-01,2007-05-01,1.5470254110612855,Adequate (1-10/month),15.470254110612855,Significantly Below (<50%),100,50.4,48.55
NCT03680742,Contour Neurovascular System - European Pre-Market Unruptured Aneurysm,COMPLETED,NA,34.0,2018-09-18,2021-02-02,1.1923502304147466,Adequate (1-10/month),11.923502304147465,Significantly Below (<50%),100,47.7,42.3
NCT02288442,Whole Muscle Exercise Training (WHOLEi+12) in Pulmonary Hypertension,COMPLETED,NA,40.0,2015-01-01,2016-06-01,2.3551257253384916,Adequate (1-10/month),23.551257253384918,Significantly Below (<50%),100,53.2,56.10000000000001
NCT03882242,Effect of a Prevention Program on Program Facilitators,UNKNOWN,NA,50.0,2016-08-01,2022-11-01,0.6666666666666666,Slow (<1/month),6.666666666666667,Significantly Below (<50%),50,34.0,13.3
NCT03364686,Transfusion of Biotin-Labeled Red Blood Cells,TERMINATED,PHASE2,6.0,2019-09-16,2021-06-29,0.2801226993865031,Slow (<1/month),2.801226993865031,Significantly Below (<50%),10,18.5,3.45
NCT06508086,Pilonidal Sinus Disease,RECRUITING,NA,30.0,2024-06-10,2025-06-01,2.5651685393258425,Adequate (1-10/month),25.65168539325843,Significantly Below (<50%),60,40.4,22.1
NCT06729086,Propofol vs Sevoflurane in Cardiac Surgery,NOT_YET_RECRUITING,NA,100.0,2025-01-04,2025-05-31,20.707482993197278,Good (10-50/month),200.0,Exceeded (≥100%),30,42.0,24.05
NCT02689986,Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease,COMPLETED,PHASE2,43.0,2013-01-01,2016-12-01,0.9153286713286714,Slow (<1/month),9.153286713286715,Significantly Below (<50%),100,48.4,44.2
NCT05562986,Impacts of Oral Irrigation in Orthodontic Patients,COMPLETED,NA,30.0,2018-03-01,2018-12-27,3.033887043189369,Adequate (1-10/month),30.33887043189369,Significantly Below (<50%),100,52.4,54.0
NCT05193786,Low Versus High PEEP in Noninvasive Ventilation for Hypoxemic Respiratory Failure,COMPLETED,NA,380.0,2022-01-11,2024-08-31,12.011630321910697,Good (10-50/month),120.11630321910698,Exceeded (≥100%),100,85.4,92.30000000000001
NCT03115086,The REPLACE Registry for Cholbam® (Cholic Acid),ACTIVE_NOT_RECRUITING,,55.0,2017-07-10,2039-07-01,0.2085970595564416,Slow (<1/month),2.0859705955644157,Significantly Below (<50%),85,43.2,26.200000000000003
NCT04213586,Effects of Whey Protein and Collagen Supplementation,COMPLETED,NA,22.0,2019-09-01,2019-12-05,7.049263157894737,Adequate (1-10/month),70.49263157894737,Below (50-75%),100,51.8,52.449999999999996
NCT05796986,Endovascular Treatment of Wide Neck Saccular Cerebral Aneurysms,RECRUITING,NA,40.0,2022-01-01,2024-12-01,1.1432863849765258,Adequate (1-10/month),11.43286384976526,Significantly Below (<50%),60,36.2,15.65
NCT03943186,"Application of Ectoin Containing Lozenges (EHT02) in Patients With Acute, Viral Pharyngitis.",COMPLETED,,102.0,2018-12-13,2019-05-13,20.562119205298014,Good (10-50/month),200.0,Exceeded (≥100%),100,61.5,72.89999999999999
NCT00364286,Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825),COMPLETED,PHASE2,17.0,2006-08-01,2012-11-01,0.2265674255691769,Slow (<1/month),2.265674255691769,Significantly Below (<50%),100,46.4,35.5
NCT02089386,Tamoxifen to Treat Barrett's Metaplasia,TERMINATED,EARLY_PHASE1,7.0,2014-07-09,2016-06-21,0.2988499298737728,Slow (<1/month),2.988499298737728,Significantly Below (<50%),10,18.6,3.65
NCT07018986,The MIND-BC Study: MIND Diet for Breast Cancer Cognition,RECRUITING,NA,200.0,2025-07-09,2030-03-01,3.5896226415094343,Adequate (1-10/month),35.89622641509434,Significantly Below (<50%),60,54.0,59.0
NCT06860386,Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC,SUSPENDED,PHASE2,75.0,2025-02-25,2028-02-01,2.131652661064426,Adequate (1-10/month),21.31652661064426,Significantly Below (<50%),20,32.0,11.0
NCT03648086,Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease,UNKNOWN,NA,30.0,2017-11-14,2020-11-01,0.843213296398892,Slow (<1/month),8.43213296398892,Significantly Below (<50%),50,32.4,11.65
NCT06840886,A Study of PHST001 in Advanced Solid Tumors,RECRUITING,PHASE1,155.0,2025-03-31,2031-04-01,2.152463503649635,Adequate (1-10/month),21.52463503649635,Significantly Below (<50%),60,50.4,48.55
NCT06855186,Symptom-Targeted Approach to Rehabilitation for Concussion (STAR-C),RECRUITING,NA,222.0,2025-09-18,2028-08-31,6.268719851576995,Adequate (1-10/month),62.68719851576995,Below (50-75%),60,55.8,63.05
NCT06079086,Evaluation of the Clinical Evolution of Breast Increase Using Prostheses,UNKNOWN,NA,60.0,2014-05-01,2024-05-30,0.4960347637153721,Slow (<1/month),4.9603476371537205,Significantly Below (<50%),50,34.8,14.299999999999999
NCT03121586,Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia,TERMINATED,PHASE3,995.0,2017-01-01,2024-05-30,11.192830746489284,Good (10-50/month),111.92830746489284,Exceeded (≥100%),10,68.0,80.5
NCT01417286,Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer,COMPLETED,PHASE2,69.0,2010-12-21,2020-02-20,0.6273476702508961,Slow (<1/month),6.273476702508961,Significantly Below (<50%),100,50.5,48.75
NCT04036370,Continuous Pectoral Nerve Block in Breast Cancer Surgery,COMPLETED,NA,48.0,2019-07-30,2019-11-15,13.52888888888889,Good (10-50/month),135.2888888888889,Exceeded (≥100%),100,58.8,69.89999999999999
NCT03650270,Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting,COMPLETED,PHASE3,198.0,2015-03-01,2018-03-01,5.499197080291971,Adequate (1-10/month),54.99197080291971,Below (50-75%),100,65.8,78.05
NCT01139970,Veliparib and Temozolomide in Treating Patients With Acute Leukemia,COMPLETED,PHASE1,66.0,2010-06-04,2018-12-01,0.6476595744680851,Slow (<1/month),6.476595744680851,Significantly Below (<50%),100,50.3,48.35
NCT00372970,Placebo Controlled Trial of Botulinum Toxin for Gastroparesis,COMPLETED,NA,32.0,2003-07-01,2008-12-01,0.491959595959596,Slow (<1/month),4.91959595959596,Significantly Below (<50%),100,47.6,41.8
NCT06551870,Xbox Kinect Sports Versus Nintendo Switch Sports,RECRUITING,NA,45.0,2024-04-14,2024-12-14,5.613934426229508,Adequate (1-10/month),56.139344262295076,Below (50-75%),60,41.6,23.400000000000002
NCT05463770,A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia,COMPLETED,PHASE1,15.0,2022-08-30,2023-08-22,1.2789915966386556,Adequate (1-10/month),12.789915966386555,Significantly Below (<50%),100,46.2,34.4
NCT01172470,Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients,COMPLETED,PHASE2,34.0,2005-06-01,2010-07-01,0.5576293103448277,Slow (<1/month),5.5762931034482754,Significantly Below (<50%),100,47.7,42.3
NCT00362570,Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma,COMPLETED,PHASE2,1.0,2005-05-01,2011-03-01,0.014291079812206573,Slow (<1/month),0.14291079812206575,Significantly Below (<50%),100,45.1,30.049999999999997
NCT00729170,Milk Supplementation and Energy Balance.,COMPLETED,NA,41.0,2006-10-01,2009-02-01,1.4614051522248244,Adequate (1-10/month),14.614051522248245,Significantly Below (<50%),100,48.3,43.9
NCT03248570,Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects,COMPLETED,PHASE2,26.0,2018-02-20,2023-09-28,0.3868230694037146,Slow (<1/month),3.8682306940371456,Significantly Below (<50%),100,47.1,39.45
NCT02489370,CHF Home Telemonitoring: A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial,UNKNOWN,NA,40.0,2014-10-01,2016-12-01,1.5373737373737375,Adequate (1-10/month),15.373737373737374,Significantly Below (<50%),50,33.2,12.35
NCT00294970,Cognitive Characteristics of PTSD Patients With OCD,COMPLETED,,76.0,2006-02-01,2006-08-01,12.781436464088397,Good (10-50/month),127.81436464088398,Exceeded (≥100%),100,59.4,70.6
NCT02551770,Emdogain Minimally Invasive Surgical Technique,COMPLETED,NA,51.0,2015-10-01,2019-08-30,1.0863820853743877,Adequate (1-10/month),10.863820853743876,Significantly Below (<50%),100,49.1,46.300000000000004
NCT03782870,Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis,UNKNOWN,,100.0,2010-02-01,2019-12-30,0.8411163304780326,Slow (<1/month),8.411163304780326,Significantly Below (<50%),50,36.3,15.8
NCT06806670,Exercise and Diet Effects in Reducing Cardiovascular Risk in Kidney Transplant Recipients,RECRUITING,NA,275.0,2025-01-07,2031-01-01,3.8311212814645312,Adequate (1-10/month),38.311212814645316,Significantly Below (<50%),60,60.0,71.65
NCT02823470,A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation,TERMINATED,PHASE4,24.0,2016-06-01,2017-08-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),10,24.9,6.8500000000000005
NCT04860570,Are Double-ring Wound-edge Protectors Effective for Preventing Superficial Surgical Site Infection After Open Appendectomy?,UNKNOWN,,671.0,2024-10-25,2024-12-31,304.85432835820893,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,91.2
NCT03446170,Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers,COMPLETED,NA,400.0,2014-09-01,2020-08-31,5.557279780921954,Adequate (1-10/month),55.572797809219544,Below (50-75%),100,82.0,90.10000000000001
NCT04083170,Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers,TERMINATED,PHASE2,1.0,2022-10-06,2022-11-30,0.5534545454545455,Slow (<1/month),5.534545454545455,Significantly Below (<50%),10,18.1,2.9000000000000004
NCT04405570,"Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",COMPLETED,PHASE2,204.0,2020-06-19,2021-02-21,25.140728744939274,Good (10-50/month),200.0,Exceeded (≥100%),100,71.3,82.69999999999999
NCT04020770,Influence of Upper Extremity Vibration on Spasticity and Function in Persons With Tetraplegia,COMPLETED,NA,12.0,2018-10-28,2019-02-20,3.176347826086957,Adequate (1-10/month),31.763478260869565,Significantly Below (<50%),100,51.0,50.2
NCT04321070,Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris,COMPLETED,PHASE1,550.0,2019-09-09,2020-03-06,93.53072625698324,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT04833270,Pragmatic Randomized Controlled Trial of Non-pharmacological Treatment for Lumbar Disc Herniation : A Pilot Study,COMPLETED,NA,30.0,2021-07-09,2022-06-28,2.5796610169491525,Adequate (1-10/month),25.796610169491522,Significantly Below (<50%),100,52.4,54.0
NCT03915470,Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection,COMPLETED,PHASE2,124.0,2019-08-29,2021-03-29,6.530380622837371,Adequate (1-10/month),65.30380622837372,Below (50-75%),100,59.9,71.45
NCT04907370,PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma,ACTIVE_NOT_RECRUITING,PHASE3,532.0,2021-08-01,2027-03-01,7.9460647693817466,Adequate (1-10/month),79.46064769381746,Met (75-100%),85,85.5,92.45
NCT00395473,Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED),COMPLETED,PHASE3,141.0,2005-03-01,2005-11-01,17.5185306122449,Good (10-50/month),175.185306122449,Exceeded (≥100%),100,66.3,78.85
NCT03884673,Dolutegravir Plus Lamivudine Simplified Therapy,RECRUITING,,300.0,2019-01-01,2030-12-31,2.083979917845733,Adequate (1-10/month),20.83979917845733,Significantly Below (<50%),60,60.3,71.89999999999999
NCT03112473,Effect of Bilateral TENS With TOT on Upper Limb Function in Patients With Chronic Stroke,COMPLETED,NA,120.0,2016-11-24,2020-10-24,2.5544055944055946,Adequate (1-10/month),25.54405594405595,Significantly Below (<50%),100,59.6,70.95
NCT05273073,Effects of Probiotics on Gut Microbiota Composition and Metabolic Outcomes in Post- Gestational Diabetes Women,COMPLETED,NA,166.0,2018-03-01,2021-04-26,4.386319444444444,Adequate (1-10/month),43.863194444444446,Significantly Below (<50%),100,63.3,75.55
NCT04628273,Treatment Strategy of Pancreatic Radiolucent Stone,COMPLETED,,52.0,2011-03-01,2020-01-30,0.4859932453177771,Slow (<1/month),4.8599324531777714,Significantly Below (<50%),100,47.5,41.3
NCT05106673,Clinical Implementation and Evaluation for the Family-oriented Care CHIMPS-NET,UNKNOWN,NA,798.0,2020-01-01,2023-09-01,18.141239731142644,Good (10-50/month),181.41239731142645,Exceeded (≥100%),50,80.0,88.64999999999999
NCT05655273,Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients,ENROLLING_BY_INVITATION,PHASE4,40.0,2024-01-01,2026-02-28,1.5432192648922687,Adequate (1-10/month),15.432192648922689,Significantly Below (<50%),55,34.7,14.099999999999998
NCT07107373,A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US,ACTIVE_NOT_RECRUITING,,150.0,2023-12-22,2025-12-31,6.1702702702702705,Adequate (1-10/month),61.70270270270271,Below (50-75%),85,55.8,63.05
NCT02543073,MSC for Treatment of Interstitial Lung Disease After Allo-HSCT,UNKNOWN,PHASE1,60.0,2014-09-01,2018-06-01,1.3341124908692477,Adequate (1-10/month),13.341124908692478,Significantly Below (<50%),50,34.8,14.299999999999999
NCT03352973,Regulation of Craving in Internet Gamers,COMPLETED,NA,20.0,2018-07-20,2018-10-20,6.6173913043478265,Adequate (1-10/month),66.17391304347827,Below (50-75%),100,51.6,51.949999999999996
NCT05833373,Vagal Nerve Stimulation for the Treatment of Persistent AF,UNKNOWN,NA,120.0,2023-11-06,2025-12-20,4.7132903225806455,Adequate (1-10/month),47.13290322580646,Significantly Below (<50%),50,44.6,28.549999999999997
NCT00782873,Balanced Propofol Sedation During Upper Endoscopy in Morbidly Obese Patients,COMPLETED,,65.0,2008-03-01,2008-09-01,10.753260869565217,Good (10-50/month),107.53260869565217,Exceeded (≥100%),100,58.5,69.55
NCT00810173,Phone Call in Type 2 Diabetes Patient,COMPLETED,NA,48.0,2008-01-01,2008-10-01,5.332554744525547,Adequate (1-10/month),53.325547445255474,Below (50-75%),100,53.8,57.9
NCT02531373,"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)",COMPLETED,PHASE1,338.0,2015-09-15,2017-04-14,17.83140381282496,Good (10-50/month),178.3140381282496,Exceeded (≥100%),100,82.0,90.10000000000001
NCT00869973,Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients,TERMINATED,PHASE3,580.0,2009-09-01,2012-07-01,17.074661508704065,Good (10-50/month),170.74661508704062,Exceeded (≥100%),10,68.0,80.5
NCT05564273,Viome Nutritional Programs to Improve Clinical Outcomes for Metabolic Conditions,RECRUITING,NA,150.0,2023-10-13,2026-12-01,3.9877729257641925,Adequate (1-10/month),39.877729257641924,Significantly Below (<50%),60,50.0,48.05
NCT04179773,Chemotherapy and Liver Cirrhosis in Frequently-associated Cancers,TERMINATED,,7.0,2019-01-24,2019-10-25,0.7776642335766423,Slow (<1/month),7.776642335766423,Significantly Below (<50%),10,16.9,2.6
NCT05894473,Effects of Telerehabilitation-Based Motor and Cognitive Dual-Task Exercise in Patients With Parkinson's Disease,COMPLETED,NA,30.0,2023-05-30,2023-08-01,14.495238095238095,Good (10-50/month),144.95238095238093,Exceeded (≥100%),100,57.4,66.9
NCT01141673,Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia,UNKNOWN,,100.0,2010-06-01,2011-06-01,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,46.3,34.949999999999996
NCT05885373,A Clinical Study to Evaluate the Effect of SIM01 in Female With NAFLD,COMPLETED,NA,40.0,2023-03-01,2023-12-31,3.992131147540984,Adequate (1-10/month),39.921311475409844,Significantly Below (<50%),100,53.2,56.10000000000001
NCT03450473,A Prospective Case Series Evaluating Surgimend Mp® In Patients Undergoing Complex Abdominal Hernia Repair,COMPLETED,NA,24.0,2018-01-03,2022-12-31,0.4007460230389468,Slow (<1/month),4.007460230389468,Significantly Below (<50%),100,46.9,38.6
NCT05371873,A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer,UNKNOWN,,250.0,2021-03-01,2025-03-01,5.208761122518823,Adequate (1-10/month),52.087611225188226,Below (50-75%),50,53.3,56.8
NCT00336973,A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent,COMPLETED,PHASE4,73.0,2006-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,45.8,31.900000000000002
NCT05269173,Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease,COMPLETED,PHASE2,240.0,2020-10-29,2024-11-05,4.976566757493188,Adequate (1-10/month),49.76566757493188,Significantly Below (<50%),100,69.2,81.3
NCT07026773,Validity of ICU Clinician's Appraisal of Proportionality in CPR,RECRUITING,,1000.0,2025-05-18,2026-12-30,51.50592216582064,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,92.85
NCT05943873,Successful Microsurgical Breast Reconstruction in Minimally Invasive Mastectomy,COMPLETED,,63.0,2023-06-30,2023-07-05,63.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,63.4,75.75
NCT01956669,Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,COMPLETED,PHASE2,57.0,2014-10-08,2019-11-05,0.9358576051779937,Slow (<1/month),9.358576051779938,Significantly Below (<50%),100,49.6,47.4
NCT04524169,Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain,UNKNOWN,PHASE4,100.0,2020-11-01,2021-12-31,7.16235294117647,Adequate (1-10/month),71.62352941176471,Below (50-75%),50,43.0,25.7
NCT04876469,Radiocontrast Media in the Pulsed Radiofrequency Treatment,UNKNOWN,NA,60.0,2021-03-01,2021-07-01,14.970491803278687,Good (10-50/month),149.70491803278688,Exceeded (≥100%),50,44.8,29.099999999999998
NCT03329469,The Value of CT-FFR Compared to CCTA or CCTA and Stress MPI in Low to Intermediate Risk ED Patients With Toshiba CT-FFR,UNKNOWN,,1142.0,2018-04-18,2024-03-31,15.990101195952164,Good (10-50/month),159.9010119595216,Exceeded (≥100%),50,78.3,87.0
NCT07289269,Prevalence of Violence Against Infertile Women Attending Infertility Treatment,NOT_YET_RECRUITING,,233.0,2025-12-01,2027-12-01,9.715780821917809,Adequate (1-10/month),97.1578082191781,Met (75-100%),30,51.0,50.2
NCT02396069,"The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers",COMPLETED,PHASE1,24.0,2015-03-01,2015-08-01,4.774901960784314,Adequate (1-10/month),47.74901960784314,Significantly Below (<50%),100,51.9,52.75
NCT05981469,Can Cervical Stiffness Predict Successful Vaginal Delivery After Induction of Labour?,COMPLETED,,100.0,2023-09-29,2024-11-29,7.128805620608899,Adequate (1-10/month),71.288056206089,Below (50-75%),100,56.3,64.0
NCT05622669,Understanding Patterns of Fatigue in Health and Disease,ACTIVE_NOT_RECRUITING,,40.0,2021-12-07,2024-03-30,1.442654028436019,Adequate (1-10/month),14.42654028436019,Significantly Below (<50%),85,42.0,24.05
NCT06670469,Flipped Learning and Escape Room Method on Nursing Students,COMPLETED,,110.0,2024-10-24,2024-12-15,64.3923076923077,Excellent (>50/month),200.0,Exceeded (≥100%),100,67.1,79.80000000000001
NCT01281969,Intravenous Immunoglobulin for PANDAS,COMPLETED,PHASE3,48.0,2011-01-01,2018-08-13,0.525393743257821,Slow (<1/month),5.253937432578209,Significantly Below (<50%),100,48.8,45.75
NCT06801769,Study for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation with Metabolic Syndrome and Insulin-Secreting Cells.,NOT_YET_RECRUITING,NA,100.0,2025-02-01,2026-12-01,4.5568862275449105,Adequate (1-10/month),45.5688622754491,Significantly Below (<50%),30,37.0,16.8
NCT06752369,Adapting Single Sessions Interventions for Type 1 Diabetes,NOT_YET_RECRUITING,NA,80.0,2026-03-02,2029-02-01,2.282286785379569,Adequate (1-10/month),22.82286785379569,Significantly Below (<50%),30,35.4,14.799999999999999
NCT00839969,Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding,UNKNOWN,NA,30.0,2009-01-01,2009-10-01,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),50,37.4,17.549999999999997
NCT03618069,Diagnosis by Comprehensive Cardiovascular Imaging for Stroke and TIA,UNKNOWN,NA,100.0,2018-09-01,2019-08-30,8.385674931129477,Adequate (1-10/month),83.85674931129478,Met (75-100%),50,48.0,42.75
NCT04226183,Natural Antioxidant Intake After Exercise Can Oxidative Stress in the Third Trimester of Pragnancy,COMPLETED,NA,24.0,2016-02-03,2016-10-17,2.842645914396887,Adequate (1-10/month),28.426459143968874,Significantly Below (<50%),100,51.9,52.75
NCT05738083,Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH,RECRUITING,,5000.0,2018-10-01,2029-12-30,37.04965920155794,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,89.64999999999999
NCT03110783,Bioseal Dural Sealing Study BIOS-14-001,COMPLETED,PHASE3,200.0,2017-09-14,2019-09-20,8.271739130434783,Adequate (1-10/month),82.71739130434783,Met (75-100%),100,66.0,78.45
NCT04738383,Feasibility and Acceptance of Changes in Medical Supervision of Exercise Groups in Cardiac Rehabilitation,COMPLETED,NA,446.0,2018-11-05,2020-05-21,24.114103019538188,Good (10-50/month),200.0,Exceeded (≥100%),100,90.7,94.39999999999999
NCT00214383,Internet Telehealth for Pediatric Asthma Case Management,COMPLETED,NA,301.0,2004-05-01,2009-05-01,5.01776560788609,Adequate (1-10/month),50.1776560788609,Below (50-75%),100,74.1,84.65
NCT05380583,Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study,RECRUITING,NA,80.0,2022-05-19,2026-03-30,1.72586817859674,Adequate (1-10/month),17.2586817859674,Significantly Below (<50%),60,44.4,28.1
NCT06541483,Multicentre Clinical Study of Ultra-Fast-Track Anaesthesia for Minimally Invasive Heart Valve Surgery,NOT_YET_RECRUITING,NA,1200.0,2024-12-01,2028-12-01,25.00205338809035,Good (10-50/month),200.0,Exceeded (≥100%),30,74.0,84.45
NCT01545583,A Study of LY3016859 in Healthy Volunteers,COMPLETED,PHASE1,56.0,2012-04-01,2012-09-01,11.141437908496732,Good (10-50/month),111.41437908496732,Exceeded (≥100%),100,59.5,70.7
NCT01055483,"A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia",COMPLETED,PHASE1,59.0,2009-09-01,2012-02-01,2.0339297848244624,Adequate (1-10/month),20.339297848244623,Significantly Below (<50%),100,54.7,60.699999999999996
NCT04978883,Interstitial Lung Diseases in Primary Sjogren's Syndrome,COMPLETED,,170.0,2016-01-01,2018-07-31,5.493418259023355,Adequate (1-10/month),54.93418259023354,Below (50-75%),100,61.9,73.5
NCT00963183,AZD5423 Single Ascending Dose Study,COMPLETED,PHASE1,72.0,2009-08-01,2009-11-01,23.822608695652175,Good (10-50/month),200.0,Exceeded (≥100%),100,60.8,72.2
NCT01047683,Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL,COMPLETED,PHASE3,229.0,2009-12-01,2011-07-01,12.08103986135182,Good (10-50/month),120.81039861351822,Exceeded (≥100%),100,73.3,84.05
NCT03460483,Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care,COMPLETED,NA,1001.0,2018-03-30,2025-06-15,11.568124525436598,Good (10-50/month),115.68124525436599,Exceeded (≥100%),100,95.0,96.2
NCT01845883,Perceptual Decision Making Under Conditions of Visual Uncertainty,UNKNOWN,NA,120.0,2013-04-01,2016-12-01,2.725970149253732,Adequate (1-10/month),27.259701492537314,Significantly Below (<50%),50,44.6,28.549999999999997
NCT06525883,Analysis of Patients With Post-traumatic Vertebral Fracture and Accompanying Rib Fracture,COMPLETED,,151.0,2023-01-01,2024-02-01,11.607171717171717,Good (10-50/month),116.07171717171718,Exceeded (≥100%),100,65.4,77.75
NCT03054883,Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy,COMPLETED,,73.0,2012-04-01,2016-12-31,1.2807608069164265,Adequate (1-10/month),12.807608069164267,Significantly Below (<50%),100,49.2,46.650000000000006
NCT03320083,Behavioral Insomnia of Childhood: Impact of Parent Education,COMPLETED,NA,157.0,2016-02-01,2016-10-30,17.57014705882353,Good (10-50/month),175.70147058823528,Exceeded (≥100%),100,67.6,80.2
NCT01269983,Effectiveness of Fascial Manipulation for Chronic Low Back Pain,UNKNOWN,NA,50.0,2009-04-01,2010-12-01,2.4991789819376025,Adequate (1-10/month),24.991789819376024,Significantly Below (<50%),50,39.0,19.900000000000002
NCT06674083,Reliability of the Gyko Inertial Sensor System in Evaluating Jumping and Postural Stability Parameters in Healthy Adults,NOT_YET_RECRUITING,,55.0,2025-02-01,2025-05-01,18.81123595505618,Good (10-50/month),188.1123595505618,Exceeded (≥100%),30,36.7,16.3
NCT02863783,EUS Fiducial for Pancreas Surgery,UNKNOWN,NA,20.0,2016-11-23,2024-02-01,0.23183549124143185,Slow (<1/month),2.318354912414318,Significantly Below (<50%),50,31.6,10.45
NCT02303483,"The Effect of Vitamin B3 on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men",COMPLETED,NA,40.0,2016-01-04,2017-04-04,2.6701754385964915,Adequate (1-10/month),26.701754385964914,Significantly Below (<50%),100,53.2,56.10000000000001
NCT03450083,Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis,COMPLETED,PHASE2,33.0,2017-07-01,2020-02-01,1.062984126984127,Adequate (1-10/month),10.629841269841272,Significantly Below (<50%),100,47.6,41.8
NCT00055783,Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma,COMPLETED,PHASE2,,2002-07-01,2003-04-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,29.65
NCT05369741,"TIME™ at Home Feasibility Study: Evaluation of a Virtually Delivered, Community-based, Task-oriented Exercise Program",COMPLETED,NA,20.0,2022-01-22,2022-07-31,3.2042105263157894,Adequate (1-10/month),32.04210526315789,Significantly Below (<50%),100,51.6,51.949999999999996
NCT05017441,TOcilizumab and Covid-19 : Risk of Severe INfection,UNKNOWN,,1200.0,2021-08-16,2024-01-31,40.67706013363029,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,87.0
NCT00379041,Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma,ACTIVE_NOT_RECRUITING,PHASE3,1158.0,1993-09-01,,,Slow (<1/month),,Significantly Below (<50%),85,75.5,85.2
NCT03938441,"Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study",TERMINATED,NA,24.0,2019-07-31,2021-05-28,1.0952923538230885,Adequate (1-10/month),10.952923538230886,Significantly Below (<50%),10,19.9,5.0
NCT00232141,Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy,COMPLETED,PHASE3,302.0,2005-10-01,2007-11-01,12.08,Good (10-50/month),120.8,Exceeded (≥100%),100,79.2,87.64999999999999
NCT04334941,Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker,ACTIVE_NOT_RECRUITING,PHASE2,103.0,2020-07-20,2027-01-21,1.3195791245791246,Adequate (1-10/month),13.195791245791247,Significantly Below (<50%),85,48.7,45.550000000000004
NCT01836341,Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation,WITHDRAWN,PHASE1,0.0,2013-04-01,2015-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT05272241,Registry of Asthma Characterization and Recruitment 3 (RACR3),RECRUITING,,1500.0,2022-04-15,2028-05-01,20.679347826086957,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,89.64999999999999
NCT05476341,A Phase I Clinical Trial of Bevacizumab Injection,COMPLETED,PHASE1,98.0,2017-04-06,2017-08-18,22.262089552238805,Good (10-50/month),200.0,Exceeded (≥100%),100,62.8,75.1
NCT06442241,"A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults",ACTIVE_NOT_RECRUITING,PHASE1,84.0,2024-07-31,2025-12-30,4.945764023210832,Adequate (1-10/month),49.457640232108325,Significantly Below (<50%),85,52.2,53.400000000000006
NCT02533141,Effect of Simvastatin Withdrawal on Ocular Endothelial Function,WITHDRAWN,PHASE4,0.0,2019-10-01,2020-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6
NCT02466841,Prospective Comparison of Techniques for Cubital Tunnel Release,WITHDRAWN,,0.0,2015-08-01,2019-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.5
NCT05092854,The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress,COMPLETED,NA,18.0,2021-09-03,2022-08-01,1.6503614457831326,Adequate (1-10/month),16.503614457831326,Significantly Below (<50%),100,46.4,35.5
NCT00527254,Telemedicine Influence in the Follow up of the Type 2 Diabetes Patient,COMPLETED,NA,328.0,2003-10-01,2005-06-01,16.394614121510674,Good (10-50/month),163.9461412151067,Exceeded (≥100%),100,81.2,89.4
NCT01060254,"A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain",TERMINATED,PHASE2,31.0,2010-04-06,2011-06-24,2.1253153153153153,Adequate (1-10/month),21.253153153153153,Significantly Below (<50%),10,25.5,7.3
NCT05805254,Neurofunctional Study of Preterm Infants' Brain Activity,COMPLETED,,30.0,2018-03-25,2022-08-08,0.5718221665623043,Slow (<1/month),5.718221665623044,Significantly Below (<50%),100,45.7,31.4
NCT02024854,Skin-to-skin After Delivery in Preterm Infants Born at 28-32 Weeks of Gestation,ACTIVE_NOT_RECRUITING,NA,108.0,2014-02-01,2025-12-01,0.7608238833603334,Slow (<1/month),7.608238833603334,Significantly Below (<50%),85,49.1,46.300000000000004
NCT03626454,Norepinephrine Addition in Spinal Anesthesia of Caesarean Section,COMPLETED,NA,300.0,2020-10-16,2024-02-01,7.5910224438902745,Adequate (1-10/month),75.91022443890274,Met (75-100%),100,74.0,84.45
NCT03148054,Computed Tomography Vs. Endoscopy Study,RECRUITING,,400.0,2017-02-17,2025-12-31,3.7591849336214884,Adequate (1-10/month),37.59184933621489,Significantly Below (<50%),60,68.3,80.85
NCT00821054,A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients,COMPLETED,PHASE1,24.0,2009-03-06,2011-03-22,0.9793029490616623,Slow (<1/month),9.793029490616622,Significantly Below (<50%),100,46.9,38.6
NCT04743154,In-hospital Versus After-discharge Complete Revascularization,COMPLETED,NA,250.0,2018-01-20,2022-12-21,4.237193763919822,Adequate (1-10/month),42.371937639198215,Significantly Below (<50%),100,70.0,81.95
NCT05567354,A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103),COMPLETED,PHASE1,27.0,2022-06-10,2022-08-31,10.022926829268293,Good (10-50/month),100.22926829268293,Exceeded (≥100%),100,57.2,65.9
NCT04489654,Immediate Implant Using Socket Shield Technique With Xenogenic Bone Graft,UNKNOWN,NA,16.0,2019-07-20,2020-10-01,1.1094305239179953,Adequate (1-10/month),11.094305239179954,Significantly Below (<50%),50,31.3,9.65
NCT03729154,Preschool First Step to Success: An Efficacy Replication Study,COMPLETED,NA,162.0,2015-10-01,2023-06-30,1.7431177094379642,Adequate (1-10/month),17.431177094379642,Significantly Below (<50%),100,63.0,75.35
NCT03515954,AS-OCT Guided Treatment of Diffuse CSCC,COMPLETED,,15.0,2014-03-01,2018-10-01,0.27259701492537314,Slow (<1/month),2.7259701492537314,Significantly Below (<50%),100,44.5,28.249999999999996
NCT03682354,ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery,COMPLETED,NA,70.0,2018-09-27,2019-03-15,12.60828402366864,Good (10-50/month),126.0828402366864,Exceeded (≥100%),100,60.6,72.1
NCT03112954,Floral Remedies for Sleep-bruxism Patients,COMPLETED,NA,74.0,2014-05-29,2014-06-20,74.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,65.9,78.2
NCT03638154,Regenerative Potential of Cultured Gingival Fibroblast- Mesenchymal Stem Cells in Treatment of Periodontitis,COMPLETED,NA,20.0,2016-03-15,2018-02-22,0.8586741889985896,Slow (<1/month),8.586741889985895,Significantly Below (<50%),100,46.6,36.7
NCT02997254,COMparison of Physiological Algorithms for Real-time Evaluation of Atrial Fibrillation,RECRUITING,,1000.0,2016-12-01,2027-06-30,7.8798860988868755,Adequate (1-10/month),78.79886098886875,Met (75-100%),60,76.3,85.45
NCT03157154,Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies,COMPLETED,,259.0,2017-06-27,2017-07-30,238.9078787878788,Excellent (>50/month),200.0,Exceeded (≥100%),100,79.1,87.5
NCT00594854,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec,TERMINATED,PHASE3,20.0,2007-09-01,2008-09-01,1.6633879781420766,Adequate (1-10/month),16.633879781420767,Significantly Below (<50%),10,19.6,4.7
NCT07002554,Bright Light Therapy for Depressed Geriatric Inpatients,ENROLLING_BY_INVITATION,PHASE2,20.0,2025-11-14,2026-04-30,3.645508982035928,Adequate (1-10/month),36.455089820359284,Significantly Below (<50%),55,38.1,18.6
NCT00000354,Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3,COMPLETED,PHASE1,0.0,1996-07-01,1997-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),100,43.3,26.450000000000003
NCT06434454,EFT AND SLEEP QUALITY,NOT_YET_RECRUITING,NA,74.0,2024-06-20,2024-09-20,24.484347826086957,Good (10-50/month),200.0,Exceeded (≥100%),30,39.9,21.0
NCT05020054,Effect of Tecartherapy in the Treatment of Localized Fat and Sagging Abdominal Skin - Clinical and Experimental Study,COMPLETED,NA,60.0,2019-02-08,2021-07-01,2.0897025171624715,Adequate (1-10/month),20.897025171624712,Significantly Below (<50%),100,54.8,61.199999999999996
NCT00852254,Validation of Minimally Invasive Ultrasound Indicator Dilution Technique in Critically Ill Children,COMPLETED,,9.0,2008-06-01,2011-05-01,0.2574812030075188,Slow (<1/month),2.5748120300751878,Significantly Below (<50%),100,44.1,27.750000000000004
NCT03107754,Buffered Lidocaine in Paracervical Blocks,COMPLETED,PHASE4,98.0,2017-05-15,2018-10-25,5.6498484848484845,Adequate (1-10/month),56.49848484848485,Below (50-75%),100,57.8,67.45
NCT01205854,Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial,COMPLETED,PHASE4,238.0,2010-09-01,2015-04-01,4.330376569037657,Adequate (1-10/month),43.30376569037657,Significantly Below (<50%),100,69.0,81.2
NCT03694054,"Care Coordination in Oncology, Quality Among Patients With Lung Cancer and Their Caregivers",COMPLETED,NA,57.0,2018-06-04,2019-03-31,5.7836,Adequate (1-10/month),57.836,Below (50-75%),100,54.6,60.099999999999994
NCT03785054,"Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242",COMPLETED,PHASE1,71.0,2018-11-14,2021-03-11,2.5486320754716982,Adequate (1-10/month),25.486320754716985,Significantly Below (<50%),100,55.7,62.9
NCT04374305,Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2),ACTIVE_NOT_RECRUITING,PHASE2,100.0,2020-06-20,2030-12-01,0.7976939203354297,Slow (<1/month),7.9769392033542985,Significantly Below (<50%),85,48.5,44.6
NCT01198405,Study of Enahnced External Counterpulsation to Treat Coronary Heart Disease,UNKNOWN,NA,1050.0,2008-09-01,2013-09-01,17.50383351588171,Good (10-50/month),175.0383351588171,Exceeded (≥100%),50,80.0,88.64999999999999
NCT04873505,Functional Validation of Lactobacillus Containing Oral Tablet,COMPLETED,NA,50.0,2020-10-30,2022-04-29,2.787545787545788,Adequate (1-10/month),27.875457875457883,Significantly Below (<50%),100,54.0,59.0
NCT01762605,Treatment of Distal Radius Buckle Fractures,TERMINATED,NA,11.0,2010-03-01,2012-11-01,0.34307377049180326,Slow (<1/month),3.4307377049180325,Significantly Below (<50%),10,18.9,4.0
NCT01368705,Nitrogen Balance in Infants After Post Cardiothoracic Surgery,COMPLETED,PHASE4,24.0,2009-08-01,2012-06-01,0.7058550724637681,Slow (<1/month),7.058550724637682,Significantly Below (<50%),100,46.9,38.6
NCT07186205,A Study to Collect Data to Build Artificial Intelligence Derived Algorithms for Estimating Risk of Iron Deficiency and Anaemia in African Children,COMPLETED,,126.0,2025-10-13,2026-01-09,43.584545454545456,Good (10-50/month),200.0,Exceeded (≥100%),100,68.4,81.0
NCT04568005,Evaluation of Lymphedema Patients Status During Covid-19 Pandemic,COMPLETED,,60.0,2020-06-01,2020-08-01,29.940983606557374,Good (10-50/month),200.0,Exceeded (≥100%),100,58.1,69.0
NCT04313205,A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule,UNKNOWN,PHASE1,8.0,2020-08-01,2020-12-01,1.9960655737704918,Adequate (1-10/month),19.960655737704915,Significantly Below (<50%),50,35.6,15.1
NCT04045405,"Clinical Study to Assess Safety, PK and PD Parameters of CDR132L",COMPLETED,PHASE1,28.0,2019-06-21,2020-06-26,2.297358490566038,Adequate (1-10/month),22.97358490566038,Significantly Below (<50%),100,52.2,53.400000000000006
NCT00508105,Comparing Two Surgical Methods of Fixation of Subscapularis During Shoulder Arthroplasty,COMPLETED,NA,87.0,2006-11-01,2011-12-01,1.4268750000000001,Adequate (1-10/month),14.268749999999999,Significantly Below (<50%),100,52.0,53.1
NCT06580405,A Feasibility Study to Evaluate the Safety of the KNP-1000 Apheresis System in Severe Preeclampsia,NOT_YET_RECRUITING,NA,13.0,2025-05-31,2028-06-30,0.35143872113676733,Slow (<1/month),3.5143872113676733,Significantly Below (<50%),30,25.0,7.049999999999999
NCT07213505,This Clinical Investigation Assesses the Safety and Performance of a New Beamformer for MED-EL Cochlear Implant Recipients.,RECRUITING,NA,40.0,2025-09-29,2026-09-29,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),60,41.2,22.650000000000002
NCT00332605,N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence,COMPLETED,PHASE2,45.0,2006-06-01,2010-01-01,1.0456488549618321,Adequate (1-10/month),10.45648854961832,Significantly Below (<50%),100,48.6,45.1
NCT02736305,Use of Regorafenib in Recurrent Epithelial Ovarian Cancer,COMPLETED,PHASE2,21.0,2016-02-03,2019-11-18,0.461878612716763,Slow (<1/month),4.61878612716763,Significantly Below (<50%),100,46.7,37.5
NCT06220305,DNA Methylation Combined With Artificial Intelligence Imaging to Identify Lung Nodules,UNKNOWN,,100.0,2022-12-01,2024-12-31,4.0,Adequate (1-10/month),40.0,Significantly Below (<50%),50,41.3,22.85
NCT04324905,"Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers",COMPLETED,PHASE1,49.0,2020-04-29,2020-10-30,8.106304347826088,Adequate (1-10/month),81.06304347826088,Met (75-100%),100,53.9,58.45
NCT04158505,Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer,UNKNOWN,,3000.0,2020-02-28,2023-11-15,67.34513274336284,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,91.2
NCT05903105,Diversity in Patients With OAB,NOT_YET_RECRUITING,,1000.0,2025-01-01,2025-12-01,91.1377245508982,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.85000000000001
NCT00976105,Effects of Repeat Dosing of GSK1521498,COMPLETED,PHASE1,49.0,2009-09-22,2010-03-09,8.878333333333334,Adequate (1-10/month),88.78333333333333,Met (75-100%),100,58.9,70.15
NCT05203705,Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty,TERMINATED,PHASE2,64.0,2022-03-07,2023-03-14,5.236989247311828,Adequate (1-10/month),52.369892473118284,Below (50-75%),10,28.1,8.200000000000001
NCT06891105,Effect of Probiotic and Synbiotic Administration on Nutritional Status in Hemodialysis Patients,NOT_YET_RECRUITING,NA,60.0,2025-04-15,2025-11-01,9.132,Adequate (1-10/month),91.32000000000001,Met (75-100%),30,38.8,19.7
NCT01802905,Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies,COMPLETED,NA,100.0,2012-06-01,2015-02-01,3.1220512820512822,Adequate (1-10/month),31.220512820512823,Significantly Below (<50%),100,58.0,68.30000000000001
NCT05465005,Perception of Electrical Stimuli in Individuals with Stroke,ACTIVE_NOT_RECRUITING,NA,45.0,2022-02-01,2026-03-01,0.919946272666219,Slow (<1/month),9.19946272666219,Significantly Below (<50%),85,44.1,27.750000000000004
NCT00159705,Trial of Efficacy and Safety of Pregabalin in Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy,COMPLETED,PHASE3,276.0,2005-04-01,2007-06-01,10.621289506953225,Good (10-50/month),106.21289506953224,Exceeded (≥100%),100,77.1,85.6
NCT02978105,Effects of Self-conditioning Techniques in Promoting Weight Loss in Patients With Obesity. A Randomized Controlled Trial,COMPLETED,PHASE3,120.0,2015-02-01,2017-09-01,3.8735949098621423,Adequate (1-10/month),38.735949098621425,Significantly Below (<50%),100,59.6,70.95
NCT03902405,Computerized Exercise to Alter Stimulant Approach Responses,UNKNOWN,NA,60.0,2018-06-11,2022-03-31,1.314902807775378,Adequate (1-10/month),13.14902807775378,Significantly Below (<50%),50,34.8,14.299999999999999
NCT01190605,Evaluating Factors That Impact Loss to Follow-up Among Postpartum HIV-infected Women in Mississippi,COMPLETED,,53.0,2010-07-01,2013-07-01,1.472007299270073,Adequate (1-10/month),14.72007299270073,Significantly Below (<50%),100,47.6,41.8
NCT05264805,Effectiveness of Port Site Bupivacaine Injection in Postoperative Pain Reduction After Lap. Chole,UNKNOWN,PHASE3,166.0,2022-03-01,2022-09-01,27.46217391304348,Good (10-50/month),200.0,Exceeded (≥100%),50,53.3,56.8
NCT02456805,Alternate Formula Feedings in Formula Intolerant Infants,COMPLETED,NA,113.0,1996-08-01,1997-06-01,11.314868421052632,Good (10-50/month),113.14868421052633,Exceeded (≥100%),100,64.0,76.35
NCT04586205,Task Augmentation of Transcranial Magnetic Stimulation (TMS),COMPLETED,,17.0,2019-04-07,2024-03-11,0.2874888888888889,Slow (<1/month),2.8748888888888895,Significantly Below (<50%),100,44.7,28.9
NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,COMPLETED,PHASE3,307.0,2013-01-24,2013-11-19,31.25444816053512,Good (10-50/month),200.0,Exceeded (≥100%),100,79.6,88.0
NCT07279194,Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes,RECRUITING,PHASE3,825.0,2025-10-14,2026-12-13,59.08941176470588,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,93.7
NCT05947994,Elucidate Outcomes of Elective High-grade/Total Occlusion Intracranial Arteries Using Low-profile Self-expanding Stent,COMPLETED,NA,156.0,2022-01-01,2024-04-20,5.653142857142857,Adequate (1-10/month),56.53142857142858,Below (50-75%),100,62.5,74.65
NCT01248494,PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer,COMPLETED,PHASE1,72.0,2010-11-01,2016-05-01,1.0914741035856574,Adequate (1-10/month),10.914741035856574,Significantly Below (<50%),100,50.8,49.55
NCT06011694,The Jinling Cohort,RECRUITING,,15000.0,2022-06-15,2027-05-15,254.37325905292482,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,92.85
NCT01647594,Pilot Study for Young Women's Intervention,COMPLETED,NA,93.0,2011-03-01,2012-07-01,5.801065573770492,Adequate (1-10/month),58.01065573770491,Below (50-75%),100,57.4,66.9
NCT06483594,Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407),NOT_YET_RECRUITING,,400.0,2024-06-30,2025-06-30,33.35890410958905,Good (10-50/month),200.0,Exceeded (≥100%),30,64.3,76.64999999999999
NCT03810794,Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease,RECRUITING,NA,180.0,2019-03-01,2026-12-30,1.915134568332751,Adequate (1-10/month),19.15134568332751,Significantly Below (<50%),60,52.4,54.0
NCT04069494,Descriptors and Predictors of Burden and Information Needs,COMPLETED,,112.0,2019-10-01,2020-02-29,22.578013245033112,Good (10-50/month),200.0,Exceeded (≥100%),100,62.3,74.4
NCT02474394,Effects of Videolaryngoscope on Intraocular Pressure,COMPLETED,PHASE4,80.0,2013-02-01,2015-06-01,2.8649411764705883,Adequate (1-10/month),28.649411764705885,Significantly Below (<50%),100,56.4,64.4
NCT03462394,Increasing Patient Engagement in the Annual Well Visits Program,COMPLETED,,5475.0,2018-02-19,2019-07-24,320.4980769230769,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT02086994,Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol,COMPLETED,PHASE3,60.0,2013-03-01,2015-08-01,2.068403171007928,Adequate (1-10/month),20.684031710079275,Significantly Below (<50%),100,54.8,61.199999999999996
NCT07353294,Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC,NOT_YET_RECRUITING,PHASE1,12.0,2026-01-01,2029-06-30,0.28626959247648903,Slow (<1/month),2.8626959247648904,Significantly Below (<50%),30,25.0,7.049999999999999
NCT00857194,Cardiovascular Disease Study,COMPLETED,,170.0,2007-03-01,2017-06-21,1.374448871181939,Adequate (1-10/month),13.744488711819388,Significantly Below (<50%),100,56.9,65.4
NCT02216994,A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study,UNKNOWN,NA,80.0,2013-01-01,2015-06-01,2.7641316685584565,Adequate (1-10/month),27.641316685584567,Significantly Below (<50%),50,41.4,23.1
NCT04229394,2ccPA Study in Patients With Symptomatic Knee Osteoarthritis,COMPLETED,PHASE1,40.0,2018-02-13,2021-03-22,1.0746690203000882,Adequate (1-10/month),10.746690203000881,Significantly Below (<50%),100,48.2,43.6
NCT04723394,Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults,COMPLETED,PHASE3,910.0,2021-01-28,2022-10-19,44.03879173290938,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT05955794,Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes,UNKNOWN,NA,500.0,2023-09-01,2025-09-20,20.293333333333337,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,88.64999999999999
NCT06504394,A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65),ACTIVE_NOT_RECRUITING,PHASE2,66.0,2024-10-14,2028-11-08,1.3519784656796772,Adequate (1-10/month),13.519784656796771,Significantly Below (<50%),85,45.8,31.900000000000002
NCT02720094,Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men,COMPLETED,PHASE2,4570.0,2016-12-19,2025-03-31,46.00224867724868,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.2
NCT00765466,"A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies",TERMINATED,PHASE2,30.0,2007-10-01,2010-05-01,0.9683987274655356,Slow (<1/month),9.683987274655356,Significantly Below (<50%),10,20.4,5.35
NCT01679366,The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients,COMPLETED,PHASE3,57.0,2012-10-01,2013-10-01,4.7536438356164386,Adequate (1-10/month),47.53643835616439,Significantly Below (<50%),100,54.6,60.099999999999994
NCT03530566,Study to Evaluate Effectiveness of a Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery,UNKNOWN,,25.0,2018-05-01,2019-03-01,2.5032894736842106,Adequate (1-10/month),25.032894736842103,Significantly Below (<50%),50,35.3,14.549999999999999
NCT00064766,Norplant and Irregular Bleeding/Spotting,UNKNOWN,PHASE4,50.0,2003-02-01,2005-02-01,2.0820793433652534,Adequate (1-10/month),20.820793433652533,Significantly Below (<50%),50,39.0,19.900000000000002
NCT02153866,The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine,UNKNOWN,PHASE4,2800.0,2013-12-01,2014-08-01,350.7489711934157,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.95
NCT06061666,Treatment of Insomnia in Patients With Breast Cancer,UNKNOWN,NA,80.0,2023-06-01,2024-06-30,6.165063291139242,Adequate (1-10/month),61.650632911392414,Below (50-75%),50,41.4,23.1
NCT01788566,A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer,COMPLETED,PHASE2,61.0,2013-03-01,2015-12-01,1.8476019900497511,Adequate (1-10/month),18.476019900497512,Significantly Below (<50%),100,54.9,61.6
NCT06939166,Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases,RECRUITING,EARLY_PHASE1,12.0,2025-06-17,2027-10-01,0.43693779904306224,Slow (<1/month),4.369377990430623,Significantly Below (<50%),60,34.0,13.3
NCT05224466,Characteristics and Clinical Outcomes of Peritoneal Dialysis Patients,UNKNOWN,,400.0,2022-03-01,2024-12-01,12.103379721669981,Good (10-50/month),121.0337972166998,Exceeded (≥100%),50,70.3,82.3
NCT05633056,An Adaptive Randomized Controlled Trial,RECRUITING,NA,360.0,2023-03-07,2029-04-01,4.942895805142085,Adequate (1-10/month),49.42895805142085,Significantly Below (<50%),60,66.8,79.25
NCT04518956,Shockwave Therapy Versus LIPUS on Mandibular Fracture Bone Healing,COMPLETED,NA,21.0,2016-12-18,2018-06-23,1.1580434782608695,Adequate (1-10/month),11.580434782608695,Significantly Below (<50%),100,46.7,37.5
NCT07282756,EVALUATION OF THE EFFECTIVNESS OF SUBGINGIVAL APPLICATION OF 1.2% LOVASTATIN GEL AS AN ADJUNCT TO NON-SURGICAL TREATMENT OF PERIODONTITIS IN GENERALLY HEALTHY SMOKERS AND NON-SMOKERS PATIENTS FROM CENTAL EUROPE- A SPLIT-MOUTH RANDOMIZED CONTROLLED TRIAL.,RECRUITING,NA,44.0,2025-07-11,2026-12-01,2.636535433070866,Adequate (1-10/month),26.365354330708655,Significantly Below (<50%),60,41.5,23.3
NCT02448056,MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma,UNKNOWN,,150.0,2015-06-01,2025-05-01,1.2606294864715628,Adequate (1-10/month),12.606294864715629,Significantly Below (<50%),50,40.3,21.9
NCT01939756,Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms,COMPLETED,PHASE1,50.0,2012-01-01,2013-06-01,2.9439071566731143,Adequate (1-10/month),29.439071566731144,Significantly Below (<50%),100,54.0,59.0
NCT01610856,Single Dose Versus Split Dose Polyethylene Glycol-based Colonic Lavage for Colonoscopy,COMPLETED,NA,250.0,2010-03-01,2010-06-01,82.71739130434783,Excellent (>50/month),200.0,Exceeded (≥100%),100,80.0,88.64999999999999
NCT04877756,Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery,COMPLETED,PHASE2,22.0,2021-08-19,2023-07-12,0.9677456647398844,Slow (<1/month),9.677456647398843,Significantly Below (<50%),100,46.8,38.05
NCT02093156,A Predictive Score Identifies Patients With Inadequate Bowel Preparation for Colonoscopy,COMPLETED,,605.0,2013-09-01,2013-12-01,202.3758241758242,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT01402856,Teenage Driving Safety Study: An Emergency Medicine-Trauma Collaborative Study,COMPLETED,,3750.0,2007-11-01,2012-05-01,69.47656725502131,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT01318356,The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment,COMPLETED,PHASE4,156.0,2011-04-01,2015-09-01,2.9421561338289965,Adequate (1-10/month),29.421561338289965,Significantly Below (<50%),100,62.5,74.65
NCT02910856,Infective Endocarditis in the Elderly,COMPLETED,,120.0,2015-03-01,2017-07-01,4.282297772567409,Adequate (1-10/month),42.82297772567409,Significantly Below (<50%),100,57.9,67.65
NCT01934556,A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema,COMPLETED,PHASE1,150.0,2013-11-01,2018-04-01,2.832506203473945,Adequate (1-10/month),28.32506203473945,Significantly Below (<50%),100,62.0,73.8
NCT02198456,"Imaging Control Study, 3D Echo, MR and RHC.",UNKNOWN,,12.0,2014-07-01,2019-12-01,0.18457806973218796,Slow (<1/month),1.8457806973218798,Significantly Below (<50%),50,29.3,8.5
NCT00871156,Tafenoquine/Chloroquine DDI Study,COMPLETED,PHASE1,68.0,2009-03-24,2009-08-26,13.354322580645162,Good (10-50/month),133.5432258064516,Exceeded (≥100%),100,60.4,72.0
NCT05558956,Total Body PET-CT Imaging of Prostate Cancer Using Illuccix,UNKNOWN,EARLY_PHASE1,100.0,2022-11-01,2023-12-01,7.706329113924052,Adequate (1-10/month),77.0632911392405,Met (75-100%),50,43.0,25.7
NCT07332156,Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas,COMPLETED,,21692.0,2009-01-01,2023-12-31,120.55951798429797,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.75
NCT03252756,Effects of Cannabidiol in Alcohol Use Disorder,COMPLETED,PHASE1,27.0,2019-09-01,2022-03-16,0.8866019417475729,Slow (<1/month),8.86601941747573,Significantly Below (<50%),100,47.2,39.85
NCT05323656,A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN),COMPLETED,PHASE2,55.0,2022-04-06,2025-08-21,1.3578264395782644,Adequate (1-10/month),13.578264395782647,Significantly Below (<50%),100,49.4,47.0
NCT03592056,Hemidiaphragmatic Paralysis With Diluted Continuous Interscalene Plexus Infusions,TERMINATED,,30.0,2018-08-10,2019-07-23,2.6317002881844385,Adequate (1-10/month),26.31700288184438,Significantly Below (<50%),10,23.7,6.0
NCT00042822,"FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma",COMPLETED,PHASE2,,2002-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.3
NCT06576622,"PERIodontal Disease, Microbiota and Miscarriage",RECRUITING,,30.0,2024-11-29,2026-12-30,1.2,Adequate (1-10/month),12.0,Significantly Below (<50%),60,33.7,13.0
NCT02633722,"Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?",COMPLETED,NA,15.0,2016-01-01,2018-07-30,0.4852284803400638,Slow (<1/month),4.8522848034006385,Significantly Below (<50%),100,46.2,34.4
NCT07082322,European Prospective Bloodstream Infection Cohort,NOT_YET_RECRUITING,,40000.0,2025-09-01,2031-01-01,625.0513347022587,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.85000000000001
NCT05536622,Hi-Res IR Thermography for the Diagnosis of Toddler's Fractures,UNKNOWN,NA,50.0,2021-02-11,2022-09-30,2.553691275167785,Adequate (1-10/month),25.536912751677853,Significantly Below (<50%),50,39.0,19.900000000000002
NCT04969822,eValuating iDA Selection Ability. The VISA Study.,COMPLETED,NA,1066.0,2020-02-20,2023-11-01,24.036325925925926,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,96.2
NCT00512122,Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients,ACTIVE_NOT_RECRUITING,PHASE4,4640.0,2007-08-01,2026-12-01,20.00022656471255,Good (10-50/month),200.0,Exceeded (≥100%),85,90.5,94.25
NCT00451022,Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies,RECRUITING,,750.0,2004-09-13,,,Slow (<1/month),,Significantly Below (<50%),60,66.3,78.85
NCT06369922,TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.,RECRUITING,NA,100.0,2024-07-01,2026-06-01,4.348571428571429,Adequate (1-10/month),43.48571428571428,Significantly Below (<50%),60,46.0,33.2
NCT04523922,Oxytocin to Enhance Integrated Treatment for AUD and PTSD,RECRUITING,PHASE2,180.0,2021-03-29,2026-12-01,2.643125904486252,Adequate (1-10/month),26.43125904486252,Significantly Below (<50%),60,52.4,54.0
NCT01168622,Impact of Race/Ethnicity on Platelet Function,COMPLETED,,625.0,2010-06-01,2013-03-30,18.41723136495644,Good (10-50/month),184.17231364956436,Exceeded (≥100%),100,93.3,95.1
NCT06824922,"""Educational Intervention 'Be Yourself': Digital Innovation to Prevent Teenage Pregnancy""",NOT_YET_RECRUITING,NA,150.0,2025-02-06,2025-06-06,38.050000000000004,Good (10-50/month),200.0,Exceeded (≥100%),30,46.0,33.2
NCT04332822,"A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma",RECRUITING,PHASE3,300.0,2020-08-19,2028-12-28,2.991156239764167,Adequate (1-10/month),29.911562397641667,Significantly Below (<50%),60,62.0,73.8
NCT01968122,Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China,COMPLETED,,300.0,2013-09-01,2015-12-01,11.123020706455542,Good (10-50/month),111.23020706455542,Exceeded (≥100%),100,77.3,85.85000000000001
NCT01747122,The Effects of Local Infiltration Versus Epidural Following Liver Resection 2,COMPLETED,NA,97.0,2012-12-01,2014-08-01,4.856381578947368,Adequate (1-10/month),48.563815789473686,Significantly Below (<50%),100,57.8,67.45
NCT05041322,Improving Ventilatory Capacity in Those With Chronic High Level SCI,COMPLETED,PHASE2,13.0,2020-11-29,2024-11-01,0.2761479413817167,Slow (<1/month),2.761479413817167,Significantly Below (<50%),100,46.0,33.2
NCT06713122,Effects of Symptom Management Education With Mobile Application in Gynecological Cancer Patients Receiving Chemotherapy,ENROLLING_BY_INVITATION,NA,70.0,2025-01-01,2026-02-02,5.367254408060454,Adequate (1-10/month),53.67254408060453,Below (50-75%),55,42.1,24.45
NCT00136422,Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia,COMPLETED,PHASE1,30.0,2000-01-01,2006-03-01,0.40568636161705907,Slow (<1/month),4.056863616170591,Significantly Below (<50%),100,47.4,40.75
NCT03444922,Effects of BPA on Insulin and Glucose Responses,COMPLETED,NA,11.0,2016-09-01,2019-02-14,0.3737053571428572,Slow (<1/month),3.737053571428571,Significantly Below (<50%),100,45.9,32.4
NCT06425822,Characterization of Left Atrial Substrate in Patients With Ventricular Arrhythmias,RECRUITING,,50.0,2023-11-08,2027-10-31,1.0474879559532002,Adequate (1-10/month),10.474879559532004,Significantly Below (<50%),60,35.3,14.549999999999999
NCT00985322,Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis,COMPLETED,PHASE3,269.0,2009-05-01,2016-04-01,3.240348239018599,Adequate (1-10/month),32.40348239018599,Significantly Below (<50%),100,71.5,82.89999999999999
NCT03022851,The Prophet Trial -Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension,COMPLETED,NA,32.0,2017-07-19,2024-01-08,0.41204737732656516,Slow (<1/month),4.120473773265652,Significantly Below (<50%),100,47.6,41.8
NCT04872751,Immune Response of Haemodialysis Patients Post Covid-19 Vaccination,UNKNOWN,,425.0,2021-04-27,2022-04-01,38.16224188790561,Good (10-50/month),200.0,Exceeded (≥100%),50,72.3,83.5
NCT03583151,Corticosteroid vs. Amniotic Fluid Injections in Patients With Trigger Finger,UNKNOWN,PHASE3,100.0,2018-05-10,2019-12-01,5.340350877192983,Adequate (1-10/month),53.40350877192983,Below (50-75%),50,43.0,25.7
NCT05565651,Retrospective Study of Intestinal Microbiota in Association With Diabetes,COMPLETED,,334.0,2020-01-01,2022-06-30,11.160219538968168,Good (10-50/month),111.60219538968168,Exceeded (≥100%),100,80.1,89.2
NCT04162951,Retrolaminar Thoracic Paravertebral Block,COMPLETED,NA,93.0,2019-11-10,2023-10-19,1.9672828353022933,Adequate (1-10/month),19.67282835302293,Significantly Below (<50%),100,57.4,66.9
NCT01492751,Effectiveness of Localized Prostate Cancer Treatments,ACTIVE_NOT_RECRUITING,,500.0,2003-04-01,2025-12-01,1.8381642512077294,Adequate (1-10/month),18.381642512077292,Significantly Below (<50%),85,83.8,91.5
NCT00920751,Comparison of on Demand Sedation With Study Method Versus on Demand Sedation With Conventional Method for Performing Colonoscopy for Colorectal Cancer Screening and Surveillance,UNKNOWN,NA,100.0,2009-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,33.0,12.1
NCT02518451,Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg,COMPLETED,NA,48.0,2013-06-01,2014-03-01,5.352087912087913,Adequate (1-10/month),53.52087912087913,Below (50-75%),100,53.8,57.9
NCT00277251,Alendronate Osteoporosis Study,COMPLETED,PHASE2,20.0,2003-03-01,2006-06-01,0.5124579124579125,Slow (<1/month),5.124579124579125,Significantly Below (<50%),100,46.6,36.7
NCT04602351,Communication in ICU During COVID-19,COMPLETED,,296.0,2021-03-22,2021-05-01,225.256,Excellent (>50/month),200.0,Exceeded (≥100%),100,82.0,90.10000000000001
NCT06159751,PROGNOSTIC ROLE OF SERUM ALBUMIN LEVEL IN RADIOLOGICAL PROGRESSION OF GONARTHROSIS: IS IT A BIOMARKER IN ITSELF? A BIOMARKER ASSOCIATED WITH SYSTEMIC INFLAMMATION?,COMPLETED,,375.0,2023-02-01,2023-03-01,375.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,88.3,94.0
NCT07194551,Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire,RECRUITING,NA,30.0,2025-08-29,2027-04-01,1.5744827586206895,Adequate (1-10/month),15.744827586206897,Significantly Below (<50%),60,35.4,14.799999999999999
NCT02389751,"Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer",COMPLETED,PHASE1,3.0,2015-04-10,2019-07-16,0.05861360718870347,Slow (<1/month),0.5861360718870348,Significantly Below (<50%),100,45.2,30.25
NCT00086151,Identifying Low-Risk Patients With Pulmonary Embolism,COMPLETED,,,2004-07-01,2007-06-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,26.450000000000003
NCT00229151,Sleep Deprivation and Advancement of Sleep Period as Treatment for Bipolar Depression.,TERMINATED,NA,5.0,2005-10-01,2011-12-01,0.06758436944937833,Slow (<1/month),0.6758436944937833,Significantly Below (<50%),10,18.4,3.3000000000000003
NCT01621451,Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?,UNKNOWN,PHASE4,400.0,2012-06-01,2014-06-01,16.679452054794524,Good (10-50/month),166.7945205479452,Exceeded (≥100%),50,72.0,83.25
NCT03928951,General Practitioner Reassessment of Urinary Infection Antibiotherapy Prescribed by Emergency Departments,COMPLETED,,50.0,2019-06-14,2019-09-12,16.91111111111111,Good (10-50/month),169.11111111111111,Exceeded (≥100%),100,57.3,66.4
NCT03618251,Automated Volume Assessment of Acute Stroke,COMPLETED,,406.0,2018-03-15,2020-12-04,12.420743718592965,Good (10-50/month),124.20743718592963,Exceeded (≥100%),100,85.8,92.60000000000001
